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This thesis describes the development of novel Pd-catalysed C–H bond functionalisation 
methodologies, with a view towards their application in sustainable chemical synthesis. The 
basis of this project focuses on the need for more efficient utilisation of precious metal 
catalysts, such as Pd, achieved by mechanistic understanding of the role of heterogeneous Pd 
nanoparticles (PdNPs) in such chemistry. An overview of observations from Pd-catalysed 
cross-coupling and C–H bond functionalisation chemistry is given initially, focusing on the 
mechanistic dichotomy between observed homogeneous and heterogeneous catalytic 
manifolds in these fields. The generation of potentially harmful stoichiometric byproducts in 
direct arylation methodologies is also examined for two classes of commonly-used 
electrophilic arylating agents, aryliodonium and aryldiazonium salts (Chapter 1). 
The synthetic utility of C–H bond functionalisation chemistry has been exemplified through 
the development of complementary conditions for the direct arylation of the amino acid 
tryptophan (I) to form highly fluorescent 2-aryltryptophans (II), all of which have been 
evaluated using several key mass-based green metrics (Chapter 2). These conditions have 
also been shown to be effective for the functionalisation of tryptophan-containing peptides. 
 
Initial rates kinetic analysis of the activity of several homogeneous and heterogeneous Pd 
catalysts in other direct arylation chemistry has highlighted remarkable similarities between 
apparently distinct catalysts, which suggests the formation of a comparable active catalyst 
phase. Heterogeneous Pd sources have also been successfully applied to the selective 
functionalisation of several biomolecules (Chapter 3). 
The final part of this thesis describes fundamental studies on the nature of the ubiquitous Pd0 
catalyst Pd2(dba)3. The major and minor isomers of this catalyst were characterised both in 
solution and in the solid state, which revealed that dynamic exchange between these species 
and free ligand varies significantly as a function of temperature. Crucially, this catalyst has 
also been shown by NMR and MS studies to be a source of catalytically competent PdNPs 
under commonly-found experimental conditions (Chapter 4).
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Chapter 1: Introduction 
1.1 Pd-Catalysed C–X Bond Functionalisation 
1.1.1 Background 
Metal-catalysed cross-coupling reactions have increased in significance since their discovery 
to the point where these methods now underpin modern synthetic chemistry. A variety of 
transformations can be effected through the reaction of activated organohalides with 
organometallics including tin, silicon, zinc, boron and magnesium in the presence of 
transition metal catalysts such as palladium, ruthenium, nickel and copper.1  
The use of palladium in particular has increased enormously in scope and synthetic 
applicability over the last fifty years so that it is now readily applied to many complex 
synthetic organic routes.2 The importance of palladium in synthetic methodology has been 
further highlighted by the awarding of the 2010 Nobel Prize in Chemistry to Heck, Negishi 
and Suzuki for their pioneering work in this field.3 Heck and co-workers are credited with 
developing aryl, benzyl or vinyl halide couplings to terminal alkenes using palladium(II) 
throughout the 1960s and 1970s, such as the coupling of iodobenzene 1 and styrene 2 in the 
presence of catalytic amounts of palladium to produce (E)-stilbene 3.4 This approach was 
also developed independently by Mizoroki and co-workers, who used palladium(II) chloride 
in an analogous system and found that the use of potassium acetate and higher temperatures 
(120 °C) allowed the yield to be increased to 90% (Scheme 1).5 Importantly, the nature of 
the base used in these two systems appears to directly affect the efficiency of the reaction; 
with Mizoroki’s use of an inorganic acetate base providing a higher yield (albeit at increased 
temperature) than Heck’s use of an organic amine base. 
 
Scheme 1 Pd-catalysed formation of (E)–stilbene 3 from iodobenzene 1 and styrene 2. 
Since this pioneering work, many different approaches for the palladium-catalysed formation 
of new C–C bonds with a variety of coupling partners have been established. Notable 
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examples using halides or pseudohalides include, but are not limited to; the Stille (organotin 
reagents),6-8 Suzuki–Miyaura (organoboronic acids),9,10 Sonogashira (terminal alkynes),11 
Kumada–Corriu (Grignard reagents),12,13 Hiyama (organosilanes),14 and Negishi (organozinc 
reagents)15 reactions (Figure 1). Note that some of these reactions require base whereas 
others require activating species such as fluoride. 
 
Figure 1 Selected examples of typical Pd-catalysed cross-coupling reactions. 
These reactions offer a huge variety of chemoselective transformations that can be applied to 
the synthesis of complex natural products, such as the use of an intramolecular Mizoroki–
Heck cyclisation in Danishefsky’s total synthesis of the important anticancer compound 
Taxol 4 (Scheme 2).16 Danishefsky’s synthesis demonstrates that upon choice of a suitable 
base and palladium source (stoichiometric in this case), selective cross-coupling reactions 
can be performed in the presence of multiple functional groups. These types of reactions can 
also be used in a combinatorial fashion, exemplified by Stoltz’s total synthesis of (+)–
Dragmacidin F 5 (Scheme 3).17 




Scheme 2 Key Mizoroki–Heck cross-coupling used in Danishefsky’s total synthesis of Taxol 4. 
 
Scheme 3 Key Mizoroki–Heck and Suzuki–Miyaura cross-couplings used in Stolz’s total synthesis 
of (+)–Dragmacidin F 5. 
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Many mechanisms have been published in the area of palladium-catalysed C–X bond cross-
coupling processes, particularly when concerning well-established and versatile reactions 
such as those highlighted above. Often these are homogeneous in nature, and revolve around 
the reaction of mononuclear Pd0 precursors with alkyl halides to generate the oxidative 
addition products. The typical picture of palladium cross-coupling found in the literature is 
summarised in Scheme 4; a Pd0 precursor undergoes oxidative addition across a C–X bond, 
followed by transmetallation with a second pre-functionalised substrate (e.g. boronic acid, 
organostanne etc.) and subsequent reductive elimination to provide the new C–C bond and 
regenerate the Pd0 catalyst. 
 
Scheme 4 Simplified mechanism for Pd-catalysed cross-coupling. 
There is however a significant body of evidence to suggest that many cross-coupling 
processes could involve both homogeneous and heterogeneous Pd species. Common 
‘homogeneous’ Pd precursors, such as Pd(OAc)2, have been conclusively shown to aggregate 
to form higher-order Pd species. The likelihood is that such species can play an active role in 
catalysis instead of, or alongside, more typical homogeneous manifolds. Such aggregates 
could also act as a reservoir for catalytically active Pd, providing a measure of control over 
the quantity of catalyst active in any given cycle. Additionally, commercially obtained Pd 
catalysts like Pd(OAc)2 can contain significant quantities of catalytically active impurities 
such as Pd3(OAc)5(NO2) and polymeric [Pd(OAc)2]n.18,19 This holistic approach to the 
question of homogeneous versus heterogeneous catalysis can be represented as shown in 
Figure 2. 




Figure 2 Schematic representation for the role of aggregated Pd in catalysis. Reproduced by 
permission of The Royal Society of Chemistry.20 
1.1.2 Mizoroki–Heck and Sonogashira Cross-Couplings 
Some of the first evidence for the existence of Pd reservoirs in cross-coupling chemistry was 
published by de Vries and co-workers, who discovered that the Mizoroki–Heck reaction of 
bromobenzene 6 with n-butylacrylate 7 in the presence of Pd(OAc)2 to produce 8 exhibited 
an inverse relationship of catalyst activity, with respect to catalyst concentration (Figure 3).21 
 
 
Figure 3 Inverse relationship between catalyst activity and concentration in a Mizoroki–Heck cross-
coupling. Adapted with permission from Org. Lett. 2003, 5, 3285–3288. 
De Vries observations with Heck couplings
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For this reaction, the optimal catalyst loading was found to be 0.08 mol% (39 ppm), with 
higher or lower catalyst loadings resulting in decreased yields. This observation is 
attributable to the formation of Pd aggregates at higher catalyst loadings, often associated 
with the precipitation of Pd black. There is however a point at which the catalyst loading 
becomes so low that the reaction cannot effectively proceed. This inverse relationship 
provides evidence for catalytically relevant Pd colloids, but the structure of the catalyst in 
this reaction is unclear; ESI–MS data did however highlight the presence of PdBr3− under 
working reaction conditions. These observations led both de Vries and Reetz to propose a 
unified mechanism for the Mizoroki–Heck reaction, which accounts for both homogeneous 
and heterogeneous manifolds (Scheme 5).22 In this mechanism Pd0 exists as both lower-order 
monomeric or dimeric catalytic species, as well as higher-order palladium species such as 
multinuclear colloids, all of which are capable of interconverting and performing the desired 
coupling transformation. Importantly however the shapes of these particles are poorly 
defined, size instead being relied upon to indicate the nature, and by extension activity, of 
these higher-order species. 
 
Scheme 5 A unified Mizoroki–Heck mechanism. 
A similar inverse relationship was also observed in work conducted by the Fairlamb group, 
who studied the Sonogashira cross-coupling of 4-bromoacetophenone 9 with 
phenylacetylene 10 to produce 11. In this reaction several palladacylic precatalysts proposed 
to act as Pd reservoirs were applied and their turnover frequencies (TOFs) studied as a 
function of catalyst loading, at either 0.1 mol% (orange), 0.01 mol% (purple) or 0.001 mol% 
(blue). In this reaction, 0.001 mol% (92 ppm) provided optimal TOFs (Figure 4). 
 






Figure 4 Inverse relationship between Pd loading and TOF in a Sonogashira cross-coupling. Figure 
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As can be inferred from Figure 2 and Scheme 5, in many cases these higher-order Pd 
aggregates are proposed to act as sources of mononuclear Pd, meaning that the active 
catalytic turnover of substrate can be considered homogeneous. Evidence for the leaching of 
catalytically active Pd from supported catalysts such as Pd/C, Pd/SiO2 and Pd/γ–Al2O3 has 
been reported.23,24 The mechanism of such leaching has been studied by Dupont and co-
workers, who demonstrated that quaternary ammonium salts can stabilise higher order Pd 
species, facilitating the release of oxidised PdII species into solution (Jeffery conditions).25 
Rothenberg et al. utilised a reactor containing a membrane which could select for particles 
<5 nm in size in their efforts to demonstrate the leaching of Pd from larger Pd species (ca. 
15 nm) under Mizoroki–Heck reaction conditions.26 Later work from the same group also 
demonstrated the formation and subsequent growth of Pd clusters from several PdII 
precursors using UV–visible spectroscopy, which allowed for modelling of the reduction, 
including cluster growth and aggregation of such species.27 Baiker and co-workers have also 
used in situ extended X-ray absorption fine structure (EXAFS) to analyse the Mizoroki–Heck 
reaction of bromobenzene 6 with styrene 2, mediated by Pd/Al2O3 (Scheme 6).  
 
Scheme 6 Mizoroki–Heck cross-coupling mediated by Pd/Al2O3. 
Baiker’s study demonstrated the formation of higher-order Pd complexes in situ, assigned as 
Pd0 colloids approximately 2 nm in diameter, which shortly preceded the formation of 
product. These complexes were observed throughout the reaction with very little change until 
complete conversion of the substrate at which point significant variations in the EXAFS data 
were seen. It was also proposed that the rate-determining step of this reaction was 
dissociation of mononuclear Pd0 from these multinuclear Pd0 colloids; hence these observed 
colloids are directly involved in the catalytic cycle and do not serve purely as a reservoir for 
mononuclear Pd species.28 
1.1.3 Suzuki–Miyaura Cross-Couplings 
Similar observations regarding the catalytic competence of higher-order Pd species have also 
been made in the Suzuki–Miyaura reaction. Fairlamb and co-workers tested well-defined 
PdNPs supported on a (poly)vinylpyrrolidone (PVP) polymer 12 (Figure 5), which is known 
to stabilise PdNPs and prevent their thermodynamically favourable agglomeration.29-31 




Figure 5 Monomer unit of (poly)vinylpyrrolidone (PVP) 12. 
A seeding method was used to synthesise PVP–Pd 13 with NPs of four different diameters, 
between 1.8 and 4.0 nm, which were then applied to the cross-coupling of phenylboronic acid 
14 and iodoanisole 15 in methanol to produce 16. The activity of each of these catalysts was 
then compared as a function of the TOF against the total number of surface Pd atoms, which 
demonstrated an inverse relationship i.e. higher activity for the smaller particles. If the TOF 
was normalised against only those Pd atoms contained within defect sites on the truncated 
cuboctahedral particles however, no difference was observed (Figure 6).32,33 This strongly 
suggests that it is the abundance of surface defect sites which determines the activity of these 
particles; simply put, the more defect sites per particle, the more active the catalyst. 
 
 
Figure 6 Relationship between TOF and particle size normalised to either total surface Pd atoms (●) 
or defect surface Pd atoms (○) in a Suzuki–Miyaura cross-coupling. Reproduced by permission of 
The Royal Society of Chemistry.33 
This trend could however be observed if low-coordinate Pd species demonstrated preferential 
solubility, so in operando X-ray absorption spectroscopy was used to monitor the 
coordination environment of the PdNPs, to determine the heterogeneity of the reaction under 
normal working conditions (Figure 7).  
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These measurements indicated no sintering or leaching of the particles during the reaction, a 
result confirmed by EXAFS, X-ray photoelectron spectroscopy (XPS) and transmission 
electron microscopy (TEM) studies. Importantly no induction period was seen, which is 
consistent with the observation that nanoparticulate Pd is not simply acting as a pre-catalyst 
or Pd reservoir. 
 
Figure 7 XAS spectra of PdNP coordination environment in a Suzuki–Miyaura cross-coupling. 
Reproduced with permission from Angew. Chem. Int. Ed. 2010, 49, 1820–1824. Copyright 2010 
WILEY-VCH Verlag GmbH & Co. 
Elemental mercury was administered to the reaction after a brief induction period (8 min) 
under normal working conditions, as mercury has been shown to inhibit surface reactions 
through poisoning of the catalyst; believed to occur as a result of surface amalgamation of 
the mercury with any heterogeneous particles present in the reaction mixture.34,35 This 
poisoning test caused immediate cessation of catalytic activity and the resultant Pd core/Hg 
shell particles were successfully characterised by XPS, showing a 1:1 correlation between 
the surface Pd and Hg atoms. This emphatically demonstrated the lack of any Pd leaching in 
this system, confirming its heterogeneous nature. These results also provide strong evidence 
that the Suzuki–Miyaura reaction can also operate in a dual-phase catalytic system for 
common Pd0 catalysts, e.g. Pd(PPh3)4 or Pd2(dba)3. 
The relevance of surface defect sites to the catalytic activity of PdNPs was also discussed by 
Blackmond and co-workers during their study on a Mizoroki–Heck reaction. They correlated 
the ratio of defect sites to terrace sites in nanoparticles of varying sizes, obtained by the 
reduction of Pd2(dba)3·dba with hydrogen in the presence of PVP 12 (Figure 8).30 




Figure 8 Ratio of defect sites to terrace sites in truncated cuboctahedral PdNPs. Adapted with 
permission from Langmuir 1999, 15, 7621–7625. Copyright 1999 American Chemical Society. 
This builds upon work performed by Knight et al. which explored the number of atoms 
contained within the stable shell structures of sodium nanoparticles (Figure 9).36 
 
Figure 9 Stable closed-shell structures of metal nanoparticles. 
The examples highlighted above serve to demonstrate the ability of nominally homogeneous 
Pd (pre)catalysts to serve as a source of heterogeneous Pd, either as a result of propagation 
to form catalytically competent PdNPs, or as a reservoir of Pd colloids which are slowly 
released into solution. There are also instances of supported Pd nanocatalysts which are 
prepared, purified and characterised independently, before being used in a range of Pd-
mediated cross-coupling reactions.37-40 
1.2 Pd-Catalysed C–H Bond Functionalisation 
1.2.1 Background 
While useful from a synthetic viewpoint, a significant drawback to C–X bond cross-coupling 
reactions is the need to pre-functionalise the substrate with activated functional groups such 
as boronic acids or organostannes, among others. This not only adds unwanted complexity 
and the potential for unwanted byproducts to the reaction but also increases the economic 
and environmental cost of syntheses employing such transformations. Removing substrate 
pre-functionalisation potentially allows for the minimisation of downstream chemical waste; 
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moreover, it eliminates the need for prior mandatory reaction steps that enable the installation 
of chemical functionality which is ultimately lost in the final and desired chemical 
transformation. Recent advances in direct C–H bond functionalisation have attempted to 
address this issue, as mild and selective methods can now be used to cleave and generate C–
H bonds directly without the need for pre-functionalised starting materials, expanding the 
toolkit of the synthetic chemist.41 These processes can include direct, oxidative or 
decarboxylative couplings, in addition to the classical cross-coupling of organometallic 
reagents highlighted above (Figure 10). 
 
 
Figure 10 Overview of Pd-catalysed processes for the formation of new carbon–carbon bonds. 
It is important at this point to note the difference in nomenclature as regards C–H bond 
activation and C–H bond functionalisation; C–H bond activation specifically refers to the 
activation of a C–H σ–bond by a metal centre while C–H bond functionalisation refers to the 
overall process by which a C–H fragment is coupled to another C–H or C–X fragment to 
generate a new C–C bond. 
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Despite its relative infancy, C–H bond functionalisation has gained a large amount of 
research interest, with an ever-increasing number of publications in this area. The ability to 
directly couple two fragments together without the need for pre-functionalisation is a 
particularly attractive prospect for the synthesis of natural products or pharmaceuticals.42 One 
such example used on an industrial scale by Bristol-Myers Squibb is the synthesis of the 
potent antitumor agent Rebeccamycin Aglycone 17 (Scheme 7).43 
 
Scheme 7 Synthesis of Rebeccamycin Aglycone 17. 
The synthetic applicability of this type of methodology is demonstrated by examples of 
C(sp3)–H bond functionalisations, which can be used to construct otherwise challenging 
motifs, such as the isolable aryl-cyclobutane intermediate 18 in the total synthesis of 
Coralydine 19 (Scheme 8).44,45 
 
Scheme 8 Baudoin’s synthesis of Coralydine 19. 
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1.2.2 Mechanistic Interpretations of C–H Bond Functionalisation 
Reported mechanistic investigations of C–H bond functionalisation processes typically focus 
on the concept of mononuclear Pd species mediating the catalytic cycle. Often these centre 
around variations on the key mechanism in this class of reactions, the concerted metalation–
deprotonation (CMD) or ambiphilic metal–ligand activation (AMLA) process (Scheme 9), 
proposed independently by Fagnou (CMD)46 and Davies/Macgregor (AMLA)47 and co-
workers. 
 
Scheme 9 CMD or AMLA-6 mechanism for direct C–H bond functionalisation. 
Given the significant body of evidence within cross-coupling catalysis however, it should be 
expected that C–H bond functionalisations possess a capacity for complex, multistep reaction 
processes involving higher-order Pd species. It is important to recognise that common Pd 
(pre)catalysts can often act as Pd reservoirs for the subsequent generation of Pd0 particles, or 
indeed as PdNP sources in their own right in this type of chemistry. Research conducted by 
Fairlamb and co-workers on the direct C8-arylation of adenosine mediated by Pd(OAc)2 
demonstrated the rapid formation of Pd agglomerates under the reaction conditions, with 
substrate turnover occurring concomitantly with the observation of Pd/Cu-containing 
nanoparticles.48 Optimisation of this protocol for the functionalisation of the more sensitive 
2ʹ-deoxyadenosine 20 to form 21 demonstrated that these nanoparticles were critical to 
precatalyst activation, with the (pre)catalyst trans-Pd(OAc)2(piperidine)2 used in this reaction 
shown to degrade rapidly to form well-defined 1.7 nm PdNPs, via a Pd(DMF)2(piperidine)2 
intermediate (Scheme 10).49 Polar aprotic solvents such as DMF have been shown by Hii et 
al. to effect a rapid dissociation of Pd(OAc)2, leading to speciation of PdNPs from this 
ubiquitous Pd precursor catalyst.50 




Scheme 10 Direct arylation of 2ʹ-deoxyadenosine 20 catalysed by DMF–PdNPs. 
While many examples exist of this type of speciation from common Pd precursors,51-56 it is 
important to note that the multinuclear colloids proposed as sources of heterogeneous Pd0 are 
often poorly defined, ranging from a few palladium atoms up to particles in the 5 nm range 
consisting of many thousands of palladium atoms. Importantly, this creates a significant 
physical difference between the surface, terrace site and bulk palladium atoms in the context 
of their catalytic activity. This, in addition to their specific morphology and other surface 
effects, must be kept in mind when attempting to demonstrate the heterogeneous nature of a 
given reaction. Such considerations regarding the activation of Pd(OAc)2 and other related 
precursors to form well-defined PdNPs can be extended to many C–H bond functionalisation 
protocols, allowing for the activity of pre-synthesised PdNP catalysts to be independently 
tested and compared in these reactions.57-64 The use of pre-supported PdNP catalysts such as 
PVP–Pd 13 allows for a greater degree of control over potentially complex catalytic 
manifolds, where a multi-ensemble of higher order Pd species often play a key role.65,66 
The relevance of higher-order Pd species in C–H bond functionalisation processes and the 
activity of pre-synthesised supported PdNPs in this chemistry has recently been reviewed in 
detail (see Appendix 1).20 
1.3 Arylating Agents for C–H Bond Functionalisations at Pd 
1.3.1 Aryliodonium and Diaryliodonium Salts 
One of the key features of many C–H bond functionalisation processes is the need for 
organohalides or organopseudohalides to act as the coupling partner for the desired C–H 
fragment (Figure 10). Choosing the appropriate coupling partner for a given methodology is 
far from trivial however, as several drawbacks exist. Iodoarenes for example are often 
employed preferentially due to the relatively weak C–I bond (ca. 240 kJ mol-1), as compared 
to either bromoarenes (ca. 276 kJ mol-1) or chloroarenes (ca. 339 kJ mol-1). This is despite 
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the toxicity of iodine-containing waste streams, the decreased mass intensity of these reagents 
or their relatively higher cost. Furthermore, external oxidants can often be required either for 
regeneration of the active catalyst following substrate turnover, or transformation of the 
substrate into the desired target molecule (in an oxidative process, Figure 10). These 
considerations have led to significant developments in the use of hypervalent iodine(III) 
reagents as coupling partners for many C–H bond functionalisation processes, as they are 
both strong electrophiles and powerful oxidants.67-70 Moreover, employing iodobenzene 1 as 
a leaving group (as opposed to I− for example), means these species are typically more 
reactive than aryl halides.71 
The reactivity of λ3-iodanes has recently been explored in a computational study, which 
provides extensive detail on the impact of differing structural motifs on the reaction 
mechanisms which may be observed.72 Unsurprisingly, it is the hypervalent nature of these 
compounds which gives rise to the wide range of synthetic applications in which they have 
been found to be effective (vide infra). Perhaps most interestingly, the authors report that the 
unique electronic nature of λ3-iodanes allows these species to isomerise through a pseudo 
Jahn-Teller effect. The iodine(III) acetates 22 and 23 for example are typically applied as 
terminal oxidants for catalytic processes, with their labile acetate groups allowing for facile 
metal binding and/or electron transfer (Figure 11). 
 
Figure 11 Structures of common hypervalent iodine(III) reagents. 
The strongly oxidative nature of λ3-iodanes can result in their acting in a non-innocent 
fashion, as studies on the ligand-directed, site-selective acetoxylation of arenes by Sanford 
et al. have shown (Scheme 11).73 The steric demands of the iodine(III) oxidant used (22 or 
23) in this case are proposed to be the source of the observed regioselectivity. It was also 
suggested that the acetate group donated to the substrate 24 is derived directly from these 
oxidants, although this claim is unsubstantiated by mechanistic evidence. It is equally likely 
that the acetate group is derived from the acetic acid/acetic anhydride solvent mixture used. 




Scheme 11 Site-selective acetoxylation of arenes using iodine(III) reagents. 
Qin and co-workers have also shown that 22 can be used facilitate the functionalisation of 
C(sp3)–H bonds, with the reactivity of this species towards acetoxylation or arylation 
regulated simply by addition of carbonate base (Scheme 11).74 In this system, the innate lack 
of reactivity in the C–H bond to be functionalised is overcome by decorating amide 25 with 
a proximal 8-aminoquinoline directing group, which also serves to provide the desired 
regioselectivity. 
 
Scheme 12 Orthogonal arylation/acetoxylation using hypervalent iodine(III) reagents. 
Exploratory mechanistic studies using (p-CO2Me)PhI(OAc)2 28 indicated that decomposition 
of the iodine(III) species to form (p-CO2Me)PhI 29 preceded product formation under the 
direct arylation conditions, suggesting that iodoarenes were the true arylating agents in this 
system. When 29 was used as the arylation agent in place of 28 however only 13% of the 
desired product was obtained, corresponding to approximately one catalyst turnover, 
signifying that the acetate anions generated from decomposition of 28 play a key role in this 
system (Scheme 13a). Replacement of Cs2CO3 with CsOAc under otherwise identical 
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conditions provided 87% of the desired product, proving that these acetate anions (or related 
complexes thereof) were effectively promoting the catalysis (Scheme 13b). 
 
Scheme 13 Effect of acetate anion on direct arylation with iodoarenes. 
These highly electrophilic species have even been demonstrated to selectively cleave the 
peptide bonds of asparagine residues in neutral aqueous media, via an elegantly designed 
Hofmann rearrangement.75 
 
Scheme 14 Selective asparagine cleavage mediated by hypervalent iodine(III) reagent.  
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In addition to iodine(III) diacetates, diaryliodonium salts are the other prominent type of 
iodine(III) reagent primarily used in catalysis. These are notable because they are able to 
provide a synthetically broad range of coupling partners, typically synthesised in one-pot 
processes from the corresponding iodoarene. They are often employed in cross-coupling 
reactions such as the Suzuki–Miyaura, the first example of which was published by Bumagin 
and co-workers, who generated biaryls through the direct coupling of symmetric 
diaryliodonium salts with sodium tetraphenylborate 31 in the presence of PdCl2 in water 
(Scheme 15).76 These conditions are especially notable as up to four equivalents (w.r.t. 
iodonium salt) of product are obtained, representing a near-perfect incorporation of the 
aromatic groups.  
 
Scheme 15 Suzuki-Miyaura cross-coupling of diaryliodonium salts. 
More recently, diaryliodonium salts have been applied to the emerging field of catalytic C–
H bond functionalisation mediated by palladium. One of the key challenges of such chemistry 
is the need to direct the desired transformation to one C–H bond, in the presence of many 
other potentially competing C–H bonds. Often this is accomplished by using either 
introduced regioselectivity (e.g. directing group strategies) or taking advantage of innate 
regioselectivity, by targeting the most acidic or most electronically activated position in a 
given molecule. Sanford and co-workers used a range of 2-phenylpyridines, quinolines and 
other directing substrates to direct selectivity in their system, which describes a direct C(sp2)–
H arylation using symmetric and asymmetric diaryliodonium salts, mediated by Pd(OAc)2 in 
AcOH (Scheme 16).77 The key feature in all of their chosen substrates is the use of proximal 
nitrogen directing groups at either the 1,3 or 1,4 position, with respect to the C–H bond being 
functionalised. 




Scheme 16 Nitrogen-directed arylation using diaryliodonium salts. 
Subsequent mechanistic investigation of this reaction led the authors to propose a key 
turnover-limiting step, involving oxidation of the PdII dimer 32 by the strongly oxidising 
[Ar2I]BF4 (Scheme 17).78 The resulting species could be considered a mixed PdII/PdIV or a 
PdIII/PdIII dimer.79 In later work, it was shown that similar transformations could be effected 
via a radical-based mechanism, with a tandem PdII–IrIII–visible light catalytic manifold.80 
 
Scheme 17 Sanford’s proposed high oxidation state bimetallic Pd intermediate. 
In later work, the same group applied similar conditions to substrates with innate electronic 
reactivity, N-methylindoles, as opposed to the directing group approach used in Scheme 16. 
This proved extremely effective, as synthetically useful yields of the desired 2-arylindoles 
could be obtained from reactions conducted at room temperature, as opposed to the elevated 
temperature previously required (Scheme 16). Furthermore, when using N-methylindole 33, 
Pd(OAc)2 provided the desired arylation product 34 in 49% yield within 5 minutes; upon 
changing the catalyst to the carbene-ligated 35, the desired product was obtained in 86%, but 
after a much longer reaction time (Scheme 18, 18 h).81 The authors use this example to 
propose evidence of electrophilic palladation in the mechanism, in support of a proposed 
PdII/PdIV catalytic pathway (as for their previous work, Scheme 17).78 It can however be 
argued that Pd(OAc)2 and 35 are intrinsically different catalysts, therefore they do not 
necessarily operate via the same catalytic manifold. That said, conditions such as these are 
extremely likely to produce speciation to form higher-order Pd species in situ, thus the 
difference in rates and final yields obtained may result from Pd(OAc)2 and 35 displaying 
varying tendencies towards this process.20 Moreover, the authors of this work obtain similar 
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results by pre-mixing a solution of 22 and 14 prior to substrate addition, which they use as 
evidence for the in situ formation of diaryliodonium species (vide infra). 
 
Scheme 18 Room temperature arylation of N-methylindole. 
Daugulis and Zaitsev demonstrated that anilides were an effective directing group in the 
ortho-arylation of the simple arene 36 to produce 37 using diphenyliodonium salts, mediated 
by catalytic Pd(OAc)2 in acetic acid (Scheme 19).82 In an interesting parallel to the work by 
Qin and co-workers (Scheme 12 and Scheme 13), they discovered that simple iodoarenes 
could be used in place of diaryliodonium salts if stoichiometric AgOAc was added, citing 
lack of commercial availability of the diaryliodonium salts as their reasons for this switch. 
No mention was made of the necessity of the silver cation in this reaction, hence it could be 
the case that the acetate anion is promoting the catalysis, as Qin et al. found many years 
later.74 
 
Scheme 19 Anilide-directed ortho-arylation using diaryliodonium salts. 
Liu and co-workers published the first reported stable complex of acyloxy-directed Pd-
insertion into a C–H bond, allowing them to postulate that triflic acid (TfOH) might be a 
useful additive to tune the elecrophilicity of PdII in C–H bond functionalisation reactions, 
allowing for modification of previously unreactive motifs. They demonstrated that a 
combination of Pd(OAc)2, catalytic TfOH and [Ph2I]OTf 38 could effectively arylate a range 
of phenol esters such as 39 to produce 40, in synthetically useful yields at low temperatures 
(Scheme 20). Interestingly, they also found that addition of Ac2O to the reaction removed 
any sensitivity to moisture. Replacement of Pd(OAc)2 and Ac2O with Pd(OPiv)2 and Piv2O 
(Piv = pivaloyl), respectively, was found to increase the yields obtained for several 
examples.83 




Scheme 20 Direct arylation of phenol esters using diaryliodonium salts. 
Greaney and co-workers applied symmetric diaryliodonium salts to their work on the direct 
arylation of simple, unactivated arenes, in order to generate biaryls of value to the chemical 
industry. Lack of directing groups in their substrates (such as p-xylene, 41) led to a 
corresponding problematic lack of selectivity in the C–H bond functionalised and product 
subsequently obtained. After extensive screening, they discovered that use of the Hermann–
Beller palladacyle 42 was effective in directing arylation of 41 to a single site to produce 43 
(Scheme 21). Furthermore, using trifluoroacetic acid (TFA) to tune the elecrophilicity of PdII 
improved the yields observed (as with the addition of TfOH in Liu’s work, vide supra).84 
 
Scheme 21 Direct arylation of p-xylene 41 mediated by the Hermann–Beller palladacycle 42. 
In the examples utilising diaryliodonium salts highlighted above, a significant drawback lies 
in the fact that typically one or more equivalents of iodoarene are lost as waste, for each 
equivalent of substrate turned over. In terms of atom economy, sustainability and simple 
economics, this significantly reduces the appeal and versatility of transformations using these 
reagents. Bumagin’s example (Scheme 15) is a rare instance of these reagents being used in 
an atom-efficient manner, yet even this requires a privileged substrate (tetraphenylborate 31). 
Greaney and co-workers have attempted to address this issue by applying tandem Cu 
catalysis to functionalised indoles, where the “byproducts” of the initial C–H arylation 
(iodoarenes) are then captured by a second Cu centre and used to effect N–H arylation on the 
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same substrate. This overall transformation can be conducted in a single reaction vessel 
(“one-pot”), although this approach is so far limited to using the phenyldimethyluracil 
iodonium salt 44, in order to provided differentiation between the two aromatic groups for 
each catalytic step (Scheme 22). Nevertheless, this example represents a current “best-in-
class” approach to removing the stoichiometric iodoarene byproducts of such reactions.85 
 
Scheme 22 Tandem C–H and N–H arylation of indoles. 
Other approaches for the atom-efficient utilisation of diaryliodonium salts include supporting 
these reagents on ionic liquids,86 polymers87 or other solid supports,88 allowing for their 
subsequent recovery and re-use. 
1.3.2 Aryldiazonium Salts 
These approaches go some way toward mitigating the disadvantages of diaryliodonium salts, 
but the fundamental limitation of these reagents is the presence of two aromatic groups. There 
is thus a need to seek alternative electrophilic reagents for Pd-catalysed direct arylation 
reactions, which can combine the generality of iodine(III) salts with more atom-efficient 
byproduct generation. Aryldiazonium salts present just such an alternative, as they bear some 
useful similarities to diaryliodonium salts in terms of their structure and reactivity, but 
importantly produce dinitrogen instead of iodoarenes as a major byproduct. It is however the 
case that despite the wide-ranging applications of iodine(III) species, investigations of their 
diazonium counterparts have largely been limited to certain Pd-catalysed cross-coupling 
reactions;89 primarily they have been applied as a replacement for aryl halides in 
Sonogashira,90 Suzuki–Miyaura91 or Heck–Matsuda reactions.92-94 This latter reaction was 
first reported by Matsuda in 1977 and combines Mizoroki–Heck palladium catalysis with 
aryldiazonium salts to generate the corresponding substituted alkenes. The reaction of 
phenyldiazonium chloride 47 with styrene 2 is shown in Scheme 23.95 The use of LiPdCl3 as 
a precatalyst is unusual and the likelihood is that the authors used a 1:1 mixture of PdCl2 and 
Li2PdCl4 as their source of catalytic palladium. 




Scheme 23 Heck–Matsuda reaction in the synthesis of (E)-stilbene 3. 
Sigman and co-workers have demonstrated that a one-pot combination of the Suzuki–
Miyaura and Heck–Matsuda cross-coupling reactions can be used to generate highly 
functionalised molecules in an elegant three-component synthesis, such as the reaction 
between phenyldiazonium 48, alkene 49 and arylboronic acid 50 in the presence of a Pd0 
(pre)catalyst (Scheme 24).96 
 
Scheme 24 One-pot combination of the Suzuki–Miyaura and Heck–Matsuda cross-couplings. 
Wei and co-workers have demonstrated the efficacy of aryldiazonium salts in several cross-
coupling reactions catalysed by the nanoparticulate Pd catalyst, Pd/Al(OH)3, which consists 
of PdNPs approximately 2–3 nm in diameter. A Suzuki–Miyaura reaction between 
arylboronic acids and aryldiazonium salts in the presence of this catalyst was shown to 
proceed effectively at room temperature in methanol without any additional base or 
phosphine (note that the counter-ion of the aryldiazonium salt could act as a base), affording 
many derivatives in synthetically useful yields (Scheme 25).97 A brief recycling experiment 
demonstrated that this catalyst rapidly decreased in efficiency over 2 recovery/re-use cycles, 
implying that leaching or at the very least sintering/agglomeration of the PdNPs was 
occurring under the reaction conditions. 
 
Scheme 25 Suzuki–Miyaura reaction of aryldiazonium salts catalysed by nanoparticulate Pd. 
This catalyst was subsequently applied to a Heck–Matsuda reaction between aryldiazonium 
salts and terminal alkenes in ethanol; once again good to excellent yields of the desired cross-
coupling products were obtained without the need for additional base or ligand (Scheme 
26).98 




Scheme 26 Heck–Matsuda reaction of aryldiazonium salts catalysed by nanoparticulate Pd. 
An analogous recycling experiment was performed and under these conditions the 
Pd/Al(OH)3 catalyst demonstrated slightly better efficiency after 2 recovery/re-use cycles, 
although its performance rapidly deteriorated after this. For their recycling experiments 
however, the authors of this work used progressively increasing reaction times for each 
subsequent re-use in order to obtain similar yields, which strongly suggests that the catalyst 
is losing its catalytic efficiency and this fact is masked by the pursuit of isolated yield of 
product over actual comparison of catalytic activity. Structural studies on the recycled 
catalyst demonstrated that the Al(OH)3 support displayed little change in either its surface 
area or pore size after several uses. Conversely, TEM images of the PdNPs displayed 
significant desorption and agglomeration had occurred under the reaction conditions. 
Inductively coupled plasma atomic emission spectroscopy (ICP–AES) demonstrated that 
substantial leaching of the Pd catalyst occurred, leading to the observed decrease in catalytic 
activity. This is certainly also occurring under the Suzuki–Miyaura reaction conditions 
detailed above (Scheme 25). The same group have also recently demonstrated the effective 
combination of aryldiazonium salts with this catalyst in a Stille cross-coupling of substituted 
tributylarylstannanes under mild conditions (Scheme 27).99 
 
Scheme 27 Stille reaction of aryldiazonium salts catalysed by nanoparticulate Pd. 
Despite the many examples of their useful application in Pd-catalysed cross-couplings, 
aryldiazonium salts are as yet vastly underexplored for direct C–H bond functionalisations. 
One notable exception combines the ruthenium-mediated visible-light photoredox catalysis 
pioneered by Macmillan et al.100 with a Pd-mediated room temperature direct C–H arylation. 
As with this group’s earlier work on Pd-mediated C–H bond functionalisations using 
diaryliodonium salts (Scheme 16),77 a directing group strategy employing proximal nitrogen 
directing groups at either the 1,3 or 1,4 position was combined with electrophilic 
aryldiazonium salts to generate a range of arylated products in methanol at 25 °C (Scheme 
28).101 This process was proposed to proceed through an aryl radical intermediate, formed by 
one-electron reduction of the aryldiazonium salt by a photoexcited Ru(bpy)32+* transient 
species. 




Scheme 28 Nitrogen-directed arylation using aryldiazonium salts. 
Correia et al. have also shown that aryldiazonium salts can be used for the direct arylation of 
N-methylindole 33, benzofuran 52 and benzothiophene 53 under mild conditions with 
typically short reaction times (Scheme 29).102 
 
Scheme 29 Direct arylation using aryldiazonium salts of a) N-methylindole 33, b) benzofuran 52 and 
c) benzothiophene 53. 
During the screening for this reaction, the authors originally found that when acetic acid was 
used as a solvent, moderate conversion of N-methylindole 33 was observed. They 
subsequently deduced that the major side product in this reaction was a diazo species, formed 
by nucleophilic attack of the arylindole formed under the reaction conditions on unreacted 
aryldiazonium salt starting material. To combat this issue, the reaction solvent was changed 
to a biphasic mixture in an attempt to separate the remaining aryldiazonium salt from the 
product; the use of a 2:1 H2O/di-iso-propyl ether (IPE) solvent mixture allowed for good 
yields of the desired products to be obtained. When attempting this reaction with the electron-
deficient 4-trifluoromethylbenzene diazonium salt 54, no reaction was seen. It required N-
Boc protection of the indole (55), an increase in catalyst loading, a change of solvent to tert-
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butanol and a much increased reaction time in order to observe the desired arylation product 
56 in good conversion (Scheme 30). It is evident that for these authors, room temperature 
must be at least 25 °C in order for the tBuOH solvent to exist as a liquid. The observation 
that the nucleophilicity of the substrates appeared to correlate with their reactivity led the 
authors to suggest that the mechanism for this process involves a nucleophilic attack on the 
palladium centre from the heteroaromatic substrates, as proposed by Zhao,103 instead of the 
radical-based mechanism proposed by Sanford and co-workers (vide supra). 
 
Scheme 30 Direct arylation of protected indole using electron-deficient aryldiazonium salt. 
The stability of aryldiazonium reagents is one possible reason why these species have not yet 
found wider application in the important field of Pd-catalysed C–H bond functionalisation. 
They are often perceived to be highly explosive, although this particular risk can be mitigated 
through the use of flow technology, particularly in large scale reactions.104,105 Additionally, 
the counter ion used has a large impact in this regard, with tetrafluoroborate and tosylate salts 
demonstrating greatly increased stability over halide anions.93 Their safe use in many varied 
applications has been demonstrated extensively,106 with in situ formation from the 
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1.4 Project Aim & Objectives 
1.4.1 Aims 
I. Develop new synthetic methodology based on the application of catalytic C–H bond 
functionalisation chemistry to access molecular complexity. 
II. Investigate the role of higher-order Pd species in catalytic C–H bond 
functionalisation reactions through the comparison of pre-synthesised heterogeneous 
nanocatalysts with those forming in situ. 
III. Study the propagation of palladium nanoparticles and clusters from commonly used 
Pd (pre)catalysts. 
1.4.2 Objectives 
I. To explore the use of electrophilic arylating agents such as diaryliodonium and 
aryldiazonium salts with a view to developing mild and sustainable C–H bond 
functionalisation processes, in order to allow the selective functionalisation of 
tryptophan and related biomolecules (Chapter 2). 
II. To demonstrate and compare the activity of heterogeneous and homogeneous Pd 
catalysts in the direct arylation of heterocycles in order to elucidate mechanistic 
information about these processes, including the application of heterogeneous 
catalysis to the selective functionalisation of biomolecules (Chapter 3). 
III. To characterise the Pd0 precursor complex Pd2(dba)3 and related solvated compounds 
in solution and in the solid state, in particular studying its behaviour in dynamic 
systems and thus its potential for the formation of palladium nanoparticles and 
clusters (Chapter 4). 
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Chapter 2: Direct C–H Bond Functionalisation of 
Tryptophans and Peptides 
2.1 Literature Syntheses of Arylated Tryptophans 
2.1.1 Cross-Couplings 
Tryptophan is a hydrophobic, indole-containing amino acid present in approximately 90% of 
proteins, which is known to alter the structure of proteins as well as providing a natural 
fluorescent marker.109 These intrinsic photophysical properties can also be enhanced by 
extension of the aromatic π-system, such as that obtained by generation of aryl-substituted 
tryptophans via direct metal-mediated catalysis. Miller and co-workers have demonstrated 
that a Suzuki–Miyaura reaction between the commercially available borylated tryptophan 
derivative 57 and bromoindole 58 provides the desired C2-arylation product 59 in good yield, 
although the high temperature required potentially limit the applicability of this method for 
more complex substrates (Scheme 31).110 
 
Scheme 31 Suzuki–Miyaura coupling to produce C2-tryptophan derivative 59. 
A similar approach by Meinke et al. utilised a Suzuki–Miyaura coupling to prepare several 
C2-functionalised derivatives of the tryptophan-containing natural product apicidin 60, 
obtained by reaction of brominated precursor 61 with the appropriate arylboronic acid 
(Scheme 32).111 The authors state that this reaction “provided good yields of the desired 2-
arylindoles”, although only an approximate yield of 65% was provided for all five analogues 
prepared (62–66). 




Scheme 32 Preparation of arylated apicidin analogues via a Suzuki–Miyaura coupling. 
Winn and co-workers also selected the Suzuki–Miyaura reaction to selectively functionalise 
several unprotected 5- and 7-bromotryptophans in water (Scheme 33).112 
 
Scheme 33 Suzuki–Miyaura coupling of unprotected bromotryptophans in water. 
The fluorescence properties of the arylated products obtained were evaluated and shown to 
provide stronger emission signals than that of the parent tryptophan compound 73 (Table 1, 
Entry 1). Importantly, the position and nature of the aromatic substituent used gave rise to 
varying emission signals and Stokes shifts; an electron-withdrawing carboxy group attached 
to the phenyl ring (70) produced the largest Stokes shift of those examples tested (Table 1, 
Entry 4), while 5-phenyltryptophan 67 (Table 1, Entry 2) was seen to be much more strongly 
fluorescent than its 7-phenyl regioisomer 72 (Table 1, Entry 5).  
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Table 1 Fluorescence spectroscopic properties for aryltryptophans.a 
Entry Compound λex / nm λem / nm Stokes shift / cm-1 
1 73 280 348 6978 
2 67 254 370 12343 
3 69 254 353 11041 
4 70 254 411 15039 
5 72 254 384 12703 
a All spectra recorded in methanol. 
2.1.2 Direct C–H Bond Functionalisations 
While these approaches provide several facile routes to access aryltryptophans, they all suffer 
from the disadvantage of having to prepare pre-functionalised halogenated or borylated 
starting materials, as is usually the case for traditional cross-coupling processes. More recent 
developments in the field of metal-mediated C–H bond functionalisations provide a way to 
obviate this potential limitation, as the desired product(s) can be obtained from the direct 
reaction of an intrinsically reactive C–H bond within the indole moiety, thus increasing the 
atom economy and mass efficiency for the overall transformation required. Lavilla and co-
workers adapted the Pd-mediated arylation conditions of Larossa et al.113 to produce a range 
of C2-aryltryptophans directly from protected tryptophan derivative 74 in synthetically 
useful yields under microwave irradiation for 5 minutes. The arylating agents in this protocol 
are iodoarenes, with AgBF4 and 2-nitrobenzoic acid used as stoichiometric additives 
(Scheme 34).114 
 
Scheme 34 Direct arylation of tryptophan 74 using a catalytic Pd/stoichiometric Ag system. 
This methodology was also adapted to allow the selective modification of several tryptophan-
containing peptides, where in phosphate buffer at pH 6.0 the temperature could be lowered 
to 80 °C while still allowing for high conversions to the desired products (Scheme 35). A 
Chapter 2: Direct C–H Bond Functionalisation of Tryptophans and Peptides 
63 
 
tenfold excess of aryl iodide was however required in these cases. Furthermore, those 
peptides with sulphur-containing amino acids in their sequence (90) proved unsuitable 
arylation substrates, due to selective hydrolysis of the peptide bond presumably caused by in 
situ palladium complex formation. The specific position of tryptophan within the peptide had 
no effect on the efficacy of this protocol. 
 
Scheme 35 Selective arylation of tryptophan-containing peptides. 
One issue observed with the protocol developed on single tryptophan residues (Scheme 34) 
was that the nitrogen protecting group was critical in providing the desired products in 
synthetically useful yields. The acetyl protecting group used in this case has poor utility for 
masking amino functionality in peptide syntheses; to address this drawback later work from 
the same group explored the effect of acid additives on several tryptophan derivatives, as 
well as unprotected tryptophan itself.115 Interestingly it was found that addition of 
stoichiometric TFA to the reaction allowed for quantitative conversion (at 90 °C in DMF) of 
unprotected tryptophan, in addition to N-Tfa (92) and N-Fmoc (93) tryptophans. As the Fmoc 
protecting group is readily compatible with solid-phase peptide synthesis it was selected to 
exemplify these new reaction conditions for a range of aryl iodides (Scheme 36). 
 
Scheme 36 Direct arylation of Fmoc-protected tryptophan 93 using a Pd/TFA system. 
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The aqueous conditions developed for short-chain peptides (Scheme 35) were also 
subsequently adapted in the post-synthetic modification of the natural product brevianamide 
102, which contains a masked tryptophan functionality (Scheme 37). This protocol was used 
to synthesise a range of novel C2-arylated analogues which displayed antitumoral activity 
distinct from that of the parent compound 102.116 
 
Scheme 37 Direct arylation of brevianamide using a Pd/Ag system. 
The arylating conditions developed by this group shown in Scheme 34 and Scheme 36 were 
subsequently adapted to allow preparation of stapled tryptophan–tyrosine/phenylalanine 
peptides through an elegant C2-activation, allowing rapid access to complex macrocyclic 
peptide architectures.117 One such product obtained from the intramolecular reaction of a 
tryptophan residue with a phenylalanine residue to produce a peptide containing the tumour-
homing signalling sequence Asn-Gly-Arg is shown in Scheme 38. 
 
Scheme 38 Stapled bond formation of peptides through intramolecular C2-arylation of tryptophan. 
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The protocols described by Lavilla et al. were also adapted by James and co-workers in a 
sophisticated Pd-mediated peptidic macrocyclisation using an intramolecular C2-arylation of 
a derivatised tryptophan residue (Scheme 39).118 
 
Scheme 39 Peptidic macrocyclisation utilising an intramolecular C2-arylation of tryptophan. 
The major drawback in the application of direct C–H bond functionalisation to the 
modification of tryptophan derivatives in the examples highlighted above is the need for high 
temperatures and microwave irradiation. To address this issue, studies conducted in the 
Fairlamb group adapted Sanford’s work on the room temperature direct arylation of indoles81 
to demonstrate the effective C2-arylation of tryptophan 74 under much milder conditions 
than had been previously achieved. This was accomplished through mixing of phenylboronic 
acid 14 and aryliodonium salt 22 in the presence of catalytic palladium and glacial acetic acid 
(Scheme 40).119 Under these conditions it was proposed that 14 and 22 form a symmetric 
diphenyliodonium salt in situ. 
 
Scheme 40 Direct C2-arylation of tryptophan with 14 and 22. 
Replacing aryliodonium salt 22 with catalytic quantities of Cu(OAc)2 allowed for moderate 
to high yields of the desired arylated products to be obtained when using a range of 
arylboronic acids (Scheme 41), while maintaining a mild reaction temperature. In this 
protocol atmospheric oxygen functions as the terminal oxidant for the copper(II) salt. 




Scheme 41 Direct C2-arylation of tryptophan using a Pd/Cu catalytic system. 
This latter methodology was also exemplified on two tryptophan-containing peptides, 
dipeptide 121 and hexapeptide 123, affording excellent conversion to the desired arylation 
products under similarly mild conditions (Scheme 42). 
 
Scheme 42 Direct arylation of di- and hexapeptides using a Pd/Cu catalytic system. 
More recently, Ackermann and co-workers have demonstrated the room temperature direct 
arylation of a protected Ala-Trp-Gly tripeptide 125 using a range of symmetric 
diaryliodonium salts, drawing comparisons with the in situ formation of such species in the 
methodology shown in Scheme 40. Application of catalytic Pd(OAc)2 in glacial acetic acid 
facilitated generation of a series of functionalised tripeptides in moderate to high yields 
(Scheme 43). This protocol was exemplified with tryptophan-containing peptides to 
selectively install a phenyl group at the C2 position of the tryptophan residue. Interestingly 
the methodology described in Scheme 43 was also shown to proceed effectively in water, 
albeit with reduced yields of the desired products, with a slightly extended reaction time (to 
24 h).120 




Scheme 43 Direct arylation of a tryptophan-containing tripeptide using a diaryliodonium salt. 
Earlier work from the Ackermann group had demonstrated that the symmetric 
diaryliodonium salt 132 can function as an effective metal-free arylating reagent for 
engineered C3-substituted indoles incorporated within non-natural peptidic scaffolds. In 
DMF at 100 °C, C2-arylation of the synthetic indole proceeded with remarkably high 
selectivity in the presence of a tryptophan residue; this was ascribed to the relative proximity 
of the pivotal amide functionalities, i.e. the length of the carbon chain linker adjacent to the 
indole moiety. An example of this bioorthogonality was exemplified using hexapeptide 133 
as outlined in Scheme 44. 
 
Scheme 44 Selective metal-free arylation of a synthetic C3-substituted indole. 
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2.2 Development of Diaryliodonium Salt Conditions 
2.2.1 Method Development 
The two sets of reaction conditions previously developed within the Fairlamb group119 were 
the first demonstration of low temperature (40 °C) direct arylations of tryptophan, however 
despite the mild conditions and synthetically useful yields obtained, some potential 
drawbacks can be identified. Addition of multiple equivalents of boron- and iodine-
containing arylating reagents severely impacts the atom economy and mass intensity of the 
process in Scheme 40 (this can be quantified using green metrics, vide infra). Addition of a 
second transition metal (copper) in the conditions shown in Scheme 41 is similarly 
undesirable. With these factors in mind, a focus was placed on investigating the role of the 
proposed oxidant in these systems, with the primary aim of identifying efficient and 
sustainable synthetic protocols. Protected tryptophan 74 was accessed in two high-yielding 
steps from commercially available ʟ-tryptophan 73 using the method of Taylor and co-
workers (Scheme 45).121 
 
Scheme 45 Synthesis of N-Ac, O-Me tryptophan 74. 
1H NMR spectroscopic analysis of 74 in CDCl3 confirmed the presence of the C-terminus 
methyl ester at δ 3.70 ppm and N-terminus amide doublet at δ 6.03 ppm (3JH–H = 8.0 Hz) and 
singlet at δ 1.95 ppm. Retention of the indole NH is seen as a broad singlet due to exchange 
on the NMR timescale at δ 8.27 ppm. The C-2 proton at δ 6.97 ppm is observed as a doublet 
3JH–H = 2.5 Hz coupling to the indole NH; likely this coupling is not observed on the indole 
NH due to the aforementioned signal broadening. A doublet of triplets at δ 4.96 ppm can be 
assigned as the enantiomeric proton, which demonstrates 3JH–H = 8.0 Hz coupling to the amide 
NH and 3JH–H = 5.0 Hz coupling to the adjacent CH2 group. These protons are inequivalent 
in their coupling to the enantiomeric proton however and so give rise to two diastereotopic 
signals, which overlap to give the misleading appearance of a complex multiplet, even more 
so due to the significant roofing observed. Correct assignment however shows a doublet of 
doublets at δ 3.35 ppm and another doublet of doublets at δ 3.30 ppm, each with 3J H–H = 5.0 
Hz and 2J H–H = 15.0 Hz (Figure 12). 




Figure 12 1H NMR spectrum of 74 (400 MHz, CDCl3). 
With 74 in hand, an analogous experiment to that shown in Scheme 40 was performed using 
d5-PhB(OH)2 (d5-14) to evaluate the nature of the arylating agent in this system i.e. whether 
this species was derived from PhB(OH)2 14, PhI(OAc)2 22 or both. ESI–HRMS analysis of 
this reaction indicated an approximately 1:1 mixture of H- and D-labelled products were 
formed, providing convincing evidence for the formation of the proposed81 symmetrical 
[Ph2I]+ species in situ (Scheme 46). Importantly this demonstrates the non-innocent role of 
PhI(OAc)2 22, often proposed to act as a simple oxidant, in this system. 
 
Scheme 46 Deuterium-labelling experiment in the direct arylation of tryptophan. 
This non-selective donation presents an issue for the introduction of substituted aromatic 
groups, so an alternative arylation strategy was sought. Replacing 22 with Cu(OAc)2 
(Scheme 41)119 circumvented this issue, but during attempts to functionalise peptides 136 
and 138 significant quantities of aromatic oxidation were noted in this Pd/Cu catalytic 
system. HPLC–MS analysis of the reaction of tripeptide 136 under these conditions 
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demonstrated complete loss of starting material, but also revealed the formation of 
dihydroxylated and diarylated side products, in addition to the desired arylation product 137. 
When these conditions were applied to tetrapeptide 138, similar dihydroxylation side 
products were observed in addition to the desired arylation product 139 (Scheme 47). Copies 
of the HPLC–MS chromatograms are provided in Appendix 4. 
 
Scheme 47 Side product formation in peptides susceptible to aromatic oxidation.  
Given the efficacy of this protocol for the selective functionalisation of other peptides 
(Scheme 42),119 a terminal alanine residue neighbouring tryptophan was proposed to be 
crucial in affecting the selectivity of the reaction in Scheme 47, in conjunction with the use 
of copper(II). 
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Free C-terminus alanines have been shown to form stable complexes with copper (II),122 
while Delboni and co-workers have published the single crystal structure of a tryptophan-
glycine copper(II) complex (Figure 13), which demonstrates the ability of free C-termini 
adjacent to tryptophan residues to coordinate copper(II).123 It is proposed therefore that such 
species are responsible for the observed hydroxylation of the arylation products in Scheme 
47. 
 
Figure 13 Crystal structure of (ʟ-tryptophyl-glycinato) copper(II). Reprinted from Inorg. Chim. Acta 
2001, 312, 133–138. Copyright 2001, with permission from Elsevier. 
This over-oxidation confirms that while addition of copper(II) as a co-catalyst facilitates high 
conversion to the desired aryltryptophans, it has limitations when applied to more challenging 
substrates. It was hypothesised that the ability to utilise a single arylating agent without 
requiring additional transition metal co-catalysts would provide a suitable solution to the 
drawbacks outlined above. The observation that in situ [Ph2I]+ species can prove effective in 
this type of transformation (Scheme 40) led to examination of pre-synthesised asymmetric 
diaryliodonium salts, where a non-transferable ‘dummy group’ could be used to generate 
arene selectivity in the products (vide supra). The simple [PhMesI]OTf salt 140 was therefore 
synthesised in a high-yielding one-pot process from mesitylene 140 and 22 using the method 
reported by Gaunt and co-workers (Scheme 48).124 
 
Scheme 48 Synthesis of [PhMesI]OTf salt 140. 
When 140 was applied to the arylation conditions shown in Scheme 40, in place of 14 and 
22 the desired arylation product 75 was obtained with a yield of 65%. Optimisation of the 
reaction conditions demonstrated that full conversion of starting material 74 could be 
achieved after 16 h at 25 °C in ethyl acetate (Table 5, Entry 5). Other solvents demonstrated 
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to be incompatible with this chemistry were; acetonitrile, acetone, DCM, DMF, DMSO, 1,4-
dioxane and water, all which provided no conversion to the desired product 75 (see Chapter 
6 for details). 
Table 2 Optimisation of direct arylation of tryptophan using [PhMesI]OTf 140.a 
 
Entry Solvent Conv. to 75b (yield)c / % Conv. to 142b (yield)c / % 
1 AcOHd 70 (65) 0 
2 MeOH 12 0 
3 EtOH 15 0 
4 iPrOH 47 3 
5 EtOAc 91 (85) 9 (3) 
6 EtOAce, f 50 10 
a All reactions conducted with 74 (50 mg, 0.192 mmol, 1 eq.), 140 (181 mg, 0.384 mmol, 2 eq.), 
Pd(OAc)2 (2 mg, 9.6 µmol, 5 mol%) and solvent (5 mL), unless otherwise specified. b As determined 
by 1H NMR spectroscopic analysis of the crude reaction mixture following an aqueous workup. c 
Following purification by silica gel flash column chromatography. d Reaction conducted at 40 °C. e 
Using 143 (0.384 mmol, 2 eq.) in place of 140. f 40% remaining starting material. 
Removal of the acidic conditions previously required, in addition to complete substrate 
conversion at 25 °C, meant that this protocol (Table 2, Entry 5) provided distinct benefits 
over the previous methodologies for generation of 2-phenyltryptophan 75. In addition to the 
desired phenylated product 75 however, a small quantity of mesityled product 142 was 
formed from partial addition of the sterically-hindered mesityl component of iodonium salt 
140. Attempts to improve upon this through use of the more sterically-demanding tri-iso-
propylphenyl (TRIP) dummy group (143) failed however, as this substrate lowered both the 
reactivity of the system and selectivity for the desired product 75 (Table 2, Entry 6). A small 
counter-ion screen was also performed which confirmed the efficacy of the triflate counter-
ion used above (Table 3). 
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Table 3 Counter-ion screen for asymmetric [PhMesI]X salts in the direct arylation of tryptophan 74.a 
 
Entry Counter-ion (X) Conv. to 75b / % Conv. to 142b / % 
1 −OTf (140) 91 9 
2 −BF4 (144) Trace Trace 
3 −PF6 (145) 65 13 
4 −SbF6 (146) 64 10 
a All reactions conducted with 74 (50 mg, 0.192 mmol, 1 eq.), [PhMesI]X (0.384 mmol, 2 eq.), 
Pd(OAc)2 (2 mg, 9.6 µmol, 5 mol%) and EtOAc (5 mL). b As determined by 1H NMR spectroscopic 
analysis of the crude reaction mixture following an aqueous workup. 
It was during development of these conditions that the selective metal-free arylation protocol 
of non-natural indoles in the presence of tryptophan residues using [Ar2I]+ salts (Scheme 44) 
was published by Ackermann and co-workers.125 Several experiments were performed to 
evaluate these conditions when applied to tryptophan 74, in the presence and absence of Pd 
and/or air (Table 4). These tests established that no reaction is observed without addition of 
Pd(OAc)2 (5 mol%) and that air has no appreciable effect on this reaction, which correlates 
with the observations of Ackermann et al.  
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Table 4 Evaluation of Ackermann conditions125 in the direct arylation of tryptophan.a 
 
Entry Pd(OAc)2 / mol% Air
 Conv.b / % 
1 0 No 0 
2 0 Yes 0 
3 5 No 93 
4 5 Yes 93 
a All reactions conducted with 74 (65 mg, 0.25 mmol, 1 eq.), 132 (170 mg, 0.375 mmol, 1.5 eq.) and 
DMF (2 mL). Where indicated, Pd(OAc)2 (2 mg, 9.6 µmol, 5 mol%) was added. b As determined by 
1H NMR spectroscopic analysis of the crude reaction mixture following an aqueous workup. 
2.2.2 Application to Peptides 
With these optimised arylation conditions (Table 2, Entry 12) in hand, more complex, 
biologically or medicinally relevant substrates were investigated in order to demonstrate the 
applicability of this methodology. Second-generation derivatives of the potent anti-cancer 
compound Sansalvamide A were thus identified, as this macrocyclic pentapeptide has unique 
reactivity against several different forms of cancer. It also displays interesting configurational 
requirements for biological activity, as modification of the side chains and optical 
configurations of the amino acid residues in this compound allows for targeting of specific 
chemotherapeutic benefits, for different mutagenic cell lines.126 Following the method of 
McAlpine and co-workers, a simple N-Boc protection/deprotection strategy was employed 
to synthesise the linear tryptophan-containing pentapeptide Boc-LeuLeuValLeuTrp-OMe 
158, itself a precursor to the macrocyclic final product 147 shown in Figure 14. This was 
accomplished by first preparing the free-amine tripeptide H2N-ValLeuTrp-OMe 153 
(Scheme 49) and free-acid dipeptide Boc-LeuLeu-OH 157 (Scheme 50), before a final 
coupling reaction to generate 158 in synthetically useful yields (Scheme 51). 




Figure 14 Tryptophan-containing Sansalvamide A derivative 147. 
 
Scheme 49 Synthesis of free-amine tripeptide precursor 153.  




Scheme 50 Synthesis of free-acid dipeptide precursor 157. 
 
Scheme 51 Amide coupling to generate linear pentapeptide 158. 
The optimised arylation conditions shown in Table 2, Entry 12 were then applied to 158 in 
an attempt to generate the arylated pentapeptide product 159 (Scheme 52). Note that for this 
complex peptide the Pd catalyst loading was increased to 30 mol%. 
 
Scheme 52 Direct arylation of linear pentapeptide 158. 
TLC analysis of the crude mixture from this reaction indicated some conversion, attempts at 
purification were however unsuccessful, although ESI–HRMS analysis of the crude mixture 
did confirm approximately 20% conversion to the desired arylation product 159 ([M+Na]+ 
855.4980). Due to the purification difficulties of this complex peptide, it was decided to first 
apply the arylation methodology to more modest peptide targets as a proof of principle. With 
this in mind the intermediate dipeptide 149 was subjected to the previously optimised CuII 
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co-catalysed conditions shown in Scheme 41, which had been proven to work effectively on 
other peptides (Scheme 53). 
 
Scheme 53 Direct arylation of Boc-dipeptide 149 using CuII co-catalysis. 
Surprisingly, only 31% of the desired arylation product 160 could be obtained, contrasting 
with the complete conversion seen when using 74 as a substrate. It was hypothesised that the 
change in protecting group (N–Boc for N–Ac) may have been the cause of this discrepancy, 
so the analogous N–Boc, O–Me protected tryptophan 161 was synthesised, before being 
tested under the optimised conditions shown in Table 2, Entry 12 (Scheme 54). 
 
Scheme 54 Synthesis and attempted direct arylation of N–Boc tryptophan 161. 
As Scheme 54 shows, under these conditions only a trace of the desired arylation product 
162 could be observed by TLC or ESI–HRMS and this could not be isolated, effectively 
demonstrating the pronounced effect of the change in protecting group on the efficiency of 
the arylation protocol; it is likely that this is rooted in steric effects due to the increased size 
of N–Boc over N–Ac. The synthesis of the N–Ac analogue of dipeptide 149 was thus 
attempted from 154 and 135 (Scheme 55). 
 
Scheme 55 Synthesis of N–Ac Leu–Trp dipeptide 164. 
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While the initial N–Ac protection of ʟ–Leucine 154 proceeded in good yield, attempts at 
coupling this to 135 resulted in an inseparable mixture of 135 and 164. While significant 
effort was expended to resolve this issue, unfortunately the desired dipeptide 164 could not 
be purified. It was therefore decided to switch the protecting group from N–Ac to N–Tfa, 
which satisfies the steric requirements, provides a useful 19F NMR handle and is easily 
removed by aqueous sodium hydroxide.127 This switch to N–Tfa produced none of the 
synthetic difficulties found with the N–Ac protecting group and three substrates were 
protected according to literature procedures (Scheme 56).128 
 
Scheme 56 Synthesis of: a) N–Tfa tryptophan 92, b) Tfa Leu–Trp 167, c) Tfa Gly–Trp 170. 
The substrates shown in Scheme 56 were then subjected to the arylation conditions outlined 
in Table 2, Entry 12. This provided the desired arylation products in moderate to good yields, 
thus demonstrating the utility of this protocol when applied to small tryptophan-containing 
peptides (Scheme 57). These conditions were also successfully applied to peptides 136 and 
138, which had proven problematic with the Cu-containing conditions shown in Scheme 41, 
affording the desired arylation products 137 and 139 in useful conversions (Scheme 58). 




Scheme 57 Arylation of a) N–Tfa tryptophan 92, b) Tfa Leu–Trp 167, c) Tfa Gly–Trp 170. 
 
Scheme 58 Arylation of peptides susceptible to dihydroxylation using a diaryliodonium salt. 
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2.3 Development of Aryldiazonium Salt Conditions 
2.3.1 Method Development and Scope 
Despite the general applicability of these methods for the generation of 2-aryltryptophans, 
the limitations highlighted above meant that efforts were redirected towards identifying 
alternative arylating conditions. Furthermore, the generation of stoichiometric byproducts 
such as iodoarenes complicates product purification, hugely limits the efficiency and 
increases the mass intensity of any given process. With these factors in mind, it was 
hypothesised that a substrate containing a single aryl group, which can be readily 
functionalised with a range of chemical moieties, would provide an ideal coupling partner. 
The use of aryldiazonium salts was therefore investigated as these bear some useful 
similarities to diaryliodonium salts, in terms of both their structure and reactivity (see Chapter 
1).91 To begin these studies, several aryldiazonium tetrafluoroborate salts were readily 
synthesised in an oxidative process from the corresponding commercially available 
anilines,129 accessing the desired products in low to moderate yields (Table 5a). Following a 
subsequent review of the literature, an improved synthesis of these salts published by 
Goossen and co-workers was found, which provided access to the same salts in excellent 
yields (Table 5b).130 
SAFETY NOTE: Aryldiazonium salts can display both thermal and shock sensitivity which 
can result in violent explosion, driven by the entropically favourable loss of dinitrogen. 
Extreme care must therefore be taken when considering syntheses either generating or 
employing such reagents. The nature of the counter anion used is critical to the stability of 
these species; halide anions which are often found in the literature should be avoided at all 
costs as these display very poor stability. Tetrafluoroborate and tosylate anions such as those 
used in the entirety of this project display vastly increased thermal and shock sensitivity.93 
All of the aryldiazonium salts used in this project and others131,132 were stored at −18 °C over 
a period of many months and no decomposition was ever observed. The safe use of 
aryldiazonium salts has been demonstrated extensively,106 with in situ formation from the 
corresponding anilines,107,108 often coupled with flow technology,104,105 a common approach 
used to limit handling of the crystalline salts of these species.  
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Table 5 Synthesis of aryldiazonium tetrafluoroborates. 
 
a Reaction performed by A. Hammarback. b Reaction not performed. c Reaction performed by T. 
Sheridan. 
When tryptophan 74 was treated with one equivalent of benzenediazonium salt 48, in the 
presence of catalytic Pd(OAc)2 in ethyl acetate, the desired arylation product 75 was obtained 
in quantitative yield after 16 h at room temperature (typically 20 °C). These conditions were 
then extended across the range of diazonium salts shown in Table 5, to generate several 
functionalised 2-aryltryptophans, the results of which are shown in Table 6. 
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Table 6 Scope of aryldiazonium tetrafluoroborate salts for the direct arylation of tryptophan 74.a 
 
a All reactions conducted with 74 (50 mg, 0.192 mmol, 1 eq.), aryldiazonium salt (0.192 mmol, 1 eq.), 
Pd(OAc)2 (2.2 mg, 9.6 μmol, 5 mol%) and EtOAc (5 mL) at RT (ca. 16–23 °C). b Reaction time 
extended to 24 h. 
Alkylated, electron-donating and halide-containing examples provided good to excellent 
yields, while the sterically encumbered 1-napthyl and 2,4,6-trimethylphenyl salts also proved 
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effective (giving 206 and 142, respectively). The quantitative synthesis of the biphenyl-
substituted product 207 provided access to a product exhibiting fluorescence at long-wave 
UV light (excitation at 365 nm), markedly distinct from that of the single arene-containing 
examples or the parent compound 74. Additionally, the tolerance of the synthetic protocol 
towards halogenated arenes provides a useful orthogonality to further functionalisation to 
produce, for example, other biaryl derivatives. It is important to note that aryldiazonium salts 
containing strongly electron-withdrawing substituents (54 and 204) were not tolerated by this 
arylation protocol, an observation also made by Correia and co-workers102 who describe the 
formation of a diazo side product generated by the nucleophilic attack of a C2-arylated indole 
on electron-deficient aryldiazonium salts. 
Peptides 136 and 138 which had previously demonstrated oxidative sensitivity to the CuII-
mediated reaction conditions (Scheme 47) were also subjected to the optimised 
aryldiazonium salts conditions, affording the desired arylation products 137 and 139 in 
excellent conversion, with no evidence of the undesired aromatic dihydroxylation (Scheme 
59). The solvent was switched to iso-propanol and the catalyst loading increased to ensure 
quantitative conversion of these challenging polar substrates. 
 
Scheme 59 Selective functionalisation of peptides using aryldiazonium salts. 
During investigation of the mechanism for this reaction in a related project,131 it was found 
that addition of catalytic quantities of acid had a profound impact, removing the observed 
induction period and thus accelerating conversion to product. When using 5 mol% of p-
toluenesulfonic acid (TsOH), the reaction reached completion within ca. one hour at 37 °C, 
compared to two hours without acid (at 37 °C). As catalytically active cyclometallated Pd–
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OTs complexes have been reported by both Brown133 and Bedford134 et al. (Figure 15), 
complex 215 was prepared according to literature procedures (Scheme 60). 
 
Figure 15 Cyclometallated Pd–OTs complexes reported by (a) Brown et al. and (b) Bedford et al. 
 
Scheme 60 Synthesis of Pd(OTs)2(MeCN)2 215. 
Complex 215 was then tested in the arylation protocol detailed above in place of Pd(OAc)2 
(Table 6), where it was found that the catalyst loading could be decreased to 1 mol%, and 
still provide the desired arylation product 75 in quantitative yield after 16 h at room 
temperature (Scheme 61). 
 
Scheme 61 Direct arylation of tryptophan 74 at 1 mol% Pd loading. 
An experiment was also performed to demonstrate that sub-stoichiometric quantities of 
MeCN were not inhibiting the reaction (Scheme 62). 
 
Scheme 62 Effect of MeCN on direct arylation of tryptophan 74 using aryldiazonium salts. 
The scope of the arylation protocol using this catalytic system was also explored (Table 7). 
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Table 7 Scope of aryldiazonium tetrafluoroborate salts for the direct arylation of tryptophan 74 
using a Pd–OTs catalytic system.a 
 
a All reactions conducted with 74 (50 mg, 0.192 mmol, 1 eq.), aryldiazonium salt (0.192 mmol), 
Pd(OTs)2(MeCN)2 (5.1 mg, 9.6 µmol, 5 mol%) and EtOAc (5 mL) at RT (ca. 16–23 °C). b Conversion 
when using 2.5 mol% catalyst, as determined by 1H NMR spectroscopic analysis of the crude reaction 
mixture following an aqueous workup. c Conversion when using 1 mol% catalyst, as determined by 
1H NMR spectroscopic analysis of the crude reaction mixture following an aqueous workup. 
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The scope of the arylation protocol using the catalytic system in Scheme 61 was explored 
initially (1 mol% Pd), however several analogues displayed decreased activity at catalyst 
loadings below 5 mol%, so 5 mol% Pd and a reaction time of 16 hours was used for the 
majority of substrates tested (Table 7). This provided the desired products in isolated yields 
comparable to those obtained using the previous reaction conditions (Table 6). 
2.4 Product Characterisation 
1H NMR spectroscopic analysis of 75 in CDCl3 confirmed the loss of the diagnostic C-2 
proton from δ 6.97 ppm, with retention of the indole NH as a broad singlet at δ 8.20 ppm. 
The additional aromatic signals are observed as several unresolvable multiplets between δ 
7.60–7.34 ppm. The C-terminus methyl ester has undergone an upfield shift from δ 3.70 ppm 
to δ 3.29 ppm, as has the N-terminus amide doublet at δ 5.79 ppm (3JH–H = 8.0 Hz) and singlet 
at δ 1.66 ppm. A similar upfield shift of the enantiomeric proton at δ 4.84 ppm (dt, 3JH–H = 
8.0, 5.0 Hz) can also be observed. Conversely, the two diastereotopic protons have undergone 
a downfield shift, to δ 3.55 ppm and δ 3.52 ppm. These signals are even more misleading 
than before due to a substantial roofing effect, resulting from a small difference in chemical 
shift (δa−δb = 0.03 ppm), rendering the 2J H–H = 15.0 Hz coupling almost impossible to observe 
(Figure 16). 
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Single crystal X-ray diffraction structures of 75, 142 and 210 were obtained (Figure 17–
Figure 19); the absolute stereochemistry of 210 was determined and the product confirmed 
as S (identical stereochemistry to the ʟ-tryptophan starting material 74). These structures all 
demonstrate that the installed aromatic group lies orthogonal to the indole ring in the solid 
state, which is presumably the ground-state configuration given that the single crystals grown 
to provide these structures were obtained by simple evaporation under ambient conditions. 
Presumably the aromaticity of these compounds is lessened as a result of the out-of-plane 
configuration across their conjugated ring systems. 
 
Figure 17 Single crystal X-ray diffraction structure of 75. Thermal ellipsoids shown with 50% 
probability and hydrogen atoms removed for clarity. Selected bond lengths (Å): C(3)–C(4): 1.500(3), 
C(4)–C(11): 1.375(3), N(2)–C(11): 1.388(2), C(11)–C(12): 1.475(3). Selected bond angles (°): C(4)–
C(11)–C(12): 131.75(18), N(2)–C(11)–C(12): 118.71(17). 
  




Figure 18 Single crystal X-ray diffraction structure of 142. Thermal ellipsoids shown with 50% 
probability and hydrogen atoms removed for clarity. Selected bond lengths (Å): C(7)–C(9): 1.506(3), 
C(7)–C(8): 1.378(3), N(1)–C(8): 1.378(3), C(8)–C(12): 1.484(3). Selected bond angles (°): C(7)–
C(8)–C(12): 128.9(2), N(1)–C(8)–C(12): 121.8(2). 
 
Figure 19 Single crystal X-ray diffraction structure of 210. Thermal ellipsoids shown with 50% 
probability and absolute stereochemistry established by anomalous dispersion. Selected bond lengths 
(Å): C(7)–C(15): 1.500(2), C(7)–C(8): 1.369(3), N(1)–C(8): 1.382(3), C(8)–C(9): 1.475(3), C(12)–
Cl(1): 1.743(2). Selected bond angles (°): C(7)–C(8)–C(9): 131.44(17), N(1)–C(8)–C(9): 119.04(16). 
Chapter 2: Direct C–H Bond Functionalisation of Tryptophans and Peptides 
89 
 
2.5 Green Metrics 
For the tryptophan analogues where complete substrate conversion was recorded the desired 
arylation product could be isolated without the need for silica gel flash column 
chromatography, which provided a distinct practical benefit over the equivalent 
diaryliodonium salt methodologies, in addition to the selective formation of one arylation 
product. This advantage is reflected through calculation of some simple green metrics, 
comparing the two novel protocols detailed in this chapter with the Fairlamb group’s 
previously developed conditions, which were produced using the Chem21 unified metrics 
toolkit for the simple phenyl derivative 75 (Table 8).135 
Table 8 Comparison of mass-based metrics for several direct arylation conditions.a 
Entry 1 2 3 4 





Yield / % 56 93 85 100 
Temp. / °C 40 40 25 RT 
Solvent AcOH AcOH EtOAc EtOAc 
AE 48 88 46 74 
RME 16 62 24 74 
OE 33 70 52 100 
MI 6902 4139 4504 602 
a Calculated using the Chem21 unified metrics toolkit.135 AE = atom economy, RME = reaction mass 
efficiency, OE = optimum efficiency, MI = (total) mass intensity. 
In addition to an increase in yield and decrease in reaction temperature from our initial set of 
conditions, several key mass-based metrics have been improved upon. Those conditions 
which utilise hypervalent iodine reagents (Table 8, Entries 1 and 3) have noticeably lower 
values for atom economy (AE), the theoretical maximum efficiency for a transformation. 
While the CuII co-catalysed conditions (Table 8, Entry 2) do not suffer from this, they do 
however require the undesirable addition of a second transition metal (in addition to the 
drawbacks with certain peptides highlighted above). These trends are also observed for the 
reaction mass efficiency (RME), which incorporates both yield and stoichiometry to the 
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simpler AE calculation, thus giving a measure of the observed reaction efficiency as 
compared to the theoretical value provided by AE. This can be rationalised through use of 
the optimum efficiency metric, which directly correlates these two factors, highlighting the 
aryldiazonium salt methodology (Table 8, Entry 4) as the most atom- and mass-efficient 
overall. 
The most striking improvement can be seen in the mass intensity (MI) value, which is an 
order of magnitude lower for the aryldiazonium salt conditions (Table 8, Entry 4) as 
compared to the initial conditions (Table 8, Entry 1). The primary reason for this dramatic 
increase is the removal of purification by flash column chromatography, with other secondary 
effects including the number of equivalents of arylating agent used for each set of conditions. 
Finally, switching the reaction solvent from neat acetic acid to the more benign ethyl acetate 
has a demonstrable health impact, as acetic acid has been ranked as a ‘problematic’ reaction 
solvent by the recently-published Chem21 solvent selection guide136 (while ethyl acetate is 
ranked as ‘recommended’). 
2.6 Conclusion 
Several different and complementary protocols for the direct Pd-mediated C2-arylation of 
tryptophan 74 have been developed and shown to proceed under mild conditions. In order to 
address issues involving undesirable peptidic dihydroxylation in a Pd/Cu co-catalytic system, 
protocols applying electrophilic diaryliodonium salts have been demonstrated to afford high 
conversions when applied to both single tryptophan residues and tryptophan-containing 
peptides. Asymmetric variants of these salts have shown good selectivity, albeit with a small 
amount of undesirable donation of the dummy aromatic component. To address this issue, 
aryldiazonium salts have been successfully applied to this transformation to afford several 
aryltryptophan analogues in excellent yield, in addition to the selective functionalisation of 
two peptides shown to be incompatible with previous reaction conditions. Calculation of 
several key green metrics has shown that these latter conditions also offer a significant 
improvement over previously reported methods in terms of optimum efficiency, mass 
intensity, synthetic utility and selectivity. Use of a Pd–OTs catalytic system has also been 
shown to allow for a significant decrease in catalyst loading in some cases. 
Part of the work described in this chapter has been included in several recent publications 
(see Appendix 1).119,137
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Chapter 3: Direct Arylation Reactions Using 
Heterogeneous Catalysis 
3.1 Background 
The importance of Pd-mediated reactions in organic synthesis is without question, as the 
ability to selectively form carbon–carbon bonds in the presence of other molecular 
functionality is unparalleled in its utility (see Chapter 1). The issue that remains however is 
the elemental sustainability of this rare and precious metal, which increasingly leads to 
prohibitive costs and issues surrounding the criticality of supply chains.138 One solution to 
this problem is to research the potential of mediating selective C–C bond formation by using 
cheaper and more elementally-sustainable first-row transition metals, such as Mn,139,140 
Fe141,142 or Co.143-145 An alternative approach is to determine whether current Pd catalysts can 
be used more effectively, by recycling the precious metal from each reaction and preventing 
it from entering waste streams.37-40 Central to this latter approach is to understand that many 
ubiquitous Pd (pre)catalysts often display heterogeneous-type catalytic behaviour, typically 
through speciation to form higher-order Pd colloids or nanoparticles under commonly-found 
experimental conditions. This is evident in both Pd-mediated cross-coupling and more 
recently in C–H bond functionalisation reactions; the activity of pre-formed PdNP catalysts 
can therefore be evaluated and compared to their in situ counterparts in such reactions.57 
Studies by the Fairlamb group on the direct arylation of benzoxazole 216 and benzothiazole 
218 under Pd/Cu-catalysed reaction conditions demonstrated a significant deleterious air 
effect when Pd(OAc)2 was used as a catalyst (Scheme 63).57 
 
Scheme 63 Direct arylation using Pd(OAc)2 and PVP–Pd of a) benzoxazole 216 and b) 
benzothiazole 218. 
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TEM analysis of the reaction mixtures demonstrated that the nanoparticles generated from 
Pd(OAc)2 were larger and more varied in size under Schlenk conditions, suggesting that these 
larger particles were more active under the reaction conditions. If the pre-synthesised 
nanoparticle catalyst PVP–Pd 13 was applied in place of Pd(OAc)2 however, rigorous 
exclusion of air (under typical Schlenk conditions) was found to be no longer necessary to 
achieve equivalent conversion to product. The PdNPs obtained from this catalyst are however 
much smaller (ca. 2 nm) than those formed from Pd(OAc)2 under air-free conditions (ca. 6 
nm), suggesting that the PVP polymer may have prevented oxidative leaching in this 
example. A long-term study on the stability of PVP–Pd catalysts by McGlacken et al. 
concludes that low-index particles display preferential susceptibility to oxidation on their 
high-energy facets, such as the (110) facets found on nanocubes. Correspondingly, octahedral 
particles display greater stability as they contain mostly lower-energy (111) facets. 
Conversely particles containing high-index surfaces, such as concave nanocubes, displayer 
superior stability due to stronger chemisorption to the PVP polymer.146 
Sanford’s reaction conditions for the direct arylation of indoles with Pd(OAc)2, using a 
mixture of 14 and 22 in acetic acid,81 were also observed by Fairlamb and co-workers to 
produce visible PdNPs within seconds of substrate addition. This discernible formation of 
Pd0 contrasts with the PdII/IV catalytic manifold proposed to operate in this system, although 
such precipitates could simply exist as a catalyst deactivation pathway. If the nominally 
heterogeneous catalyst PVP–Pd 13 was applied in place of Pd(OAc)2 however, a significant 
quantity of the desired arylation product 34 was formed (Scheme 64), providing evidence for 
Pd0/II catalysis.57 
 
Scheme 64 Direct arylation of N-methylindole using Pd(OAc)2 and PVP–Pd 13. 
When analogous examination was applied to the direct arylation of tryptophan 74 using 
similar conditions, rapid propagation of PdNPs was again observed to occur within minutes, 
presumably concomitant with substrate turnover. Importantly, an aliquot taken from this 
reaction and analysed by TEM demonstrated the presence of PdNPs of ca. 2 nm in size. When 
the nanoparticulate catalyst PVP–Pd 13 was again used in place of Pd(OAc)2 under otherwise 
identical conditions, an equivalent yield of isolated product 75 was obtained, demonstrating 
the utility of nominally heterogeneous Pd catalysts in this manifold (Scheme 65).  




Scheme 65 Direct arylation of tryptophan 74 using Pd(OAc)2-derived and supported PdNPs. 
While the PVP–Pd catalyst 13 used in the examples above demonstrates excellent versatility 
and reproducibility in terms of its nanoparticle size and morphology, it could be argued that 
bespoke catalysts such as this will always have an intrinsically lower utility than those with 
widespread commercially availability, particularly within time-critical industries such as 
drug discovery. This leads to the conclusion that research efforts should be directed towards 
the re-appropriation of more commonly available heterogeneous Pd catalysts for direct C–H 
bond functionalisation chemistry. Palladium supported on activated carbon (Pd/C), widely 
used as a heterogeneous hydrogenation catalyst for many years, has also attention for its 
utility in the formation of carbon–carbon bonds in cross-coupling catalysis.37-40 Glorius and 
co-workers have recently described the use of this catalyst for the direct arylation of 
benzo[b]thiophenes with aryl chlorides, to afford a range of C3-arylated products with 
excellent regioselectivity (Scheme 66).147 
 
Scheme 66 Direct C3-arylation of benzo[b]thiophenes with aryl chlorides using Pd/C. 
Several tests for heterogeneous catalysis20 were performed and no active homogeneous Pd 
species could be detected under the reaction conditions; rapid stirring was also found to be 
critical to ensure good conversion to product, which is often suggestive of heterogeneous 
catalysis. Several nominally homogeneous Pd sources such as Pd(OAc)2 proved able to 
catalyse this reaction, although fascinatingly these demonstrated a complete switch in 
regioselectivity to form exclusively the C2-arylated products. Subsequent development by 
the same group on the arylation of thiophenes, benzo[b]thiophenes and other related 
heterocycles demonstrated that a switch from aryl chlorides to diaryliodonium salts allowed 
for much milder conditions to be applied (Scheme 67).148 




Scheme 67 Direct arylation using Pd/C of a) thiophenes and b) related heterocycles. 
The same heterogeneity tests as in their previous work were performed and again these 
demonstrated evidence of heterogeneous catalysis, although poor catalyst recyclability was 
also observed which suggested that Pd leaching likely occurred under these oxidising 
conditions. Pd leaching is also suggested as the source of catalytically active palladium in 
later work from the same group, which detailed the direct arylation of triphenylene 220, 
naphthalene 221 and other polyaromatic hydrocarbons (PAHs) using Pd/C. In many of these 
examples, functionalisation of the most hindered C–H bond typically occurred, giving 
generally high α:β selectivity in the products obtained (Scheme 68).149 
 
Scheme 68 Direct arylation of PAHs using Pd/C including a) triphenlyene 220 and b) naphthalene 
221. 
The relevance of higher-order Pd species in C–H bond functionalisation processes and the 
activity of pre-synthesised PdNPs encapsulated by a wide variety of supports (including 
Pd/C) in this chemistry has recently been reviewed in detail (see Appendix 1).20 
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3.2 Direct Arylations Using Aryldiazonium Salts 
The mild and atom efficient conditions for the direct arylation of tryptophan 74 using 
aryldiazonium salts previously developed in this project (see Chapter 2) represent a 
synthetically useful method of performing direct arylation reactions, without the 
stoichiometric iodoarene waste usually generated from their electrophilic iodine(III) 
counterparts, diaryliodonium salts. It was hypothesised that combination of these atom 
efficient coupling partners with recyclable heterogeneous Pd catalysis would represent a 
significant improvement in the sustainability of direct arylation processes, as well as 
generating valuable novel methodology. Thus far, the combination of heterogeneous PdNPs 
with aryldiazonium salts has been limited to applications in the Suzuki–Miyaura,97 Heck–
Matsuda98,104 and Stille99 cross-couplings. Initial efforts at developing a general direct 
arylation methodology focused on the attempted reaction of several simple yet medicinally 
relevant nitrogen heterocycles.150 Reaction of indole 45 or N-methylindole 33 with 
phenyldiazonium salt 48 and Pd(OAc)2 at 60 °C afforded a complex mixture of products due 
to violent reaction with 48, so were abandoned as substrates (Table 9, Entries 1 and 2). 
Indazole 222 was unreactive under these conditions, purification of this reaction mixture by 
silica gel column chromatography afforded complete recovery of starting material (Table 9, 
Entry 3). 7-azaindole 223 was unstable under these conditions, so two further reactions were 
performed at reduced temperatures (40 °C and room temperature), which prevented 
decomposition but afforded no conversion of starting material (Table 9, Entry 4). 
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Table 9 Nitrogen heterocycle screening for direct arylation with phenyldiazonium salt 48.a 
 
Entry Substrate Reaction outcome 
1 
 
Complex mixture obtained 
2 
 






Decomposition of starting materialb 
a All reactions conducted with substrate (0.30 mmol, 1 eq.), 48 (58 mg, 0.30 mmol, 1 eq.), Pd(OAc)2 
(3.4 mg, 0.015 mmol, 5 mol%) and EtOAc (3 mL) at 60 °C for 22 h. b Analogous reactions of this 
substrate at 40 °C and RT showed no conversion of starting material. 
In an attempt to address the lack of reactivity of indazole 222, the free NH group was 
protected according to literature conditions151,152 using methyl iodide and base, providing the 
desired methyl indazole 224 in good yield (Scheme 69). 
 
Scheme 69 Methyl protection of indazole 222. 
224 was then subjected to the conditions described in Table 9, Entry 3, but no conversion of 
starting material was observed (Scheme 70). 




Scheme 70 Attempted direct arylation of 224. 
Carbonyl-containing protecting groups were proposed as an alternative to methyl protection, 
as these could potentially aid coordination of the Pd catalyst, facilitating C–H bond 
functionalisation. Reaction of 222 with ethyl trifluoroacetate 165 under basic conditions in 
either THF or acetonitrile however afforded no conversion to the desired N-Tfa protected 
indazole 226 (Scheme 71). 
 
Scheme 71 Attempted Tfa-protection of indazole 222. 
Reaction of 222 with Boc2O under basic conditions153 however proceeded smoothly to 
provide a single product by TLC analysis of the reaction mixture. Following purification by 
silica gel column chromatography a clear oil was obtained in a yield of 98%, 1H NMR 
spectroscopic analysis of which subsequently revealed an equal mixture of two species 
(Scheme 72). 
 
Scheme 72 Boc protection of indazole 222. 
One of these two species was confirmed as the desired N-Boc indazole 227 through 
comparison of the 1H NMR signals with literature values, while the other is putatively 
assigned as 228, obtained through isomerisation of the indazole 222 anion following 
deprotonation (Scheme 73). 




Scheme 73 Proposed isomerisation of indazole 222 following deprotonation. 
Reaction of indazole 222 with Ac2O under basic conditions also proceeded smoothly to give 
a single product by TLC analysis of the reaction mixture. Once again however, following 
purification a clear oil was obtained (in a yield of 79%) which 1H NMR spectroscopic 
analysis demonstrated to be a mixture of two products, analogous to those formed in the 
attempted Boc protection (Scheme 74). 
 
Scheme 74 Acetyl protection of indazole 222. 
Following this lack of success with indazole 222, efforts were turned to the remaining 
nitrogen-containing heterocycle, 7-azaindole 223. Reaction of 223 with methyl iodide154 
afforded the methyl protected azaindole 231 in high yield (Scheme 75). 
 
Scheme 75 Methyl protection of 7-azaindole 223. 
The attempted reaction of 231 with phenyldiazonium salt 48 in the presence of Pd(OAc)2 at 
40 °C in ethyl acetate afforded no conversion after 24 h. A switch of solvent to ethanol 
however provided the desired C2-arylation product in 39% conversion, as determined by 1H 
NMR spectroscopic analysis (Scheme 76). 




Scheme 76 Direct arylation of protected azaindole 231 with phenyldiazonium salt 48. 
Application of palladium on activated charcoal or PVP–Pd to this reaction afforded no 
conversion of starting material, even after 40 h at 60 °C (Scheme 77). 
 
Scheme 77 Attempted direct arylation of 231 using heterogeneous Pd catalysts. 
With all attempts at developing a general C–H bond functionalisation methodology to 
combine aryldiazonium salts with heterogeneous Pd catalysts stymied, the specific reaction 
between tryptophan 74 and phenyldiazonium salt 48 (Chapter 2) was examined. When 
palladium supported on activated carbon (Pd/C) was applied in place of the previously used 
Pd(OAc)2 however, no reaction was seen in either ethyl acetate or ethanol at 60 °C (Scheme 
78). 
 
Scheme 78 Attempted functionalisation of tryptophan 74 mediated by Pd/C. 
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3.3 Direct Arylations Using Diaryliodonium Salts 
3.3.1 Simple Nitrogen-Containing Heterocycles 
Due to the lack of success in combining heterogeneous Pd catalysis with atom efficient 
aryldiazonium salt coupling partners, a return to the use of diaryliodonium salts was 
proposed, as there is a greater body of evidence in the literature to suggest that these species 
can be mediated by heterogeneous Pd0 catalysis (vide supra). To begin, the symmetric 
diphenyliodonium tetrafluoroborate salt 233 was synthesised in a one-pot process from 
iodobenzene 1 using the method of Olofsson and co-workers (Scheme 79).155 
 
Scheme 79 Synthesis of diphenyliodonium tetrafluoroborate 233. 
The mild conditions published by Glorius et al. (Scheme 67)148 utilising this species were 
then initially applied to a substrate screen of the same medicinally relevant nitrogen 
heterocycles as used previously,150 the results of which are summarised in Table 10. Note 
that Pd(OAc)2 was used in place of Pd/C for this initial screening. Under these conditions, 
indole 45 was successfully reacted to form the C2-arylated product 234 in moderate yield 
(Table 10, Entry 1). The heterocycles indazole 222 or 7-azaindole 223 were however 
unreactive under these conditions (Table 10, Entries 2 and 3). Pyridazine 235 and 
methylindazole 224 were similarly unreactive, an observation also made when these 
reactions were conducted over 4 days, or in ethyl acetate (Table 10, Entries 4 and 5). The 
methyl-protected azaindole 231 was however cleanly converted to give the C2-arylation 
product 232 in good yield (Table 10, Entry 6). 
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Table 10 Nitrogen heterocycle screening for direct arylation with diaryliodonium salt 233.a 
 


















a All reactions conducted with substrate (0.30 mmol, 1 eq.), 233 (155 mg, 0.42 mmol, 1.4 eq.), 
Pd(OAc)2 (3.4 mg, 0.015 mmol, 5 mol%) and EtOH (1.5 mL) at 60 °C for 22 h. b Where applicable, 
isolated yield following purification by silica gel flash column chromatography is provided. c 
Extension of the reaction time to 4 days showed no conversion of starting material, while analogous 
reactions of these substrates in EtOAc also demonstrated no conversion of starting material. 
Following successful transformation of azaindole 231 mediated by Pd(OAc)2, this substrate 
was then screened against a range of heterogeneous palladium sources to test their efficacy 
in this protocol (Table 11). 
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Table 11 Catalyst screen for direct arylation of azaindole 231.a 
 
Entry Pd catalyst Conv. / %b 
1 Pd/C (5 wt% Pd) 19 
2 Pd/C (10 wt% Pd) 0 
3  Pd/charcoal 100 
4 Pd ‘black’ 0 
5 Pd/CaCO3/Pb (Lindlar catalyst) 3 
6 Pd(OH)2/C (Pearlman’s catalyst) 0 
7 PdO 0 
a All reactions conducted with 231 (40 mg, 0.30 mmol, 1 eq.), 233 (155 mg, 0.42 mmol, 1.4 eq.), Pd 
catalyst (0.015 mmol, 5 mol%) and EtOH (1.5 mL) at 60 °C for 22 h. b As determined by 1H NMR 
spectroscopic analysis of the crude reaction mixture following an aqueous workup. 
Two different forms of palladium supported on activated carbon were tested, each containing 
a different Pd loading. In the first example, a catalyst containing 5% by weight palladium 
supported on activated carbon (Sigma Aldrich, catalogue number 205680) provided modest 
conversion to the desired product 232 (Table 11, Entry 1). Surprisingly, when the analogous 
catalyst containing 10% by weight palladium (Sigma Aldrich, catalogue number 205699) 
was tested, no activity was observed (Table 11, Entry 2). Even more surprisingly, when a 
catalyst containing 5% by weight palladium supported on activated charcoal (Sigma Aldrich, 
catalogue number 75992) was used, complete conversion to the desired product 232 was 
noted (Table 11, Entry 3). The heterogeneous Pd0 catalysts Pd ‘black’ and the Lindlar 
catalyst provided no activity in this reaction (Table 11, Entries 4 and 5), while the 
heterogeneous PdII catalysts Pd(OH)2/C and PdO were similarly unreactive (Table 11, 
Entries 6 and 7). These observations agree with those made by Glorius and co-workers, who 
noted severe incongruities in the activities and yields obtained thereof when utilising Pd/C 
from different commercial sources in this chemistry.148 It is clear that differing manufacturing 
methods and even variances between batches of supposedly identical catalysts have to be 
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seriously considered in these reactions, as they will undoubtedly significantly impact on the 
size and morphology of the resultant Pd particles. 
3.3.2 Biologically Relevant Heterocycles 
With the proof that simple nitrogen heterocycles could be functionalised directly under 
relatively mild conditions, using a combination of heterogeneous palladium and 
diaryliodonium salts, the amino acid tryptophan was examined in order to provide an 
exemplification of this approach for more complex substrates. While commercially available 
Pd catalysts such as Pd/C present many practical advantages, the lack of control over particle 
size and morphology adds a significant element of irreproducibility to syntheses employing 
such catalysts. It was decided therefore that the PdNP catalyst PVP–Pd 13 would be tested 
alongside Pd/C, as its synthesis provides well-controlled, regular nanoparticles typically 
between 2–5 nm in diameter (vide supra).32,33 Simple reduction of PdCl2 with aqueous acid 
in the presence of a (poly)vinylpyrrolidone polymer 12 provides quantitative amounts of a 
well-dispersed nanoparticle catalyst (Scheme 80). 
 
Scheme 80 Synthesis of PVP–Pd 13. 
The nanoparticles are prevented from thermodynamically favourable agglomeration through 
interaction with the amide functionality in the polymer 12, creating a stabilising 
encapsulation effect (Figure 20). 
 
Figure 20 Cartoon schematic of PdNP encapsulation in PVP–Pd 13. 
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Analysis of these polymer-supported particles (8 wt% Pd) was performed by TEM, with 
several images recorded in order to ensure that data representative of the population as a 
whole was used for subsequent analysis. A typical image is shown in Figure 21, which 
indicates that well-defined PdNPs of approximately 3 nm in diameter are encapsulated by the 
PVP, remaining stable in the solid-state after evaporation of the reaction solvent. The images 
obtained all correlate well and have over 68% of the particles lying within the normal 
Gaussian distribution range (mean ± std. dev.). 
 
n = 100, mean = 2.98 nm, std. dev. 0.80, median = 3.00, mode = 3.30 
Figure 21 TEM image and particle size analysis for PVP–Pd 13. 
Protected tryptophan derivative 74 was subjected to the previously optimised conditions for 
direct C–H bond functionalisation using the asymmetric diaryliodonium salt [PhMesI]OTf 
140 (see Chapter 2), with PVP–Pd 13 used in place of Pd(OAc)2; no conversion of starting 
material was observed under these conditions however (Scheme 81). 
 
Scheme 81 Attempted functionalisation of tryptophan 74 with PVP–Pd 13. 
When performing this reaction, it was noted that the PVP–Pd 13 catalysed used had changed 
significantly in both colour and composition since its synthesis, approximately 30 months 
previously. Freshly synthesised this catalyst is a black crystalline solid; the sample used for 
the reaction in Scheme 81 was a greyish powder containing large metallic particles, 
presumably of agglomerated Pd. This implies that this catalyst slowly decreases in stability 
over time when stored at ambient temperature under air, losing its coordination from the PVP 
polymer 12 and forming large unreactive Pd agglomerates, in an oxidative process as 
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suggested by McGlacken and co-workers.146 PVP–Pd 13 was thus freshly synthesised and 
simple visual inspection highlighted the significant changes that had occurred over time 
(Figure 22). This catalyst was used for all of the experiments subsequently detailed in this 
chapter, except where specifically indicated otherwise.  
 
Figure 22 PVP–Pd 13 after approximately 30 months (left) and freshly-synthesised (right).  
While these investigations were ongoing, a preparation of surfactant-free, DMF-stabilised 
PdNPs of approximately 1–1.5 nm in diameter was noted in the literature.59 Recalling the 
high activity of DMF–PdNPs formed in situ in previous work from the Fairlamb group,48,49,57 
it was decided to investigate the potential of this catalyst. Following several attempted 
syntheses, it was found that modifications to the original procedure had to be made in order 
to prepare the DMF–PdNPs 236. Specifically, the reaction had to be carried out in the 
presence of air, performing the reaction under an inert atmosphere led only to the formation 
of visible Pd black; a large reaction headspace was also found to be beneficial, as were low 
levels of amine impurities in the DMF used. DMF–PdNPs 236 were applied to a low 
temperature Stille cross-coupling and were demonstrated to have activity equivalent to that 
of a succinimide-based Pd catalyst in DMF, consistent with the proposal that DMF-stabilised 
particles were forming in situ in this system.156 The synthetic reliability of this catalyst was 
a source of concern however, so two reactions were performed side-by-side under identical 
conditions, using the same glassware and starting materials. These demonstrated 
substantially different outcomes; one reaction produced the intended clear yellow solution of 
DMF–PdNPs 236, while the other resulted in a black particulate suspension (Figure 23). 
These experiments provided a stark indication of the capricious nature of the synthesis of this 
catalyst, so plans to use it for the direct arylation reactions in this chapter were abandoned. 





Figure 23 Synthesis of DMF–PdNPs 236. 
Returning to the direct arylation of tryptophan, it was decided to use a symmetric 
diaryliodonium salt rather than the asymmetric 140, in order to reduce the number of potential 
products from this reaction; unselective donation of the mesityl ‘dummy’ group having been 
previously noted (see Chapter 2). Diphenyliodonium triflate 38 was therefore synthesised in 
a high-yielding one-pot process from iodobenzene diacetate 22 and benzene 237 (Scheme 
82),124 in addition to the tetrafluoroborate salt 233 already synthesised (Scheme 79). 
 
Scheme 82 Synthesis of diphenyliodonium triflate 38. 
A screening of various conditions was then undertaken against tryptophan 74 using 
heterogeneous Pd sources PVP–Pd 13, Pd/C (Sigma Aldrich, catalogue number 205680) and 
Pd/charcoal (Sigma Aldrich, catalogue number 75992), in combination with diaryliodonium 
salts (Table 12). 
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Table 12 Reaction screening for direct arylation of tryptophan 74 with heterogeneous Pd sources.a 
 
Entry Solvent Temp. / °C Pd. catalyst X Conv.b (yield)c / % 
1 EtOAc 37 PVP–Pd 13 −OTf 0 
2 EtOAc 60 PVP–Pd 13 −OTf 0 
3 EtOAc 60 PVP–Pd 13 −BF4 0 
4 AcOH 37 PVP–Pd 13 −OTf 8 
5 AcOH 60 PVP–Pd 13 −OTf 80 
6 AcOH 60 PVP–Pd 13 −BF4 80 
7 AcOH 80 PVP–Pd 13 −OTf 91 
8 AcOH 37 Pd/C −BF4 0 
9 AcOH 60 Pd/C −BF4 100 
10 EtOH 60 Pd/C −BF4 84 
11 EtOH 60 Pd/C −BF4 100 (85)
d 
12 EtOH 60 Pd/charcoal −BF4 100 (98)
d 
a All reactions conducted with 74 (52 mg, 0.20 mmol, 1 eq.), 38 (172 mg, 0.40 mmol, 2 eq.) or 233 
(147 mg, 0.40 mmol, 2 eq.), Pd catalyst (0.01 mmol, 5 mol%) and solvent (2 mL) at 60 °C for 16 h. b 
As determined by 1H NMR spectroscopic analysis of the crude reaction mixture following filtration 
through a silica gel pad using EtOAc. c After purification by silica gel column chromatography. d 
Reaction time extended to 22 h. 
This screening demonstrated that this protocol has a strong temperature dependence, with no 
conversion observed at 37 °C, the temperature at which complete conversion was observed 
when using Pd(OAc)2 (Table 12, Entries 1, 4 and 8). Additionally, no conversion was seen 
in EtOAc, even at elevated temperatures (Table 12 Entries 1–3). No counter-ion effect was 
observed in those examples tested (Table 12, Entries 2–3 and 5–6). The sudden change in 
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reactivity when the protic solvents AcOH or EtOH were applied hints at leaching behaviour 
to generate the active catalytic species, as evidenced by previous studies within the Fairlamb 
group48,49 and others,25 although evidence to contradict this is presented by Glorius and co-
workers.148 All three catalysts tested displayed good reactivity in this transformation, 
although PVP–Pd 13 was arguably less active than Pd/C, providing slightly lower conversion 
after 16 h under otherwise comparable reaction conditions (Table 12, Entries 6 and 9). A 
successful switch from AcOH to the less harmful EtOH was facilitated by an increase in 
reaction time from 16 h to 22 h (Table 12, Entries 9–11). When purification was performed, 
it was noted that in order to obtain isolated yields comparable to the conversion seen by 1H 
NMR spectroscopic analysis of the crude reaction mixture (Table 12, Entries 11–12), care 
had to be taken during workup and purification. The ideal method was found to be filtration 
through a silica gel pad using EtOAc, followed by evaporation of the solvent and direct 
purification by dry-loaded silica gel column chromatography. This effect is believed to result 
from the relatively high quantities of activated carbon in these reaction mixtures potentially 
sequestering some organic reaction products during other workup protocols e.g. filtration 
through Celite™ and/or aqueous washing. 
The acidic conditions shown in Table 12, Entry 6 were also exemplified on two peptides, 
previously functionalised using analogous conditions with Pd(OAc)2 (see chapter 2). High 
conversions to the desired arylation products were seen when using Pd/C, albeit at higher 
temperatures than when using Pd(OAc)2 (Scheme 83). 
 
Scheme 83 Direct arylation of peptides using Pd/C. 
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3.4 Kinetic Studies 
It is clear that when evaluating heterogeneous-like behaviour in Pd catalysis, significant 
differences can be observed not only between different catalysts (vide supra) but also 
between supposedly uniform catalysts, obtained from different suppliers (see work by 
Glorius et al. using Pd/C).147,148 This difference in activity is usually observed in the literature 
merely as a function of isolated yield or more commonly, conversion by GC–MS, used 
primarily as a tool to identify the most effective method of improving conversion under 
otherwise fixed conditions. This manner of evaluating catalytic behaviour however conceals 
a multitude of sins, as the most efficient catalysts may not always be identified in this fashion. 
For example, imagine a direct arylation reaction conducted using Pd catalysis in DMF at 140 
°C. Single variable solvent and temperature screening for this reaction has indicated that 
when using Pd(OAc)2, these conditions provide the desired product in 20% conversion after 
8 hours and 40% conversion after 24 hours. The experimentalists therefore conclude that a 
reaction time of 24 hours is ‘optimal’, and begin their heterogeneous catalyst screening. At 
this point one can propose two potential scenarios for two different Pd catalysts. In the first, 
catalyst A cleanly converts the substrate of choice in 80% conversion within 1 hour, but is 
then deactivated by some other process (such as the elevated temperature causing 
nanoparticle agglomeration and thus loss of activity). No further conversion occurs, so 
measurement of crude reaction conversion by GC analysis after 24 hours indicates that 
catalyst A gives a product conversion of 80%. Meanwhile, catalyst B only reaches 10% 
conversion after 1 hour, but is not deactivated by the reaction conditions so continues to react 
with the substrate at the same rate. After 24 hours therefore, 100% conversion to product is 
observed by GC analysis, catalyst B is declared the most active catalyst and all subsequent 
investigations are performed using this catalyst. From these scenarios, one can infer that 
catalyst A has superior activity in this reaction (in terms of TOF), yet this would have gone 
unnoticed by the experimentalists merely examining the outcome of their reactions by crude 
GC conversion. It may even be the case that catalyst A would have tolerated lower reaction 
temperatures while maintaining its activity. 
Kinetic analysis of novel reactions is therefore of paramount importance in this field,66 
particularly where non-linear kinetic effects often associated with heterogeneous catalysis 
are likely to occur.34,35,157-159 These principles were applied to studying the direct arylation of 
some simple heterocycles using diaryliodonium salts and Pd catalysis using the conditions of 
Glorius and co-workers (vide supra).148 Four Pd catalyst sources were identified which 
provide a useful test of two ubiquitous precatalysts, a supported catalyst and well-defined Pd 
nanoparticulate catalyst, namely: Pd(OAc)2 (>99% purity, Precious Metals Online), 
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Pd2(dba)3·CHCl3 238 (91% purity, based on Ananikov’s method, see Chapters 4 and 6),11 
Pd/C (5 wt%, Sigma Aldrich, catalogue number 205680, lot number 06230AJ-298) and PVP–
Pd 13. These four catalysts were initially applied to the direct arylation of N-methylindole 33 
and the reaction followed by ex situ GC analysis (details provided in Appendix 5) as shown 
in Figure 24. 
 
 
Figure 24 Direct arylation of N-methylindole 33 at 60 °C over 2 h. Fitting to an exponential decay 
equation is shown where appropriate. × = starting concentration of substrate at t = 0. Reactions 
performed by L. Neumann. 
N-methylindole 33 demonstrated high reactivity with all four catalysts tested, especially so 
when using either 13 or 238 as a catalyst; within 5 minutes 72% and 81% conversion of 
starting material was observed, respectively. Line fitting to an exponential decay equation 
for the other catalysts (Pd(OAc)2 and Pd/C) suggests that these reactions are 1st order with 
respect to substrate, although more detailed studies would be required to validate this 
approximation (details provided in Appendix 5). The above kinetic studies were repeated at 
a lower temperature (50°C), in order to provide greater discrimination between the activity 
of these catalysts (Figure 25).  





Figure 25 Direct arylation of N-methylindole 33 at 50 °C over 24 h.  Fitting to an exponential decay 
equation is shown where appropriate. Detailed analysis over the initial 7 hours shown, final 
conversions by GC after 24 h; Pd/C: 83%, PVP–Pd 13: 100%, Pd(OAc)2, 66%, Pd2(dba)3 238: 88%.  
Reactions performed by L. Neumann. 
Once again, 13 and 238 proved to be the most active catalysts for this transformation. It is 
interesting to note that these two catalysts produced similar reaction profiles, which implies 
similarly between the active catalytic species in these examples (see Chapter 4 for other 
evidence of PdNP propagation from Pd2(dba)3·CHCl3 238). Conversely, Pd/C and Pd(OAc)2 
produced wholly different reaction profiles, which were however akin to one another. These 
results suggest that the nanoparticles produced from Pd(OAc)2 and Pd/C are similar, yet 
distinct from the nanoparticles produced by 13 and 238. It may be that PdNPs are not actively 
catalysing this reaction, the active species instead consisting of leached mononuclear/lower-
order Pd species. If this is the case, then perhaps the parallels between catalysts manifests as 
a result of similar leaching rates. It is also interesting to note that of the catalysts tested, only 
PVP–Pd 13 led to complete starting material consumption after 24 h. Despite its relatively 
slow initial rate, Pd/C eventually provides conversion akin to that using 238, which is much 
more active in the early stages of the reaction. Pd(OAc)2 however does not however achieve 
these levels of conversion; the activity of this catalyst eventually drops off, despite matching 
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that of Pd/C initially. This type of behaviour can be rationalised if the deactivating 
agglomeration of PdNPs is more facile in the absence of a supporting matrix such as activated 
carbon, even if the PdNPs originally formed from Pd(OAc)2 and Pd/C are similar. 
Conversely, little difference is seen in the reaction profiles when using either 13 or 238 as 
the catalyst. 
A quantitative comparison was also made between the old and new batches of 13, which were 
qualitatively compared above (Figure 22). Monitoring of the activity of these two catalysts 
for the direct arylation of N-methylindole 33 demonstrated significant differences in activity 
(Figure 26). A comparison of freshly synthesised PVP–Pd catalysts with their artificially 
time- and heat-aged counterparts found that the nanoparticle size in this catalyst had a strong 
heat dependence, but no discernible time-dependence (when stored at ambient 
temperature).160 This investigation was however carried out over a few months, as opposed 
to the 30-month period of time covered by the PVP–Pd 13 shown in Figure 22. 
 
 
Figure 26 Direct arylation of N-methylindole 33 using freshly synthesised and 30-month old PVP–
Pd 13. × = starting concentration of substrate at t = 0. Reactions performed by L. Neumann. 
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The four catalysts shown above were also studied in the reaction of benzofuran 239 at 60 °C, 
the kinetic profiles from which are shown in Figure 27. 
 
 
Figure 27 Direct arylation of benzofuran 239 over 24 h. Fitting to an exponential decay equation is 
shown where appropriate. Detailed analysis over the initial 7 hours shown, final conversions by GC 
after 24 h; Pd/C: 88%, PVP–Pd 13: 91%, Pd(OAc)2, 31%, Pd2(dba)3 238: 31%.    × = starting 
concentration of substrate at t = 0. Reactions performed by L. Neumann. 
Overall, this substrate demonstrated lower activity towards the desired transformation than 
methylindole 33. PVP–Pd 13 was again the most active catalyst, providing ca. 29% 
conversion within 5 minutes, and >90% after 24 hours. Interestingly, Pd/C performed very 
similarly to 13, in stark contrast to its poor performance when using 33 as a substrate. 
Pd(OAc)2 and 238 however displayed poor activity for this transformation. These results 
demonstrated a clear substrate dependence on the catalytic activity for this transformation; 
whether this is due to variation in PdNP formation or behaviour, or a difference in leaching 
rates is unclear. The major product was confirmed by 1H NMR spectroscopic analysis as the 
C2-arylated regioisomer, after isolation using silica gel column chromatography in a yield of 
31%, from a separate reaction catalysed by Pd(OAc)2. Butylthiophene 241 was also examined 
under these conditions, the kinetic profiles from which are shown in Figure 28. 





Figure 28 Direct arylation of butylthiophene 241 over 24 h. Fitting to an exponential decay equation 
is shown where appropriate. Final conversions by GC after 24 h; Pd/C: 66%, PVP–Pd 13: 86%, 
Pd(OAc)2, 75%, Pd2(dba)3 238: 42%.  Reactions performed by L. Neumann. 
This substrate demonstrated activity lower than that of either 33 or 239, as expected, but did 
reach 86% conversion after 24 hours when using 13 as a catalyst (which was again the most 
reactive catalysts of those tested). Little difference between catalysts was observed in the 
initial period of reactivity, which provided such a clear discrimination between catalysts 
when using either 33 or 239 as substrates. The final conversion obtained however varied 
between the worst-performing catalyst 238 (42%) and the best-performing catalyst 13 (86%). 
The major product was confirmed by 1H NMR spectroscopic analysis as the C3-arylated 
regioisomer, after isolation using silica gel column chromatography from two separate 
reactions catalysed by Pd(OAc)2 (49%) and PVP–Pd 13 (69%). 
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The substrates tested thus far were all reported by Glorius et al. to be active under their 
conditions, when using Pd/C as a catalyst.148 It was hypothesised that 2-n-butylfuran 243 
should also prove effective in this protocol, but the original publication148 states that reaction 
of this substrate with 233 using Pd/C leads to degradation of the starting materials. 
Conversion to the desired arylated product 245 is however reported when the strongly 
electron-deficient diaryliodonium salt 244 is used (Scheme 84). 
 
Scheme 84 Direct arylation of butylfuran 243 with electron-deficient diaryliodonium salt 244. 
No other details on this degradation were provided, so some initial studies were performed 
to evaluate the reaction of this substrate (Figure 29). Surprisingly, reaction of 243 under the 
standard conditions using the same four catalysts as used previously provided good 
conversion of starting material. Reactivity not dissimilar to that of benzofuran 239 was 
realised, with 13 and Pd/C proving the most effective catalysts with complete conversion 
after 24 hours seen. Pd(OAc)2 and 238 were less effective, with ca. 70–75% conversion 
observed after 24 hours. The activity of these four Pd catalysts is similar over the first hour 
of the reaction, but the distinction between the different catalysts tested becomes apparent 
after this point. 
  





Figure 29 Direct arylation of butylfuran 243 over 24 h. Fitting to an exponential decay equation is 
shown where appropriate. Final conversions by GC after 24 h; Pd/C: 100%, PVP–Pd 13: 95%, 
Pd(OAc)2, 62%, Pd2(dba)3 238: 65%. × = starting concentration of substrate at t = 0. Reactions 
performed by L. Neumann. 
In order to gain a complete picture of the reactivity of this substrate under conditions 
catalysed by Pd/C, this reaction was repeated at a higher temperature (70 °C) and samples 
taken at regular intervals until reaction completion after ca. ten hours. This demonstrated loss 
of starting material 243 concomitant with product 246 formation, with no evidence of side-
products as a result of degradation behaviour observed (Figure 30). 
  





Figure 30 Direct arylation of butylfuran 243 over 10 h at 70 °C. Fitting to an exponential decay 
(substrate 243) or logarithmic growth (product 246) equation is shown where appropriate. × = 
starting concentration of substrate at t = 0. Reactions performed by L. Neumann. 
It is not clear at this point why this substrate provides excellent reactivity in this system, in 
contrast to that reported. It may be that the different sources of Pd/C used provide 
fundamentally different forms of catalytically active Pd, alternatively an impurity such as 
those reported for other commercially available Pd catalysts may be present,18 which 
manifests itself when using this substrate. It was noted during these investigations that 
purification of the 2-arylated product 246 from the Pd/C-catalysed reactions was challenging, 
as was the case when using tryptophan 74 as a substrate (vide supra). Attempted purification 
of several reactions catalysed by Pd/C afforded inseparable mixtures of the desired product 
and biphenyl, as confirmed by TLC, EI–GC–MS and 1H NMR spectroscopic analysis. 
Iodobenzene is also present as a major byproduct (b.p. 188 °C), which complicates matter 
further due to the relatively low boiling point of the desired product (95 °C).161 Purification 
by silica gel column chromatography of a separate reaction catalysed by PVP–Pd 13 afforded 
the desired product in a yield of 45%, which was confirmed as the C2-arylated regioisomer 
by 1H NMR spectroscopic analysis. 
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Analysis of the initial stages of reaction using these substrates allowed fitting of simple 
exponential decay equations, as shown in the appropriate figures. Good fits were obtained in 
the majority of cases; where line fitting could not be performed this is suspected to be the 
result of rapid initial reactivity followed by loss of catalytic activity, for example the reaction 
of benzofuran with Pd(OAc)2 as catalyst (Figure 27). These analyses allowed for a rough 
approximation of the initial rate of reaction (kobs) for the majority of substrate and catalyst 
combinations; these are shown in Table 13. 
Table 13 Approximate observed rate constants (kobs) for direct arylation reactions.a 
Entry Substrate Pd/C PVP–Pd 13 Pd(OAc)2 Pd2(dba)3 238 
1 
 
(9.2 ± 0.5)     
× 10-6 
(1.3 ± 0.1)     
× 10-5 





(6.3 ± 0.8)     
× 10-6 
- - - 
3 
 
(6.1 ± 0.6)     
× 10-6 
- - 




(7.1 ± 0.6)     
× 10-6 
(4.8 ± 0.5)     
× 10-6 
(1.6 ± 0.1)     
× 10-6 




(9.3 ± 0.9)     
× 10-6 
N/A N/A N/A 
6b 
 
(9.4 ± 1.6)     
× 10-6 
N/A N/A N/A 
a Rate constants calculated from initial rates using a fitted exponential decay equation, using at least 5 
recorded data points with ≥90% correlation. All rates shown in s-1. In many cases, extremely rapid 
conversion occurs within ca. 5 mins (the first recorded data point), which has not been considered in 
these data. Hyphens indicate those reactions which cannot be fitted to this exponential decay equation. 
b Rate constant for product 246 formation calculated from initial rates using a fitted logarithmic growth. 
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It should be noted that these cannot be considered as empirically accurate values due to the 
rough approximation present in the exponential decay line fitting. They are intended simply 
as a guide to the approximate activity of each of the catalysts tested. Errors in these values 
are calculated from the standard deviation of a linear regression of the initial reaction rates, 
obtained by the ‘least squares’ method. These rate constants are broadly similar to one 
another, lying between ca. 1 × 10-6 and 1 × 10-5 s-1 for all the catalyst/substrate combinations 
tested. By comparison, a pseudo first-order rate of constant of 3.5(2) × 10-4 s-1 for the 
arylation of 2-methylthiophene has been previously reported, although this was measured 
when using the bespoke dimeric catalyst [PdAr(µ-OAc)(PPh3)]2.162 
3.5 Conclusion 
Several attempts have been made to develop a generic protocol for the arylation of nitrogen-
containing heterocycles using aryldiazonium salts, building on the methodology successfully 
applied to the amino acid tryptophan 74 (see Chapter 2). These have met with limited success; 
of those examples tested, only 7-azaindole 231 could be functionalised in the desired manner. 
Attempted application of heterogeneous Pd sources to this class of reactions have been 
similarly unsuccessful, the scarcity of such examples in the literature perhaps indicates the 
significant challenge this poses. 
The direct arylation of several simple heterocycles, in addition to the amino acid tryptophan 
74 and tryptophan-containing peptides, has however been achieved using a combination of 
diaryliodonium salts and heterogeneous Pd sources. Significant discrepancies in reaction 
conversions when using several variations of palladium supported on activated carbon have 
been noted. The pre-synthesised nanoparticle catalyst PVP–Pd 13 has also been demonstrated 
as an effective catalyst in this chemistry; 13 has however been shown both qualitatively and 
quantitatively to degrade over many months under air at ambient temperature, with a 
concomitant loss of activity in the direct arylation of methylindole 33. Reaction profile 
analysis has shown a substrate effect on catalyst activity in these transformations, in addition 
to the observation of similar activity between apparently distinct catalysts (e.g. Pd(OAc)2 and 
Pd/C), which suggests Pd speciation and higher-order Pd catalyst effects. Butylfuran 243 
which was reported to be unstable under these reaction conditions has in fact been shown to 
react effectively to provide the desired direct arylation product in quantitative conversion. 
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Chapter 4: Analysis of Pd2(dba)3 Complexes 
4.1 Introduction 
The widely-used Pd0 precursor complex, Pd2(dba)3 (dba = E, E′-dibenzylideneacetone 247), 
is ubiquitous in synthetic chemistry.163 It has been extensively studied within the Fairlamb 
group, where work has shown that modifying the core structure with a variety of ligands to 
generate ‘L2Pd0(η2-dba)’ complexes, can provide profound variations in catalytic 
behaviour.164 The reasons for this are simple; the dba ligand plays a non-innocent role in the 
catalytic activity of ‘LnPd0’ complexes, generated in situ prior to oxidative addition reactions 
with aryl halides. This was first reported by Jutand and co-workers, who studied the 
equilibrium behaviour of solvated ‘L2Pd0’ and ‘L2Pd0(η2-dba)’ species, using phosphine 
ligands.165 The concentration of the active oxidative addition species ‘L2Pd0’ was found to be 
dependent on its equilibrium position with unreactive ‘L2Pd0(η2-dba)’ species; an increase in 
the number of equivalents of phosphine used therefore shifts the equilibrium towards the 
active ‘L2Pd0’ species, increasing activity (Scheme 85). 
 
Scheme 85 Equilibrium between L2Pd0(η2-dba) and L2Pd0 species. 
This key complex is typically synthesised by reduction of sodium tetrachloropalladate(II) in 
MeOH in the presence of the free ligand 247 (Scheme 86). Initially this complex was 
incorrectly characterised as Pd(dba)2 based on IR and elemental analysis data;166 it was later 
proposed to consist of three dba ligands asymmetrically coordinated around two palladium 
centres, with a fourth loosely coordinated or ‘solvating’ dba ligand, giving complex 
Pd2(dba)3·dba 248.167-169 
 
Scheme 86 Synthesis of Pd2(dba)3·dba 249. 
More recently, preparation of this complex from the readily available precursor palladium(II) 
acetate has been published in a procedure purporting to afford both high yields and purities 
(Scheme 87).170 This is achieved via recrystallisation from chloroform, affording the adduct 
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complex Pd2(dba)3·CHCl3 238, while allowing removal of excess free dba ligand 247 and 
elemental Pd (i.e. nanoparticulate Pd0). It is important to note that Pd2(dba)3 has been reported 
to react with CHCl3 under certain conditions to form cluster complexes.171 
 
Scheme 87 Synthesis of Pd2(dba)3·CHCl3 238. 
This synthesis is proposed to avoid the pitfalls resulting from poor characterisation of 
commercially available ‘Pd2(dba)3’, as high levels of variation were found, with up to 40% 
of Pd nanoparticles (PdNPs) present in many samples. These PdNPs were found in a range 
of sizes, from 10–200 nm, along with free ligand 247 and the desired complex 248. 
Recrystallisation such as that in Scheme 87 allows for the ‘purity’ of the catalyst to be 
determined prior to its use, as diffusion-ordered spectroscopy (DOSY) was utilised to 
delineate the typically complex 1H NMR of complex 238, allowing for characterisation of 
the major and minor isomers, in addition to free ligand 247 (Figure 31).  
 
Figure 31 Partial 1H NMR spectrum of Pd2(dba)3·CHCl3 in CDCl3 at 600 MHz: alkene signals 
corresponding to the major (blue) and minor (green) isomers of complex 238, along with free ligand 
247 (red). Integral regions used for calculation of purity are highlighted as I1–I3. Reprinted with 
permission from Organometallics 2012, 31, 2302–2309. Copyright 2012 American Chemical 
Society. 
The ‘purity’ (i.e. the amount of complexed ligand 238 versus free ligand 247) can thus be 
evaluated simply by comparing the 1H NMR ratios of the appropriate signals (Equation 1). 




[major isomer + minor isomer]










 × 100% 
Equation 1 Purity determination of complex 238 from 1H NMR integrals. 
In this work the solution-phase structure of complex 238 was also discussed, with high-field 
1H NMR spectroscopic data being used to assert that the dba ligands were coordinated in a 
symmetric s-cis, s-cis fashion around the palladium centres. This contradicted an earlier study 
by Kawazura et al., who found that the dba ligands coordinated in an asymmetric s-cis, s-
trans fashion (Figure 32).172 These latter observations were subsequently supported by 
detailed 1H and 13C NMR studies, in addition to DFT calculations, performed within the 
Fairlamb group.173 
 
Figure 32 Possible conformational alignment of dba ligand 247. 
The facile propagation of PdNPs from this complex was proposed in the Ananikov study as 
a potentially useful source of catalytically competent, heterogeneous Pd nanocatalysts. In a 
subsequent publication from the same group, activated carbon was shown to exhibit an 
efficient capture mechanism of these particles, obtained by degradation of complex 238 in 
chloroform at 40 °C. These reactive Pd markers were used to demonstrate >2000 reactive Pd 
centres per 1 µm2 of carbon surface area.174 
The ambiguity surrounding the true coordination environment of this complex in solution 
and in the solid state, in addition to its ability to form PdNPs under very mild conditions, 
provided ample opportunity for further study of this important Pd0 (pre)catalyst. 
4.2 Synthesis and Characterisation 
To complete characterisation of the complex of interest (238), preparation of the chloroform 
adduct via the protocol in Scheme 87 was performed. Recrystallisation in several solvents 
was successful and single crystal X-ray structures obtained for three analogues; 
Pd2(dba)3·CHCl3 238, Pd2(dba)3·CH2Cl2 249 and Pd2(dba)3·C6H6 250. The high quality 
structures obtained for the chloroform adduct is shown in Figure 33 and Figure 34, with all 
structures included in Appendix 2. 




Figure 33 Single crystal X-ray diffraction structure of 238 (major isomer). Thermal ellipsoids shown 
with 50% probability, hydrogen atoms and solvating chloroform removed for clarity. Selected bond 
lengths (Å): Pd(1)–C(7): 2.303(3), Pd(1)–C(8): 2.248(3), C(7)–C(8): 1.358(4), Pd(1)–C(24): 
2.279(4), Pd(1)–C(25): 2.251(4), C(24)–C(25): 1.364(6), Pd(1)–C(41): 2.202(3), Pd(1)–C(42): 
2.220(3), C(41)–C(42): 1.393(5), Pd(2)–C(10): 2.222(3), Pd(2)–C(11): 2.244(3), C(10)–C(11): 
1.395(4), Pd(2)–C(27): 2.244(4), Pd(2)–C(28): 2.241(4), C(27)–C(28): 1.392(6), Pd(2)–C(44): 
2.244(3), Pd(2)–C(45): 2.280(3), C(44)–C(45): 1.359(5). Pd(1)–Pd(2) bond distance: 3.244 Å. 
 
Figure 34 Single crystal X-ray diffraction structure of 238 (minor isomer). Thermal ellipsoids 
shown with 50% probability, hydrogen atoms and solvating chloroform removed for clarity. Selected 
bond lengths (Å): Pd(1)–C(7A): 2.275(11), Pd(1)–C(8A): 2.297(11), C(7A)–C(8A): 1.368(19), 
Pd(1)–C(24A): 2.243(6), Pd(1)–C(25A): 2.254(6), C(24A)–C(25A): 1.390(9), Pd(1)–C(41A): 
2.211(7), Pd(1)–C(42A): 2.207(7), C(41A)–C(42A): 1.339(10), Pd(2)–C(10A): 2.192(11), Pd(2)–
C(11A): 2.272(10), C(10A)–C(11A): 1.332(9), Pd(2)–C(27A): 2.274(6), Pd(2)–C(28A): 2.242(6), 
C(27A)–C(28A): 1.352(9), Pd(2)–C(44A): 2.267(7), Pd(2)–C(45A): 2.311(7), C(44A)–C(45A): 
1.394(10). Pd(1)–Pd(2) bond distance: 3.244 Å. 
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In these structures, each of the three dba ligands are disordered over two positions, with the 
major isomer depicted in Figure 33 and the minor isomer depicted in Figure 34 (ratio 
major:minor is 79:21). These isomers result from the asymmetric environment of the 
coordinating alkenes, as they can occupy either an s-cis (green) or s-trans (orange) orientation 
with respect to the carbonyl group of the ligand. The average C=C bond distances are 1.3603 
Å for the s-cis alkenes and 1.3930 Å for the s-trans alkenes, indicating a weaker s-trans 
alkene bond. Additionally, the C–Pd distances for the s-cis alkenes are Cα–Pd = 2.247 Å and 
Cβ–Pd = 2.287 Å, and Cα–Pd = 2.228 Å and Cβ–Pd = 2.229 Å for the s-trans alkenes, 
indicating a higher level of asymmetry in the s-cis bonds than in the s-trans bonds. These 
two observations taken together appear to demonstrate a higher level of π-backbonding (and 
thus more sp3, cyclometallopropane-like character) in the s-trans alkenes (Figure 35). 
 
Figure 35 Representative alkene binding from dba ligand 247 to palladium. 
When complex 238 was analysed by 1H NMR spectroscopy and the integrals applied to 
Equation 1, the purity was found to be 91%, contrasting with the reported value of 98% 
immediately post-synthesis.170 This value is the maximum obtained during the course of this 
project, representing ca. ten syntheses of complex 238 (and was in fact obtained under 
rigorously air-free conditions, using dry distilled solvent, which was not specified in the 
published procedure).170 Representative purities lie in the region of 80–89%. The exchange 
rates of the different isomers of complex 238 in solution was proposed as a source of this 
discrepancy, so a variable temperature NMR (VT–NMR) study was performed to evaluate 
the effect of temperature on the rate of exchange. The hypothesis in this instance was that 
cryogenic temperatures could slow down the exchange process sufficiently to allow the 
delineation of this effect on the NMR timescale. When a 1H NMR spectrum of complex 238 
was recorded at −35 °C (238 K), it became apparent that a small quantity of an as-yet 
unidentified species overlapped with the signal typically used to calculate the quantity of the 
major isomer (ca. 5.29 ppm, ■). Another suitable region was thus identified (ca. 6.12 ppm, 
●) and used as a measure of the concentration of the major isomer in solution (Figure 36). 
The signal used to calculate the quantity of minor isomer remained unchanged from that 
shown in Figure 31 (ca. 5.60 ppm, ○). The integrals recorded (and thus the derived purity) 
differed slightly as a function of temperature (in this experiment, 89% at 298 K and 83% at 
238 K), giving credence to the explanation that complex exchange in solution introduces 
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variability in the purity measurement. The measurements made by Ananikov et al. were 
recorded on a different spectrometer, at 600 MHz,170 so these factors alone could easily have 
introduced the ca. 10% error observed in this calculation of purity. 
 
Figure 36 1H NMR spectra of 238 in CDCl3 at a) 298 K b) 238 K; major isomer signal used by 
Ananikov et al. (■), major isomer signal (●) and minor isomer signal (○) used in this study. 
To further evaluate the exchange process of both isomers of complex 238, as well as the free 
ligand 247, 1H NMR spectra of complex 238 (at 500 MHz using 64 scans, in CDCl3) were 
recorded at several temperatures between 238–298 K. The full-width at half-maximum 
(FWHM) of each of the key integral signals used in the purity determination (with the 
exception of the signal at ca. 5.29 ppm, vide supra) was then measured and compared. This 
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gave an indication of the relative exchange rates of these species, as signal broadening is an 
effect typically associated with exchange on the NMR timescale i.e. the larger the measured 
FWHM, the greater the degree of exchange. The results from this experiment are provided in 
Figure 37. 
 
Figure 37 Intensity of key integrals for complex 238 as a function of temperature. 
Interestingly, this experiment demonstrated that the exchange rates of the species involved 
differ significantly at non-cryogenic temperatures. This means that the two isomers of 
complex 238 display different intra- and intermolecular exchange rates, introducing error into 
the integral signals used in the purity determination proposed by Ananikov et al., 170 
supporting the same conclusion drawn through comparison of the integrals at different 
temperatures (Figure 36). 
4.3 Activation/Degradation to Form Pd Clusters 
The facile propagation of PdNPs from this complex, as detailed by Ananikov et al.,170 was 
proposed to occur through initial dissociation of the dba ligand 247 followed by rapid 
agglomeration of the resulting thermodynamically unstable Pd0 atoms. A putative model for 
this process could centre around protonation of the keto moiety of the dba ligand 247, 
reducing the electron density of the alkene and resulting in dissociation from the metal centre. 
If this were the case, degradation of complex 238 should be initiated either by water or acid; 
indeed, in their work Ananikov and co-workers note that degradation could result “by 
reaction with acid traces and other impurities in the [NMR] solvent”. 
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To probe the formation of these PdNPs (or Pd clusters) indirectly, the 1H NMR method 
detailed above (despite its limitations) could therefore be used to monitor the ratio of 
complexed versus free ligand as a function of time; by definition, as free ligand 247 is 
released there should also be a concomitant release of elemental Pd0. Several experiments 
were therefore performed to evaluate the effect of water and acid independently. For the 
control study 5 mg of complex 238, manipulated in a glovebox, was dissolved in 0.5 mL of 
CDCl3 that had been degassed, dried and de-acidified over CaH2. 1H NMR spectra were then 
recorded under air-free conditions in a Young’s tap NMR tube after 10 min, then every 30 
min for 24 h; the resulting integrals were subsequently used to generate values for the 
quantity of complex over time. A second analogous experiment was then performed using 
reagent grade CDCl3, which was measured by 1H NMR to contain 144 ppm water, using 
1,3,5-trimethylbenzene 141 as an internal standard. Two further experiments were also 
performed in dry, degassed and de-acidified CDCl3 that had been doped with the acid 
[HNPhMe2]+ [BF4]− 252, used primarily because of its solubility in chloroform. This acid is 
readily prepared from commercially available N, N-dimethylaniline 251 in one step (Scheme 
88). 
 
Scheme 88 Synthesis of chloroform-soluble acid 252. 
The amounts used to initiate degradation were one equivalent of acid 252 with respect to 
complex 238 and three equivalents with respect to complex 238 (1 equivalent per dba ligand 
247). The results from these four experiments are overlaid in Figure 38. 




Figure 38 Behaviour of complex 238 in CDCl3, monitored by 1H NMR spectroscopic analysis. 
Figure 38 clearly shows that the relative concentration of complex 238 decreases over time, 
with respect to free ligand 247 concentration, in the presence of both water and acid. 
Conversely, it displays relatively higher stability in solution under anhydrous, air-free 
conditions (eventually reaching complete decomposition after 11 days in solution). When 
treated with one equivalent of acid 252, complete degradation of complex 238 occurs in less 
than 11 hours, with the resultant 1H NMR spectrum matching that of free ligand 247 and 
visible Pd ‘mirroring’ on the sides of the NMR tube qualitatively indicating elemental Pd0 
formation. The profile for the acid-catalysed degradation appears to demonstrate two distinct 
phases; a slow first step occurring between 0–6 hours after dissolution where the relative 
concentration of complex 238 decreases by 8%, followed by a rapid second step between 6–
11 hours after dissolution where the relative concentration decreases by 70%. This behaviour 
is difficult to rationalise by the simple model proposed above, but could be explained by 
autocatalytic Pd complex formation; the [BF4]− counter-ion of acid 252 is known to stabilise 
PdNPs in other systems.175 While not identical, this broad trend is also seen when using three 
equivalents of acid 252. Notably, during the initial period degradation of the complex is more 
rapid, possibly due to an increased rate of initial ligand protonation. 
To delineate any potential counter-ion effect, complex 238 was treated with two other organic 
soluble acids, acetic acid (AcOH) and trifluoroacetic acid (TFA). Treatment with AcOH (10 
eq. or 359 eq. w.r.t 238, 100 µL in 5 mL CDCl3) had no effect on complex 238, with no 
degradation seen by 1H NMR after several days. Ten equivalents of TFA did however initiate 
degradation, the profile for which is shown in Figure 39, with the data from acid 252 overlaid 
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for comparison. When 298 equivalents of TFA were used (100 µL in 5 mL CDCl3), 
decomposition to free ligand 247 and elemental Pd occurred within seconds. This also 
occurred when complex 238 was treated with HBF4·OEt2 (1 eq. w.r.t 238). 
 
Figure 39 Behaviour of complex 238 in CDCl3 when treated with acid, monitored by 1H NMR 
spectroscopic analysis. 
Comparison of the experiments shown in Figure 39 indicates that using TFA to initiate 
decomposition of complex 238 produces a simpler kinetic profile, which lacks the two-phase 
behaviour seen when using acid 252. As highlighted above this may result from the ability 
of [BF4]− to stabilise PdNPs in the latter case, producing unusual degradation profiles due to 
involvement by higher-order Pd species, such as [Pd0xdbay] clusters. To probe this more 
directly (as opposed to the indirect observations provided by 1H NMR signals of ligand 247), 
Fourier-transform ion cyclotron resonance mass spectrometry (FT–ICR–MS) was performed 
on a methanol/DCM solution of complex 238 and demonstrated the presence of Pd clusters 
containing between three and eight Pd atoms, all with two dba ligands. (Figure 40). 




Figure 40 FT–ICR–MS spectrum showing [Pdxdba2H]+ cluster species formed from complex 238. 
The most abundant ion detected via this method was [Pd4(dba)2H]+, so density functional 
theory (DFT) calculations were performed by a collaborating group in Birmingham176 to 
determine the relative energies of several possible conformations for this specific cluster in 
the gas phase (Figure 41). Perhaps surprisingly, the conformation of calculated lowest 
energy was the linear conformer of four Pd atoms, positioned in-between the two dba ligands 
(Figure 41a). 
 
Figure 41 DFT-calculated possible structures for the species [Pd4(dba)2H]+ in the gas phase: (a) 
linear, (b) Y-shaped, (c) rhombic, (d) tetrahedral. 
This cluster formation would result in a small increase in the concentration of free dba by 1H 
NMR initially, as complex 238 degrades to elemental Pd0 and free dba ligand (Figure 38 and 
Figure 39). The free dba liberated would then be sequestered by multinuclear elemental Pd0, 
forming [Pd0xdbay] clusters. As these clusters grow, eventually they would reach a point 
where they were no longer soluble and would precipitate out, liberating a large quantity of 
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free dba ligand into solution. This would cause a large increase in the observed concentration 
of free dba by 1H NMR, leading to the observed rapid decomposition several hours after 
dissolution of complex 238 (Figure 38 and Figure 39). In an analogous experiment, 
electrospray ionisation mass spectrometry (ESI–MS) was used to demonstrate that clusters 
containing varying numbers of both Pd atoms and dba ligands could also be observed (Figure 
42). 
 
Figure 42 ESI–MS spectrum showing [PdxdbayH/Na]+ cluster species formed from complex 238. 
Once again, the most abundant ion detected in solution was [Pd4(dba)2H]+, the detected 
masses for which are shown in Figure 43. A full comparison of the observed isotope patterns 
against their calculated values is provided in Appendix 6. 
 
Figure 43 Measured vs. simulated mass values for [Pd4(dba)2H]+ cluster detected by ESI–MS. 
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During this experiment, the ion corresponding to the [Pd4dba5H]+ cluster was isolated and 
subjected to secondary ionisation (ESI–MS–MS), producing the smaller clusters [Pd4dba3H]+ 
and [Pd4dba2H]+. Interestingly, the relative intensity of these ions increased as a function of 
collision energy (0–65 V); in other words, the greater the secondary collision energy, the 
greater the relative concentration of clusters with fewer dba ligands (Figure 44).  
 
Figure 44 ESI–MS–MS spectra of [Pd4dbayH]+ cluster species. 
The evidence from Figure 44 implies that the larger Pd04dbay species form from the smaller 
ones i.e. there is rapid addition of dba ligands to the initially forming, stable [Pd4dba2H]+ ion. 
This is highlighted by the fractional bar chart presented in Figure 45, which compares the 
relative abundance of the observed ions as a function of secondary collision energy. 




Figure 45 Relative abundance of [Pd4dbayH]+ cluster species as a function of secondary collision 
energy. 
As ESI–MS proved a suitable method by which to study the dynamic, cluster-forming 
behaviour of complex 238 in solution, two similar experiments were devised to attempt to 
extrapolate structural and kinetic data. These would ideally provide direct evidence of Pd 
cluster formation from complex 238 as a function of time, complementary to the 1H NMR 
experiments shown in Figure 38 and Figure 39 which provided indirect evidence of this 
process. 
In the first experiment, a solution of acid 252 in anhydrous chloroform was added to a 
solution of complex 238 in anhydrous chloroform under nitrogen. This mixture was then 
stirred at room temperature for eight hours, with a sample taken every 30 minutes and 
analysed by ESI–MS. The Pd4(dba)2 species was again the major Pd cluster signal seen in all 
spectra, so the peak height for this cluster (ion [Pd2(dba)4Na]+) was normalised to 100% and 
the peak heights for all other species were monitored relative to this value. While similar ions 
were observed as in the previous study (Figure 42), no appreciable change in the relative 
intensities of these ions was observed as a function of time. Specifically, no increase in the 
relative concentration of larger Pd clusters, as compared to smaller Pd clusters, was observed. 
An analogous experiment was thus performed, with samples taken every two minutes for a 
half hour period, which were subsequently analysed by ESI–MS, in order to monitor any 
rapid changes that might occur in the early stages of the reaction (Table 14). 
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Table 14 Pdxdbay clusters formed from 238 as a function of time.a 
Time / min 0 2 4 6 8 10 30 
Ion Detected Relative Intensity / %b 
[Pd2(dba)2H]+ 0
 22.1 21.3 22.6 24.5 20.1 25.1 
[Pd2(dba)4H]+ 91.2 0 0 0 0 0 0 
[Pd2(dba)4Na]+ 65.1 14.3 15.6 14.3 13 19.2 9.1 
[Pd2(dba)5Na]+ 34.3 4.4 4.4 4.1 3.8 5.5 2.8 
[Pd4(dba)2H]+ 0 0 0 0 0 0 0 
[Pd4(dba)2Na]+ 100 100 100 100 100 100 100 
[Pd4(dba)3H]+ 0 0 0 2 2.1 0 2.5 
[Pd4(dba)4Na]+ 0 0 0 0 0 0 0 
[Pd4(dba)5H]+ 8.4 19.8 18.3 25.9 23.6 24.1 19.9 
[Pd4(dba)7Na]+ 15.5 7.6 9 7.7 7.5 10.4 5 
[Pd4(dba)8Na]
+ 11 4.4 4.5 3.9 3.7 5.3 2.6 
[Pd6(dba)5Na]+ 15.9 41.4 40.8 55 58 55.1 44.4 
[Pd6(dba)8H]+ 1.4
 8.3 6.6 15.8 16.5 10.6 9 
[Pd6(dba)9Na]+ 7.5 8.2 8.2 7.7 6.9 8 1.7 
[Pd6(dba)10Na]+ 0 1.3 0 0 0 0 0 
a Reaction conducted with 238 (100 mg, 0.09 mmol, 1 eq.) and 252 (18 mg, 0.09 mmol, 1 eq.) in dry 
CHCl3 (10 mL) under N2. b Intensities normalised to the [Pd4(dba)2H]+ ion at 100%. 
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The only significant change in ion distribution was observed before and after addition of the 
acid, this distribution did not however change further as a function of time. The intensity of 
two clusters containing two Pd atoms, Pd2(dba)4 and Pd2(dba)5, is markedly reduced after 
addition of acid. The relative intensity of the Pd2(dba)2 cluster is increased however, possibly 
due to greater stability of this species versus those Pd clusters with two Pd atoms and a greater 
number of dba ligands. Conversely, the quantity of Pd4(dba)5 and Pd6(dba)5 clusters 
significantly increases upon addition of acid 252, which may indicate a growth of Pd clusters 
upon addition of acid, as suggested above. 
These studies provide some structural information about the degradation observed by 1H 
NMR (Figure 38 and Figure 39). Direct evidence for the growth of Pd0x(dba)y clusters has 
been found, with at least two pathways observed. The first appears spontaneous; in solution 
dissociation of dba ligand 247 releases Pd0 from complex 238, which agglomerates to form a 
relatively stable Pd04(dba)2 cluster. Rapid addition of free ligand 238 in solution then occurs 
to give secondary Pd04(dba)2+x clusters. Upon addition of acid 252, a decrease in the 
concentration of smaller clusters is concurrent with an increase in the concentration of larger 
clusters, importantly these secondary clusters contain not just additional ligand 247 but 
consist of greater number of Pd atoms. This behaviour is suggestive of increased 
concentrations of free ligand 247 and elemental Pd0 in solution, as a result of acid-promoted 
ligand dissociation from complex 238. The expected increase in the concentration of larger 
Pd clusters as a function of time was not observed, it may be however that the ions observed 
are on the limit of solubility. Large species are therefore not observable under these 
conditions due to rapid growth and subsequent insolubility. These observations would agree 
with the unusual two-phase degradation behaviour seen through observation of the ligand 
signals by 1H NMR (Figure 38 and Figure 39). Finally, it is important to note that when 
stored at 5 °C in the dark, complex 238 shows long-term stability in the solid state, 
ascertained by both 1H NMR spectroscopic analysis and elemental (CHN) analysis. 
Atmospheric air has no appreciable deleterious effect on the stability of this complex in the 
solid state. 
  




The important Pd0 precursor complex Pd2(dba)3 has been prepared and recrystallized in 
several solvents. Several high-quality single-crystal X-ray diffraction structures have been 
obtained, allowing for the complex asymmetric alkene binding of the dba ligands to be 
characterised in both the major and minor isomers of the complex. The exchange rates of 
these two isomers in solution were shown to differ from one another and free ligand 247 
through the use of VT–NMR. The stability of the chloroform adduct of this complex (238) 
when exposed to both water and acid has been probed by NMR and MS studies; direct and 
indirect evidence of Pd0x(dba)y cluster formation under these conditions has been obtained. 
These observations taken together appear to demonstrate that complex 238 is a viable source 
of catalytically active PdNPs under commonly found experimental conditions. 
Part of the work described in this chapter has been included in a recent publication (see 
Appendix 1).173 
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Chapter 5: Conclusions and Future Work 
5.1 Conclusions 
The research presented in this thesis has explored the development and application of Pd-
catalysed C–H bond functionalisation methodologies, with a particular focus on direct 
arylation reactions. Central to this work has been the pursuit of novel methods for the 
selective functionalisation of the essential amino acid tryptophan 74, as well as related 
tryptophan-containing peptides. Arylated tryptophan compounds such as 75, the key target 
compound in this project, display greatly enhanced fluorescence compared to their parent 
structures.109,112,119 Previous approaches have required either; pre-functionalisation through 
borylation,110 bromination112 and iodination,117 or high temperatures114 and stoichiometric 
additives such as AgBF4 or TFA.115 A combination of diaryliodonium salts and catalytic 
palladium has been established to provide access to this important class of compounds, 
without these disadvantages. Further development has led to the application of aryldiazonium 
salts as electrophilic coupling partners, allowing access to a wide range of derivatised 
tryptophan structures in excellent yields. Using these in tandem with a Pd–OTs catalytic 
system has also allowed the catalyst loading to be significantly reduced. (Scheme 89). 
 
Scheme 89 Reaction conditions for the direct arylation of tryptophan 74 developed in this project. 
Calculation of some simple mass-based green metrics for these processes has demonstrated 
that these latter conditions offer a significant improvement over all previously reported 
methods in terms of optimum efficiency, mass intensity, synthetic utility and selectivity. 
These protocols have also been demonstrated to be effective in the modification of several 
small tryptophan-containing peptides, affording several novel functionalised molecules 
(Figure 46). 




Figure 46 Key molecules obtained through the direct arylation of peptides. 
The reaction conditions using aryldiazonium salts shown in Scheme 89 were subsequently 
explored as a more general direct arylation methodology, with a view to combining these 
atom-efficient coupling partners with heterogeneous Pd catalysis. Efforts to apply this 
chemistry to the functionalisation of several medicinally relevant nitrogen heterocycles met 
with limited success; of the substrates and conditions screened only 7-azaindole 231 
demonstrated any reactivity when using Pd(OAc)2 as a catalyst, and this protocol 
demonstrated no activity when using heterogeneous Pd catalysts. This observation was also 
made when returning to tryptophan 74 as a substrate, indicating that direct arylation reactions 
combining aryldiazonium salts and heterogeneous Pd catalysis is a significant challenge, a 
deduction supported by the scarcity of examples in the literature. 
Following recently published work by Glorius and co-workers,148 the combination of 
diaryliodonium salts and heterogeneous Pd catalysts has been shown able to produce high 
reactivity in several direct arylation reactions. The direct arylation of the amino acid 
tryptophan 74 and tryptophan-containing peptides 167 and 170 has for example been 
achieved under these conditions. The pre-synthesised nanoparticle catalyst PVP–Pd 13 was 
also demonstrated as an effective catalyst in this chemistry; 13 has however been shown both 
qualitatively and quantitatively to degrade over many months under air at ambient 
temperature, with a concomitant loss of activity. An interesting dichotomy in activity 
between several apparently similar forms of Pd supported on activated carbon has been noted 
in this chemistry, suggestive of distinct sizes and/or morphologies of the Pd particles present 
in these ubiquitous catalysts. The activity of these catalysts for the direct arylation of 7-
azindole 231 is shown as an example (Scheme 90). 




Scheme 90 Direct arylations of 231 highlighting differences in Pd/C catalysts. 
Reaction profile analysis using ex situ GC sampling has been used to evaluate the activity of 
four Pd catalysts, Pd(OAc)2, Pd2(dba)3·CHCl3 238, Pd/C and PVP–Pd 13, in the direct 
arylation of several simple heterocycles. This demonstrated remarkable similarities in 
catalytic behaviour between apparently distinct catalysts, implying that dissimilar catalysts 
can function as precatalysts for the formation of a single comparable active catalyst phase; 
speciation to form PdNPs or clusters is proposed as one possible mechanism in this process. 
A pronounced substrate effect has also been noted in these studies, which goes some way 
towards suggesting that reaction conditions including model substrate choice may in some 
cases be more important than the particular Pd (pre)catalyst used. These studies highlighted 
the importance of kinetic analysis in reactions mediated by Pd catalysis, as opposed to 
evaluating catalyst performance merely as a function of yield. 
The structure and degradation behaviour of the important Pd0 pre-catalyst Pd2(dba)3·CHCl3 
238 has also been studied, with a view to its potential as a source of catalytically active 
PdNPs. Analysis of the X-ray diffraction structures of several solvent adducts of this complex 
has allowed the asymmetric binding of the dba ligands to the metal centres to be 
characterised, in both the major and minor isomers of this complex (ratio major:minor is 
79:21). Solution-phase analysis of 238 by 1H NMR spectroscopy has also demonstrated that 
the exchange rates of the two isomers and free dba ligand differ from one another; they also 
vary significantly as a function of temperature. This means that reported170 methods of 
determining the absolute amount of complex as compared to free ligand by 1H NMR cannot 
be viewed as an empirically accurate measure. Finally, the stability of 238 when exposed to 
water and acid has been probed by both 1H NMR and MS studies; direct and indirect evidence 
of speciation to form Pd0x(dba)y clusters has been observed, which are proposed as a 
precursor to larger PdNPs (Figure 47). These observations demonstrate that 238 is a viable 
source of catalytically active PdNPs under commonly found experimental conditions, such 
as those observed in the direct arylation methodologies detailed above. 




Figure 47 Degradation behaviour of 238 as observed by 1H NMR and ESI–MS analysis. 
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5.2 Future Work 
5.2.1 Mechanism of Tryptophan Functionalisation 
The synthetic work performed during this project has produced several protocols for the 
direct C–H bond functionalisation of tryptophan and tryptophan-containing peptides 
(Scheme 89). The methodology utilising aryldiazonium salts is particularly novel, further 
investigation into the mechanism of this transformation therefore has significant value. The 
C2-arylated product 75 possesses a Stokes shift of 62 nm relative to starting material 74, 
enabling the kinetic profile of the arylation reaction to be examined by UV–visible 
spectroscopic analysis. Initial studies performed within the Fairlamb group have shown that 
the product evolution curve from a reaction catalysed by Pd(OAc)2 exhibits an unusual 
sigmoidal kinetic trace (Figure 48),131 which certainly merits further investigation. 
 
Figure 48 (a) UV–visible spectra showing formation of 75 at 304 nm (5 min intervals) at 37 °C.  (b) 
Plot showing evolution of 75 over time. 
As highlighted in Chapter 2, significant rate enhancements were observed with the addition 
of catalytic TsOH due to removal of the observed induction period;131,132 this effect was also 
seen when using pre-catalyst Pd(OTs)2(MeCN)2 215, which is known to form the 
catalytically relevant species 253.133,134 It is therefore possible that the arylation proceeds via 
a key tryptophan coordination complex such as 254 (Scheme 91). 
 
Scheme 91 Pre-catalyst activation and proposed tryptophan intermediate. 
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If species 254 is indeed a key intermediate, it implies a non-innocent role for the amine 
protecting group used. Mono-protected amino acids are well established as useful ligands for 
the acceleration of catalytic processes,177 tailoring of these protecting groups could therefore 
provide significant mechanistic information. Investigation of the initial rates of reaction for 
the cross-section of substrates shown in Figure 49 would provide a useful platform to probe 
this hypothesis. 
 
Figure 49 Alternative N-terminus protected tryptophan substrates. 
5.2.2 Further Tryptophan Derivatives 
A recent publication has detailed the selective C7-borylation of tryptophans using Ir 
catalysis,178 providing a facile method of generating valuable tryptophan structures to test in 
the novel arylation conditions developed in this project (Scheme 92). 
 
Scheme 92 Orthogonal borylation/arylation conditions for tryptophan 74. 
Along similar lines, those tryptophan derivatives containing C2-aryl halide motifs already 
synthesised (Chapter 2) could be subjected to standard cross coupling conditions in order to 
generate products with modified fluorescence properties (Scheme 93). 
 
Scheme 93 Sequential arylation/cross-coupling for tryptophan 74. 
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5.2.3 Direct Arylations Using Aryldiazonium Salts 
Examples of direct arylation reactions using aryldiazonium salts as the arene coupling partner 
are rare in the literature.101,102 The work performed on tryptophan 74 within this project 
provides a stark indication of their potential utility, if suitable reaction conditions can be 
found. Attempts in this direction have met with limited success in this project; some 
encouraging signs, such as the successful arylation of 7-azaindole 231, have however been 
seen (Chapter 3). While there is great interest in the arylation of indoles both in the literature 
and in this report, recent developments in medicinal chemistry have highlighted the need for 
research to focus on more unusual scaffolds, based on both the statistical trends seen in the 
hit-rate of potential drug candidates and the need for novel structures to ensure intellectual 
property rights.179 With this in mind, a focus on the direct arylation of non-typical 
heterocycles would provide an interesting avenue of research, particularly if this could be 
coupled with the heterogeneous palladium catalysis detailed above. A recent paper by Groom 
et al. highlights a range of such heterocycles180 and some potential candidates that might be 
suitable for direct arylations are shown in Figure 50. 
 
Figure 50 Potential heterocyclic substrates for novel direct arylation methodologies. 
To paraphrase a recent review, “a significant increase in the number of new ring systems 
would not necessarily lead to an associated increase in success rates for drug discovery 
projects. A suggested alternative strategy is to focus first on the assembly of existing drug 
ring systems in novel configurations”.150 Development of a versatile direct arylation 
methodology with good green metrics such as that shown in Scheme 89 would provide a 
suitable platform to explore novel drug space in this fashion. Several of the potential 
substrates shown in Figure 50 have more than one site which could be functionalised by 
direct arylation, so there is a possibility that a site-selective arylation methodology could be 
developed to functionalise at more than one position on the heteroaromatic. Glorius and co-
workers have shown that appropriate choice of Pd catalyst can provide such regioselectivity 
in similar protocols.147 This is an area where research efforts could be focused in an attempt 
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to not only produce selective arylation procedures for medicinally-useful compounds, but 
also to provide a link to the development of a range of rationally-designed palladium catalysts 
which can be used to perform differing, selective transformations. 
5.2.4 Direct C–H Bond Functionalisations Using Pd Nanocatalysts 
Despite its widespread use as a heterogeneous hydrogenation catalyst, Pd/C has only recently 
been explored for other Pd-mediated catalysis in any detail, usually in cross-coupling 
reactions.37-40 Glorius and co-workers are particularly notable for their continuing 
development of C–H bond functionalisation reactions using this catalyst.147-149 The direct 
arylation of several common heterocycles such as (benzo)thiophene, indole and (benzo)furan 
have been demonstrated to be effectively catalysed by this cheap, readily available Pd source. 
One drawback of these protocols however lies in the poor degree of characterisation of such 
catalysts; Glorius and co-workers have in fact noted severe incongruities in the activities and 
yields obtained thereof when utilising Pd/C from different commercial sources. To date, no 
specific analysis of how the catalyst structure/morphology relates to its activity in these 
reactions has been performed. In this project (Chapter 3) similarities in catalytic behaviour 
between apparently distinct Pd catalysts have been demonstrated, suggesting formation of a 
comparable active catalytic phase, such as PdNPs, in these reactions. It may be that PdNPs 
are not actively catalysing these reactions, the active species instead consisting of leached 
mononuclear/lower-order Pd species. If this is the case, then perhaps the parallels between 
catalyst type manifests as a result of similar leaching rates. 
Conversely many well-defined Pd nanocatalysts have been synthesised and their catalytic 
activities (often in hydrogenation reactions) correlated to specific features of their size and/or 
shape.181-183 Effectively controlling the morphology of these nanocatalysts, usually through 
appropriate choice of stabilising and surface-capping agents along with carefully-tailored 
reduction rates, is far from a routine operation however. Such specific syntheses are typically 
capricious, with centrifugation often applied to produce the desired nanocatalysts in very low 
yields, thus reducing the synthetic appeal of these processes.184-187 These species can also 
demonstrate significant deterioration from their original size or shape over time.146 
In light of this dichotomy, between the development of operational ease in elegant C–H bond 
functionalisation protocols using Pd nanocatalysts and the judicious structure/activity 
relationships explored in other heterogeneous catalytic processes, there is significant scope 
for an exploration of how these two concepts can be effectively combined. Typical conditions 
for the synthesis Pd nanocatalysts begin with reduction of the Pd precursor Na2PdCl4 by 
ascorbic acid, in the presence of PVP 12 as a stabiliser and KBr as a surface capping agent. 
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By using varying ratios of these reagents, as well of modification of the temperature and 
duration of the synthesis, a number of structurally varied catalysts can be prepared (some 
examples are highlighted in Table 15).188 
Table 15 Nanoparticle shapes obtained through variation of synthetic conditions. 
Entry Reducing agent Capping agent Temp. / °C Particle shape 
1 Ascorbic acid - 100 Truncated octahedron 
2 - - 100 Hexagonal/triangular plate 
3 Ascorbic acid KBr 100 Rod 
4 Ascorbic acid KBr 80 Cube 
 
The nanocatalysts could be supported on activated carbon to generate supported particles,189 
in order to mimic the operational ease found with commercially available Pd/C, as well as 
preventing distortions of the size or morphology of the desired catalyst. With these well-
defined Pd catalysts in hand, a screen of various heterocyclic compounds against the direct 
arylation protocols developed in this project could be performed. There is also potential for 
site selectivity to be affected in those heterocycles with multiple activated C–H bonds. It 
would be remarkable if this site selectivity could be achieved through perceptive choice of 
nanocatalyst morphology, providing an important link to the development of rationally-
designed heterogeneous palladium nanocatalysts which can be used to perform differing, 
selective transformations. 
Finally, the evidence that Pd2(dba)3·CHCl3 238 serves as a competent source of PdNPs raises 
the possibility that the activity of these particles can be evaluated (Chapter 4). Aging studies 
on 238 could be used to provide PdNPs of different sizes and/or morphologies, the activity 
of which could be tested and compared in a model catalytic reaction, in order to gain 
important mechanistic insight. Crucially, this would extend the reported equilibrium between 
‘L2Pd0’ and ‘L2Pd0(η2-dba)’ to include multinuclear Pd colloids with varying ratios of dba 
247 ligand (Figure 47). 
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Chapter 6: Experimental 
6.1 General Experimental Details 
Solvents and Reagents 
Commercially sourced solvents and reagents were purchased from Acros Organics, Alfa 
Aesar, Fisher Scientific, Fluorochem, Sigma-Aldrich or VWR and used as received unless 
otherwise noted. Petrol refers to the fraction of petroleum ether boiling in the range of 40–60 
°C. Dry acetonitrile, dichloromethane, THF and toluene were obtained from a Pure Solv MD-
7 solvent machine and stored under nitrogen. The acetonitrile, dichloromethane and THF 
were also degassed by bubbling nitrogen gas through the solvent with sonication. Dry 
methanol was obtained by storing over activated 3 Å molecular sieves under nitrogen. Dry 
chloroform was obtained by stirring with K2CO3 overnight, then distilling over P2O5 under 
N2. Dry acetone was obtained by distilling over K2CO3 under N2. Dry Et3N and DIPEA were 
obtained by distillation over potassium hydroxide and stored under nitrogen. Dry DMSO was 
purchased from Acros Organics and used as received. Dry, degassed CDCl3 was obtained by 
stirring over anhydrous CaH2 for 24 h then using the freeze-pump-thaw method (3 cycles). 
This was then distilled at high vacuum (0.03 mm Hg) and stored in a Braun Unilab dry glove 
box. Dry, degassed DMSO-d6 was obtained by stirring over activated molecular sieves for 4 
days then using the freeze-pump-thaw method (3 cycles). This was then distilled at high 
vacuum (0.03 mm Hg) under heating and stored in a Braun Unilab dry glove box. 
Typical Conditions 
Room temperature (RT) refers to reactions where no thermostatic control was applied and 
was recorded as 16–23 °C. Reactions requiring anhydrous or air-free conditions were 
performed in dry solvent under an argon or nitrogen atmosphere using oven- or flame-dried 
glassware. Nitrogen gas was oxygen-free and dried immediately prior to use by passing 
through a column of potassium hydroxide pellets and silica. Where indicated, a Braun Unilab 
dry glove box was used (<0.5 ppm O2). 
Flash Chromatography 
Thin layer chromatography (TLC) analysis was performed using Merck 5554 aluminium 
backed silica plates. Spots were visualised by the quenching of ultraviolet light (λmax = 254 
nm) then stained and heated with one of p-anisaldehyde or potassium permanganate as 
appropriate. Retention factors (Rf) are quoted to two decimal places and reported along with 
the solvent system used in parentheses. All flash column chromatography was performed 
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using either Merck 60 or Fluorochem 60 Å silica gel (particle size 40–63 µm) and the solvent 
system used is reported in parentheses. 
Optical Rotations 
Optical rotations were recorded using a digital polarimeter at 20 °C (using the sodium D line, 
259 nm) with a path length of 100 mm, with the solvent and concentration used indicated in 
the text. The appropriate solvent was used as a background with ten readings taken for each 
sample and the average [α]ᴅ values in units of 10−1 deg cm3 g−1 quoted to one decimal place. 
Melting Points 
Melting points were recorded using a Stuart digital SMP3 machine using a temperature ramp 
of 3 °C min-1 and are quoted to the nearest whole number. Where applicable, decomposition 
(dec.) is noted. 
Nuclear Magnetic Resonance Spectroscopy 
All NMR spectra were recorded on either a Jeol ECS400, Jeol ECX400 or Bruker AV500 
spectrometer at 298 K, unless otherwise specified. Chemical shifts are reported in parts per 
million (ppm) of tetramethylsilane. Coupling constants (J) are reported in Hz and quoted to 
±0.5 Hz. Multiplicities are described as singlet (s), doublet (d), triplet (t), quartet (q), quintet 
(quin), sextet, (sext), heptet (hept), multiplet (m), apparent (app) and broad (br). Spectra were 
processed using MestReNova. Copies of NMR spectra for all compounds are provided in 
Appendix 7. 
Proton (1H) spectra were typically recorded at 400 MHz. Alternatively and where specified, 
spectra were recorded on a Bruker AV500 spectrometer at 500 MHz. Chemical shifts are 
internally referenced to residual undeuterated solvent (CHCl3 δH = 7.26 ppm) and given to 
two decimal places. 
Carbon-13 (13C) spectra were recorded at 101 MHz. Chemical shifts are internally referenced 
to residual solvent (CDCl3 δC = 77.16 ppm) and given to one decimal place. 
Boron-11 (11B) spectra were recorded at 128 MHz and obtained with 1H decoupling. 
Chemical shifts are externally referenced to BF3·OEt2 and given to one decimal place. 
Fluorine-19 (19F) spectra were recorded at 376 MHz and obtained with 1H decoupling. 
Chemical shifts are externally referenced to CFCl3 and given to one decimal place. 
Phosphorus-31 (31P) spectra were recorded at 162 MHz and obtained with 1H decoupling. 
Chemical shifts are externally referenced to H3PO4 and given to one decimal place. 




Electrospray ionisation (ESI) mass spectrometry was performed using a Bruker Daltronics 
micrOTOF spectrometer. Liquid induction field desorption ionisation (LIFDI) mass 
spectrometry was performed using a Waters GCT Premier mass spectrometer. Mass to charge 
ratios (m/z) are reported in Daltons with percentage abundance in parentheses along with the 
corresponding fragment ion, where known. Where complex isotope patterns were observed, 
the most abundant ion is reported. High resolution mass spectra (HRMS) are reported with 
less than 5 ppm error. 
Infrared Spectroscopy 
Infrared spectra were recorded using a Bruker Alpha FT-IR spectrometer and were carried 
out as ATR. Absorption maxima (νmax) are reported in wavenumbers (cm-1) to the nearest 
whole number and described as weak (w), medium (m), strong (s) or broad (br). 
UV-Visible Spectroscopy 
UV-visible spectroscopy was performed on a Jasco V-560 spectrometer, with a background 
taken in the appropriate solvent prior to recording spectra, using a quartz cell with a path 
length of 1 cm. The wavelength of maximum absorption (λmax) is reported in nm along with 
the extinction coefficient (ε) in mol dm-3 cm-1. Copies of the appropriate absorption spectra 
and Beer–Lambert plots are given in Appendix 3. 
Gas Chromatography 
Gas chromatographic analysis was carried out using a Varian GC-430 gas chromatogram. 
Statistical analyses were performed using Microsoft Excel and Origin. Method details and 
copies of the appropriate calibration plots are provided in Appendix 5. 
Elemental Analysis 
Elemental (CHN) analysis was carried out using an Exeter Analytical CE-440 Elemental 
Analyser. All values are given as percentages to two decimal places. 
X-Ray Crystallography 
Diffraction data were collected at 110 K on an Agilent SuperNova diffractometer MoKα 
radiation (λ = 0.71073 Å). Data collection, unit cell determination and frame integration were 
carried out with CrysalisPro. Absorption coefficients were applied using face indexing and 
the ABSPACK absorption correction software within CrysalisPro. Structures were solved 
and refined using Olex2190 implementing SHELX algorithms and the Superflip191-193 structure 
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solution program. Structures were solved by charge flipping, Patterson or direct methods and 
refined with the ShelXL194 package using full-matrix least squares minimisation. All non-
hydrogen atoms were refined anisotropically. Where applicable, absolute configurations 
were established by anomalous dispersion. Resolved structures, crystal data and structural 
refinement are provided in Appendix 2. 
Transmission Electron Microscopy 
Transmission electron microscopy was performed at the Department of Biology Technology 
Facility, University of York, using an FEI Technai 12 G2 BioTWIN microscope operating at 
120 kV, and images were captured using an SIS Megaview III camera. Samples were 
prepared by suspending ca. 1 mg of material in reagent grade ethanol with vigorous shaking, 
applying a small amount to a TEM grid, and allowing the solvent to evaporate. The grids 
used were 200 mesh copper grids with a Formvar/carbon support film. The resulting images 
were enlarged and particle sizes measured manually. Statistical analyses were performed and 
histograms drawn using Microsoft Excel 2010 with the Data Analysis ToolPak. 
6.2 General Procedures 
General Procedure A: Synthesis of aryldiazonium tetrafluoroborates in water129 
The appropriate aniline (1 eq.) was dissolved in deionised water and HBF4 (50 wt% in H2O, 
2 eq.) before being cooled to 0 °C with stirring. A solution of NaNO2 (1 eq.) in deionised 
water was then added dropwise and the mixture was stirred vigorously for 30 min during 
which time a precipitate formed. After 30 min this was collected by filtration through a glass 
sinter and the solid dissolved in a minimum amount of acetone. Et2O was then added to 
precipitate the aryldiazonium tetrafluoroborate which was collected by filtration through a 
glass sinter and washed with further Et2O until the filtrate ran clear, then dried in vacuo to 
afford the desired compound, which was subsequently stored at −18 °C. 
General Procedure B: Synthesis of aryldiazonium tetrafluoroborates in ethanol130 
The appropriate aniline (1 eq.) was dissolved in ethanol and HBF4 (50 wt% in H2O, 2 eq.) 
before being cooled to 0 °C with stirring. A 90% solution of tert-butylnitrite (2 eq.) was then 
added dropwise and the mixture was allowed to warm to room temperature with stirring for 
1 h. After 1 h Et2O was added to precipitate the aryldiazonium tetrafluoroborate which was 
collected by filtration through a glass sinter and washed with further Et2O until the filtrate 
ran clear, then dried in vacuo to afford the desired compound, which was subsequently stored 
at −18 °C. 
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General Procedure C: Direct arylation of tryptophan with aryldiazonium salts 
To a microwave tube was added tryptophan 74 (50 mg, 0.192 mmol, 1 eq.), the appropriate 
aryldiazonium salt (0.192 mmol, 1 eq.), Pd(OAc)2 (2.2 mg, 9.6 μmol, 5 mol%) and EtOAc 
(5 mL). The reaction mixture was stirred at RT for 16 h. After 16 h the resulting brown 
reaction mixture was filtered through Celite then washed with sat. aq. NaHCO3. The organic 
layer was collected and dried over MgSO4, filtered and evaporated to give a brown solid. 
When purification was required, it was performed using dry-loaded flash column 
chromatography with a SiO2 stationary phase and the solvent system specified for each 
compound. 
General Procedure D: Kinetic study of the direct arylation of heterocycles  
To a microwave vial fitted with magnetic stirrer bar was added diaryliodonium salt 233 (309 
mg, 0.84 mmol, 1.4 eq.), Pd catalyst (5 mol%) and EtOH (3 mL). To initiate the reaction, 
substrate (0.6 mmol, 1 eq.) was added, the vial sealed with a septum and the reaction stirred 
at 60 °C for 24 h in a pre-heated solid heating block. The progress of the reaction was 
monitored by GC, using an external standard solution of mesitylene (139 µL in 100 mL 
EtOH, 9.975 × 10-3 mol dm-3). Sampling was performed by taking 80 µL aliquots, adding 
these to an Eppendorf tube containing Celite and centrifuging for 10 min. After 10 min 30 
µL of the supernatant layer was removed and diluted with mesitylene standard (0.6 mL). This 
sample was then analysed by GC, using an initial temperature of 60 °C (1 min), followed by 
a ramp of 30 °C min-1 to 250 °C, giving a total run time of 9.33 min. Three injections were 
performed for each data point. 
6.3 Synthetic Procedures and Compound Data 
Throughout this section, laboratory notebook references are given for the experiment from 
which the synthetic procedure is quoted. For experiment references for specific data, see the 
relevant NMR spectra in Appendix 7. Known compounds prepared using literature 
procedures are indicated with a literature reference next to the compound name. Known 
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Methyl (2S)-2-amino-3-(1H-indol-3-yl)propanoate hydrochloride (135)121 
 
To a round-bottomed flask was added MeOH (50 mL) which was cooled to −15 °C, before 
addition of thionyl chloride (4.3 mL, 7.02 g, 59 mmol, 2.4 eq.) dropwise at −15 °C. After 
complete addition, ʟ-Tryptophan 73 (5 g, 24.5 mmol, 1 eq.) was added in three portions, 
resulting in a white suspension. The mixture was then warmed to RT and stirred for 24 h, 
during which time a clear orange solution was formed. Deionised water (5 mL) was added to 
the reaction mixture and the solvent evaporated to afford the title compound as an off-white 
solid (6.24 g, quant.). 
M.P. 205–206 °C dec. (lit.195 214 °C dec.); 1H NMR (400 MHz, CD3OD, δ): 10.61 (br s, 1H), 
7.54 (dt, J = 8.0, 1.0 Hz, 1H), 7.40 (dt, J = 8.0, 1.0 Hz, 1H), 7.22 (s, 1H), 7.14 (ddd, J = 8.0, 
7.0, 1.0 Hz, 1H), 7.07 (ddd, J = 8.0, 7.0, 1.0 Hz, 1H), 4.33 (dd, J = 7.5, 5.5 Hz, 1H), 3.79 (s, 
3H), 3.46 (dd, J = 15.0, 5.5 Hz, 1H), 3.37 (dd, J = 15.0, 7.5 Hz, 1H); 13C NMR (101 MHz, 
CD3OD, δ): 170.8, 138.3, 128.2, 125.6, 122.9, 120.3, 118.8, 112.7, 107.4, 54.6, 53.6, 27.5; 
ESI–MS m/z (ion, rel. %): 219 ([C12H15N2O2]+, 100); ESI–HRMS m/z: 219.1130 
[C12H15N2O2]+ (C12H15N2O2 requires 219.1128); IR (solid-state ATR, cm-1): 3259 (w), 2856 
(w, br), 1747 (s), 1501 (m), 1436 (m), 1351 (m), 1210 (m), 1108 (m), 730 (s); Elemental 
anal.: C 56.44, H 5.85, N 10.87 (C12H15ClN2O2 requires C 56.58, H 5.94, N 11.00). 
Lab book reference number: AJR-8-710 
Methyl (2S)-2-acetamido-3-(1H-indol-3-yl)propanoate (74)121 
 
To a two-necked round-bottomed flask fitted with a reflux condenser was added tryptophan 
135 (3 g, 13.7 mmol, 1 eq.), Et3N (2 mL, 1.45 g, 14.3 mmol, 1.05 eq.) and THF (150 mL). 
The mixture was stirred to give a white suspension before being cooled to 0 °C, then acetic 
anhydride (1.4 mL, 1.5 g, 15.1 mmol, 1.1 eq.) was added in one portion. The reaction was 
then stirred for 2 h at reflux to give a white suspension. After 2 h this was added to deionised 
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water (150 mL) and extracted into EtOAc (3 × 150 mL). The organic layers were combined 
and washed sequentially with 1 M aq. HCl (100 mL), sat. aq. NaHCO3 (100 mL) and brine 
(100 mL). The organic layer was collected, dried over MgSO4, filtered and evaporated to 
afford the title compound as an off-white solid (2.69 g, 75%). 
Rf 0.08 (petrol/EtOAc, 1:1.5, v/v); [α]ᴅ = +41.5 (c 0.10, CHCl3); M.P. 154–155 °C (lit.195 
155–156 °C); 1H NMR (400 MHz, CDCl3, δ): 8.27 (s, 1H), 7.53 (dd, J = 8.0, 1.0 Hz, 1H), 
7.39–7.33 (m, 1H), 7.19 (ddd, 8.0, 7.0, 1.0 Hz, 1H), 7.12 (ddd, J = 8.0, 7.0, 1.0 Hz, 1H), 6.97 
(d, J = 8.0 Hz, 1H), 6.03 (d, J = 8.0 Hz, 1H), 4.96 (dt, J = 8.0, 5.0 Hz, 1H), 3.70 (s, 3H), 3.35 
(dd, J = 15.0, 5.0 Hz, 1H), 3.30 (dd, J = 15.0, 5.0 Hz, 1H), 1.95 (s, 3H); 13C NMR (101 MHz, 
CDCl3, δ): 172.6, 169.4, 136.1, 127.1, 123.7, 120.1, 118.4, 118.0, 111.5, 109.6, 53.2, 51.8, 
27.1, 22.3; ESI–MS m/z (ion, %): 261 ([M+H]+, 5), 283 ([M+Na]+, 100); ESI–HRMS m/z: 
283.1053 [M+Na]+ (C14H16N2O3Na requires 283.1053); IR (solid-state, ATR, cm-1): 3405 
(w), 3315 (m), 1732 (s), 1661 (s), 1520 (s), 1434 (m), 1220 (s), 1123 (m), 746 (s), 665 (m), 
613 (m), 519 (s), 427 (s); Elemental anal.: C 64.34, H 6.23, N 10.47 (C14H16N2O3 requires C 
64.60, H 6.20, N 10.76). 
Lab book reference number: AJR-8-711 
Methyl (2S)-2-acetamido-3-(2-phenyl-1H-indol-3-yl)propanoate (75) 
 
Method A: To a microwave tube was added phenylboronic acid 14 (47 mg, 0.384 mmol, 2 
eq.), aryliodonium salt 22 (123 mg, 0.384 mmol, 2 eq.), Pd(OAc)2 (2 mg, 9.6 μmol, 5 mol%) 
and AcOH (5 mL). The reaction mixture was stirred at 40 °C for 10 min. To the resulting 
orange-brown solution was added tryptophan 74 (50 mg, 0.192 mmol, 1 eq.). The reaction 
was stirred at 40°C for 16 h. After 16 h the resulting black reaction mixture was filtered 
through Celite and evaporated to give a brown solid. This was dissolved in EtOAc (10 mL) 
then washed with sat. aq. NaHCO3. The organic layer was collected, dried over MgSO4, 
filtered and evaporated to give a brown solid. Purification by dry-loaded flash column 
chromatography (SiO2, petrol/EtOAc, 1:1.5, v/v) afforded the title compound as an off-white 
solid (36 mg, 56%). 
Method B: To a microwave tube was added tryptophan 74 (50 mg, 0.192 mmol, 1 eq.), 
diaryliodonium salt 140 (181 mg, 0.384 mmol, 2 eq.), Pd(OAc)2 (2 mg, 9.6 μmol, 5 mol%) 
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and EtOAc (5 mL). The reaction mixture was stirred at 25 °C for 16 h. After 16 h the resulting 
black reaction mixture was filtered through Celite then washed with sat. aq. NaHCO3. The 
organic layer was collected and dried over MgSO4, filtered and evaporated to give a brown 
solid. Purification by dry-loaded flash column chromatography (SiO2, petrol/EtOAc, 1:1.5, 
v/v) afforded the title compound as an off-white solid (55 mg, 85%). 
Method C: Synthesised using general procedure C with aryldiazonium salt 48 (37 mg, 0.192 
mmol, 1 eq.) to afford the title compound as an off-white solid (65 mg, quant.). 
Method D: Synthesised as in method C using Pd(OTs)2(MeCN)2 215 (5.1 mg, 9.6 µmol, 5 
mol%) in place of Pd(OAc)2 and a reaction time of 6 h to afford the title compound as an off-
white solid (65 mg, quant.). 
Method E: Synthesised as in method D using Pd(OTs)2(MeCN)2 215 (1 mg, 1.92 µmol, 1 
mol%) and a reaction time of 16 h to afford the title compound as an off-white solid (65 mg, 
quant.). 
Method F: To a microwave tube was added tryptophan 74 (52 mg, 0.20 mmol, 1 eq.), 
diaryliodonium salt 233 (147 mg, 0.40 mmol, 2 eq.), Pd/C (5 wt%, 21 mg, 10 μmol, 5 mol%) 
and EtOH (2 mL). The reaction mixture was stirred at 60 °C for 22 h. After 22 h the reaction 
mixture was allowed to cool to RT, then filtered through a silica pad with EtOAc. The solvent 
was evaporated and the crude mixture purified by dry-loaded flash column chromatography 
(SiO2, petrol/EtOAc, 1:1.5, v/v) afforded the title compound as an off-white solid (57 mg, 
85%). 
Method G: Synthesised as in method F using Pd/charcoal (5 wt%, 21 mg, 10 μmol, 5 mol%) 
in place of Pd/C. Purification by dry-loaded flash column chromatography afforded the title 
compound as an off-white solid (66 mg, 98%). 
Rf 0.27 (petrol/EtOAc, 1:1.5, v/v); [α]ᴅ = +47.3 (c 0.10, CHCl3); M.P. 83–84 °C (lit.196 85–86 
°C); 1H NMR (400 MHz, CDCl3, δ): 8.20 (s, 1H), 7.60–7.54 (m, 3H), 7.51–7.45 (m, 2H), 
7.42–7.34 (m, 2H), 7.21 (ddd, J = 8.0, 7.0, 1.0 Hz, 1H), 7.14 (ddd, J = 8.0, 7.0, 1.0 Hz, 1H), 
5.79 (d, J = 8.0 Hz, 1H), 4.84 (dt, J = 8.0, 5.0 Hz, 1H), 3.55 (dd, J = 15.0, 5.0 Hz, 1H), 3.52 
(dd, J = 15.0, 5.0 Hz, 1H), 3.29 (s, 3H), 1.66 (s, 3H); 13C NMR (101 MHz, (CDCl3, δ): 172.3, 
169.8, 136.1, 135.8, 133.3, 129.6, 129.3, 128.9, 128.4, 128.2, 127.4, 122.7, 120.2, 119.0, 
111.1, 106.9, 52.9, 52.2, 26.7, 23.0; ESI–MS m/z (ion, %): 337 ([M+H]+, 40), 359 ([M+Na]+, 
100); ESI–HRMS m/z: 337.1546 [M+H]+ (C20H21N2O3 requires 337.1547); IR (solid-state 
ATR, cm-1): 3272 (w, br), 1735 (m), 1651 (m), 1519 (m), 1436 (m), 1373 (m), 1215 (m), 739 
(s), 696 (s), 496 (m); UV–vis (EtOAc, nm): λmax 304 (ε = 17626 mol dm-3 cm-1). 
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Crystals suitable for X-ray diffraction were grown by slow diffusion from a solution of 
hexane/Et2O (1:3, v/v). 
The analytical data obtained was in accordance with the literature.196 
Lab book reference number (method A): AJR-1-82 
Lab book reference number (method B): AJR-3-252 
Lab book reference number (method C): AJR-4-365 
Lab book reference number (method D): AJR-6-596 
Lab book reference number (method E): AJR-7-605 
Lab book reference number (method F): AJR-8-741 
Lab book reference number (method E): AJR-8-759 
Deuterium-labelling experiment in the direct arylation of tryptophan (75/d5-75) 
 
To a microwave tube was added d5-phenylboronic acid d5-14 (49 mg, 0.384 mmol, 2 eq.), 
aryliodonium salt 22 (123 mg, 0.384 mmol, 2 eq.), Pd(OAc)2 (2 mg, 9.6 μmol, 5 mol%) and 
AcOH (5 mL). The reaction mixture was stirred at 40 °C for 10 min. To the resulting orange-
brown solution was added tryptophan 74 (50 mg, 0.192 mmol, 1 eq.). The reaction was stirred 
at 40 °C for 16 h. After 16 h the resulting black reaction mixture was filtered through Celite 
and evaporated to give a brown solid. This was dissolved in EtOAc (10 mL) then washed 
with sat. aq. NaHCO3. The organic layer was collected, dried over MgSO4, filtered and 
evaporated to give a brown solid. Purification by dry-loaded flash column chromatography 
(SiO2, petrol/EtOAc, 1:1.5, v/v) afforded the two title compounds as inseparable off-white 
solids (24 mg, 37%). 
Rf 0.27 (petrol/EtOAc, 1:1.5, v/v); ESI–MS m/z (ion, %): 337 ([M+H]+, 8), 342 ([d5-M+H]+, 
10), 359 ([M+Na]+, 90), 364 ([d5-M+Na]+, 100); ESI–HRMS m/z: 359.1369 [M+Na]+ 
(C20H20N2NaO3 requires 359.1366), 364.1681 [d5-M+Na]+ (C20H15D5N2NaO3 requires 
364.1680). 
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Lab book reference number: AJR-2-93 
(2S)-2-[(2R)-2-[(2S)-2-acetamidopropanamido]-3-(2-phenyl-1H-indol-3-yl) 
propanamido]propanoic acid (137) 
 
Method A: To a microwave tube was added peptide 136 (10 mg, 0.026 mmol, 1 eq.), 
phenylboronic acid 14 (16 mg, 0.13 mmol, 5 eq.), Cu(OAc)2 (2.8 mg, 0.0156 mmol, 60 
mol%), Pd(OAc)2 (1.8 mg, 7.8 µmol, 30 mol%) and AcOH (1 mL). The reaction mixture was 
stirred at 40 °C for 16 h. The solvent was removed under reduced pressure to give a brown 
residue, which was analysed by HPLC–ESI–MS. 
Method B: To a microwave tube was added peptide 136 (10 mg, 0.026 mmol, 1 eq.), 
diaryliodonium salt 140 (25 mg, 0.052 mmol, 2 eq.), Pd(OAc)2 (0.6 mg, 2.6 µmol, 10 mol%) 
and iPrOH (1 mL). The reaction mixture was stirred at 25 °C for 16 h. The resulting brown 
reaction mixture was filtered through Celite with MeOH (5 mL) and the solvent removed 
under reduced pressure to give a brown residue, which was analysed by HPLC–ESI–MS. 
Method C: To a microwave tube was added peptide 136 (10 mg, 0.026 mmol, 1 eq.), 
aryldiazonium salt 48 (10 mg, 0.052 mmol, 2 eq.), Pd(OAc)2 (1.2 mg, 5.2 µmol, 20 mol%) 
and iPrOH (1 mL). The reaction mixture was stirred at RT for 16 h. The resulting brown 
reaction mixture was filtered through Celite with MeOH (5 mL) and the solvent removed 
under reduced pressure to give a brown residue, which was analysed by HPLC–ESI–MS. 
ESI–MS m/z (ion, %):  465 ([M+H]+, 100). 
Lab book reference number (method A): TJW/7/53/597 (reaction conducted by T. Williams) 
Lab book reference number (method B): AJR-6-543 
Lab book reference number (method C): AJR-6-539 
 
 




1H-indol-3-yl)propanamido]propanoic acid (139) 
 
Method A: To a microwave tube was added peptide 138 (10 mg, 0.022 mmol, 1 eq.), 
phenylboronic acid 14 (13 mg, 0.11 mmol, 5 eq.), Cu(OAc)2 (2.4 mg, 0.0132 mmol, 60 
mol%), Pd(OAc)2 (1.5 mg, 0.0066 mmol, 30 mol%) and AcOH (1 mL). The reaction mixture 
was stirred at 40 °C for 16 h. The solvent was removed under reduced pressure to give a 
brown residue, which was analysed by HPLC–ESI–MS. 
Method B: To a microwave tube was added peptide 138 (10 mg, 0.022 mmol, 1 eq.), 
diaryliodonium salt 140 (21 mg, 0.044 mmol, 2 eq.), Pd(OAc)2 (0.5 mg, 0.0022 mmol, 10 
mol%) and iPrOH (1 mL). The reaction mixture was stirred at 25 °C for 16 h. The resulting 
brown reaction mixture was filtered through Celite with MeOH (5 mL) and the solvent 
removed under reduced pressure to give a brown residue, which was analysed by HPLC–
ESI–MS. 
Method C: To a microwave tube was added peptide 138 (10 mg, 0.022 mmol, 1 eq.), 
aryldiazonium salt 48 (8.4 mg, 0.044 mmol, 2 eq.), Pd(OAc)2 (1.0 mg, 4.4 µmol, 20 mol%) 
and iPrOH (1 mL). The reaction mixture was stirred at RT for 16 h. The resulting brown 
reaction mixture was filtered through Celite with MeOH (5 mL) and the solvent removed 
under reduced pressure to give a brown residue, which was analysed by HPLC–ESI–MS. 
ESI–MS m/z (ion, %):  538 ([M+H]+, 100). 
Lab book reference number (method A): TJW/7/55/598 (reaction conducted by T. Williams) 
Lab book reference number (method B): AJR-6-544 
Lab book reference number (method C): AJR-6-540 
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Phenyl(2,4,6-trimethylphenyl)iodonium trifluoromethanesulfonate (140)124 
 
Aryliodonium salt 22 (3.22 g, 10 mmol, 1 eq.) and 1,3,5-trimethylbenzene 141 (1.54 mL, 
1.32 g, 11 mmol, 1.1 eq.) were added to a round-bottomed flask and dissolved in CH2Cl2 (20 
mL) with stirring. The mixture was cooled to 0 °C then trifluoromethanesulfonic acid (0.96 
mL, 1.65 g, 11 mmol, 1.1 eq.) was added dropwise with stirring. After complete addition the 
reaction was stirred for 2 h over which time it was allowed to warm to RT. After 2 h the 
mixture was evaporated to give an orange-white residue to which Et2O was added to 
precipitate a white solid. This was filtered through a glass sinter and washed on the filter with 
further Et2O until the filtrate ran clear. This was then dried in vacuo at 100 °C to afford the 
title compound as a white solid (4.49 g, 95%). 
M.P. 149–150 °C (lit.197 147–148 °C); 1H NMR (400 MHz, CDCl3, δ): 7.69 (d, J = 7.5 Hz, 
2H), 7.51 (t, J = 7.5 Hz, 1H), 7.39 (t, J = 7.5 Hz, 2H), 7.09 (s, 2H), 2.61 (s, 6H), 2.34 (s, 3H); 
13C NMR (101 MHz, CDCl3, δ): 144.5, 142.6, 133.1, 132.4, 131.9, 130.5, 120.5, 111.8, 27.2, 
21.2; 19F NMR (376 MHz, CDCl3, δ): −78.2; ESI–MS m/z (ion, %): 323 ([M−OTf]+, 100); 
ESI–HRMS m/z: 323.0303 [M−OTf]+ (C15H16I requires 323.0291); IR (solid-state, ATR, cm-
1): 3060 (w), 2919 (w), 1445 (m), 1247 (s), 1222 (s), 1158 (s), 1025 (s), 985 (m), 945 (w), 
857 (m), 741 (s), 683 (m), 632 (s), 574 (m), 515 (s), 454 (m); Elemental anal.: C 40.43, H 
3.24 (C16H16F3IO3S requires C 40.69, H 3.41). 
Lab book reference number: AJR-4-318 
Optimisation of the direct arylation of tryptophan 
 
To a microwave tube was added tryptophan 74 (50 mg, 0.192 mmol, 1 eq.), diaryliodonium 
salt 140 (181 mg, 0.384 mmol, 2 eq.), Pd(OAc)2 (2 mg, 9.6 μmol, 5 mol%) and solvent (5 
mL). The reaction mixture was stirred at 25 °C for 16 h. After 16 h the resulting reaction 
mixture was filtered through Celite then washed with sat. aq. NaHCO3. The organic layer 
was collected and dried over MgSO4, filtered and evaporated to give a brown solid, which 
was subsequently analysed by 1H NMR spectroscopy. 
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Lab book reference number (AcOH): AJR-3-212 (conducted at 40 °C) 
Lab book reference number (MeCN): AJR-3-247 
Lab book reference number (Acetone): AJR-3-249 
Lab book reference number (DCM): AJR-3-248 
Lab book reference number (DMF): AJR-4-285 
Lab book reference number (DMSO): AJR-3-251 
Lab book reference number (1,4-dioxane): AJR-3-260 
Lab book reference number (H2O): AJR-3-258 
Lab book reference number (MeOH): AJR-3-255 
Lab book reference number (EtOH): AJR-3-256 
Lab book reference number (iPrOH): AJR-3-261 
Methyl (2S)-2-acetamido-3-[2-(2,4,6-trimethylphenyl)-1H-indol-3-yl]propanoate (142) 
 
Method A: Title compound was isolated as an off-white solid side product from the synthesis 
of 75 by method B (2 mg, 3%). 
Method B: Synthesised using general procedure C (with a reaction time of 24 h) with 
aryldiazonium salt 48 (45 mg, 0.192 mmol, 1 eq.). Purification by dry-loaded flash column 
chromatography (SiO2, petrol/EtOAc, 1:1, v/v) afforded the title compound as an off-white 
solid (60 mg, 83%). 
Method C: Synthesised as in method B using Pd(OTs)2(MeCN)2 215 (5.1 mg, 9.6 µmol, 5 
mol%) in place of Pd(OAc)2. Purification by dry-loaded flash column chromatography (SiO2, 
petrol/EtOAc, 1:1, v/v) afforded the title compound as an off-white solid (55 mg, 75%). 
Method D: Reaction conducted as in method C using Pd(OTs)2(MeCN)2 215 (2.5 mg, 4.8 
µmol, 2.5 mol%) to afford a crude brown solid. 1H NMR spectroscopic analysis indicated 
72% conversion to the title compound, which was not purified. 
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Method E: Reaction conducted as in method C using Pd(OTs)2(MeCN)2 215 (1 mg, 1.92 
µmol, 1 mol%) to afford a crude brown solid. 1H NMR spectroscopic analysis indicated 45% 
conversion to the title compound, which was not purified. 
Rf 0.31 (petrol/EtOAc, 1:1, v/v); [α]ᴅ = +35.2 (c 0.10, CHCl3); M.P. 158–159 °C; 1H NMR 
(400 MHz, CDCl3, δ): 7.89 (br s, 1H), 7.61 (m, 1H), 7.37–7.33 (m, 1H), 7.20 (ddd, J = 8.0, 
7.0, 1.5 Hz, 1H), 7.14 (ddd, J = 8.0, 7.0, 1.5 Hz, 1H), 6.99 (s, 1H), 6.97 (s, 1H), 5.64 (d, J = 
7.5 Hz, 1H), 4.72 (dt, J = 7.5, 5.0 Hz, 1H), 3.47 (s, 3H), 3.17 (dd, J = 15.0, 5.0 Hz, 1H), 3.02 
(dd, J = 15.0, 5.0 Hz, 1H), 2.35 (s, 3H), 2.11 (s, 3H), 2.10 (s, 3H), 1.75 (s, 3H); 13C NMR 
(101 MHz, (CDCl3, δ): 172.5, 169.9, 138.9, 138.3, 138.2, 135.9, 134.7, 128.8, 122.1, 119.9, 
118.8, 110.9, 108.0, 100.1, 53.1, 52.3, 27.2, 23.1, 21.3, 20.4, 20.3; ESI–MS m/z (ion, %): 379 
([M+H]+, 40), 401 ([M+Na]+, 100); ESI–HRMS m/z: 379.2015 [M+H]+ (C23H27N2O3 requires 
379.2016); IR (solid-state, ATR, cm-1): 3402 (w), 3289 (w, br), 2953 (w), 2919 (w), 2852 
(w), 1741 (s), 1646 (s), 1515 (m), 1458 (m), 1435 (s), 1373 (m), 1304 (w), 1293 (w), 1260 
(w), 1239 (w), 1218 (s), 1129 (m), 1031 (m), 1012 (m), 987 (w), 854 (m), 798 (m), 744 (s), 
591 (m), 505 (s), 445 (m); UV–vis (DMSO, nm): λmax 288 (ε = 15092 mol dm-3 cm-1). 
Crystals suitable for X-ray diffraction were grown by overnight diffusion from a solution of 
CH2Cl2. 
Lab book reference number (method A): AJR-3-252 
Lab book reference number (method B): AJR-5-402 
Lab book reference number (method C): AJR-7-654 
Lab book reference number (method D): AJR-7-647 
Lab book reference number (method E): AJR-7-631 
Phenyl(2,4,6-tri-iso-propylphenyl)iodonium trifluoromethanesulfonate (143)124 
 
Aryliodonium salt 22 (805 mg, 2.5 mmol, 1 eq.) and 1,3,5-tri-iso-propylbenzene (665 µL, 
562 mg, 2.75 mmol, 1.1 eq.) were added to a round-bottomed flask and dissolved in CH2Cl2 
(5 mL) with stirring. The mixture was cooled to 0 °C then trifluoromethanesulfonic acid (241 
µL, 413 mg, 2.75 mmol, 1.1 eq.) was added dropwise with stirring. After complete addition 
the reaction was stirred for 2 h over which time it was allowed to warm to RT. After 2 h the 
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mixture was evaporated to give an orange-white residue to which Et2O was added to 
precipitate a white solid. This was filtered through a glass sinter and washed on the filter with 
further Et2O until the filtrate ran clear. This was then dried in vacuo at 100 °C to afford the 
title compound as a white solid (1.19 g, 86%). 
M.P. 177–179 °C (lit.124 169–179 °C); 1H NMR (400 MHz, CDCl3, δ): 7.70–7.65 (m, 2H), 
7.58–7.52 (m, 1H), 7.47–7.40 (m, 2H), 7.19 (s, 2H), 3.25 (quin, J = 6.5 Hz, 2H), 2.96 (hept, 
J = 7.0 Hz, 1H), 1.26 (dd, J = 15.0, 7.0 Hz, 18H); 13C NMR (101 MHz, CDCl3, δ): 155.9, 
152.6, 132.7, 132.1, 125.5, 120.4, 113.0, 39.7, 34.4, 24.4, 23.8; ESI–MS m/z (ion, %): 407 
([M−OTf]+, 100); ESI–HRMS m/z: 407.1247 [M−OTf]+ (C21H28I requires 407.1230); 
Elemental anal.: C 47.26, H 4.93 (C22H28F3IO3S requires C 47.49, H 5.07). 
Lab book reference number: AJR-2-165 
Phenyl(2,4,6-trimethylphenyl)iodonium tetrafluoroborate (144)124 
 
Phenylboronic acid 14 (305 mg, 2.5 mmol, 1 eq.) was added to a round-bottomed flask, 
dissolved in CH2Cl2 (50 mL) and cooled to 0 °C. BF3·OEt2 (0.3 mL, 390 mg, 2.75 mmol, 1.1 
eq.) was added dropwise and the solution stirred for 10 min before addition of a solution of 
aryliodonium salt 23 (910 mg, 2.5 mmol, 1 eq.) in CH2Cl2 (10 mL) dropwise over 10 min. 
After complete addition the reaction was stirred for 2 h over which time it was allowed to 
warm to RT. After 2 h a sat. aq. sodium tetrafluoroborate solution (50 mL) was added and 
the solution stirred vigorously for 30 min. After this time the phases were separated and the 
aqueous layer extracted twice with CH2Cl2 (2 × 50 mL). The organic layers were combined, 
dried over MgSO4, filtered and evaporated to give an off-white solid. The product was 
precipitated from a hot CH2Cl2 solution of the crude residue by addition of cold Et2O. This 
solid was filtered through a glass sinter and washed with Et2O before being dried in vacuo to 
afford the title compound as a white solid (728 mg, 71%). 
1H NMR (400 MHz, CDCl3, δ): 7.75–7.65 (m, 2H), 7.62–7.52 (m, 1H), 7.44 (ddt, J = 8.5, 
8.0 Hz, 2H), 7.13 (dd, J = 1.5, 1.0 Hz, 2H), 2.63 (s, 6H), 2.37 (s, 3H); 13C NMR (101 MHz, 
CDCl3, δ): 145.1, 143.1, 133.0, 132.8, 132.2, 130.8, 118.9, 110.7, 101.0, 27.4, 21.3; 11B NMR 
(128 MHz, CDCl3, δ): −2.0; 19F NMR (376 MHz, CDCl3, δ): −147.3 (m, 1JF–10B, 4F), −147.3 
(m, 1J
F–11B
, 4F); ESI–MS m/z (ion, %): 323 ([M−BF4]+, 100); ESI–HRMS m/z: 323.0306 
Chapter 6: Experimental 
161 
 
[M−BF4]+ (C15H16I requires 323.0291); Elemental anal.: C 44.04, H 3.83 (C15H16BF4I 
requires C 43.94, H 3.93). 
Lab book reference number: AJR-2-158 
Phenyl(2,4,6-trimethylphenyl)iodonium hexafluorophosphate (145)124 
 
Phenylboronic acid 14 (305 mg, 2.5 mmol, 1 eq.) was added to a round-bottomed flask, 
dissolved in CH2Cl2 (50 mL) and cooled to 0 °C. BF3·OEt2 (0.3 mL, 390 mg, 2.75 mmol, 1.1 
eq.) was added dropwise and the solution stirred for 10 min before addition of a solution of 
aryliodonium salt 23 (910 mg, 2.5 mmol, 1 eq.) in CH2Cl2 (10 mL) dropwise over 10 min. 
After complete addition the reaction was stirred for 2 h over which time it was allowed to 
warm to RT. After 2 h a sat. aq. sodium hexafluorophosphate solution (50 mL) was added 
and the solution stirred vigorously for 30 min. After this time the phases were separated and 
the aqueous layer extracted twice with CH2Cl2 (2 × 50 mL). The organic layers were 
combined, dried over MgSO4, filtered and evaporated to give an off-white solid. The product 
was precipitated from a hot CH2Cl2 solution of the crude residue by addition of cold Et2O. 
This solid was filtered through a glass sinter and washed with Et2O before being dried in 
vacuo to afford the title compound as a white solid (443 mg, 38%). 
M.P. 182–183 °C ; 1H NMR (400 MHz, (CD3)2SO, δ): 8.03–7.92 (m, 2H), 7.68–7.58 (m, 1H), 
7.55–7.45 (m, 2H), 7.22 (s, 2H), 2.60 (s, 6H), 2.29 (s, 3H); 13C NMR (101 MHz, (CD3)2SO, 
δ): 143.1, 141.6, 134.5, 131.9, 129.8, 122.6, 114.5, 26.3, 20.5; 19F (376 MHz, (CD3)2SO, δ): 
−70.0 (d, 1JF–P = 711.5 Hz); 31P NMR (162 MHz, (CD3)2SO, δ): −143.6 (hept, 1JP–F = 711.5 
Hz); ESI–MS m/z (ion, %): 323 ([M−PF6]+, 100); ESI–HRMS m/z: 323.0303 [M−PF6]+ 
(C15H16I requires 323.0291); IR (solid-state, ATR, cm-1): 1584 (w), 1564 (w), 1470 (w), 1444 
(w), 1383 (w), 1302 (w), 982 (w), 825 (s), 732 (m), 677 (w), 648 (w), 556 (s), 448 (w); 
Elemental anal.: C 38.70, H 3.28 (C15H16F6IP requires C 38.48, H 3.44). 
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Phenyl(2,4,6-trimethylphenyl)iodonium hexafluorostibate (146)198 
 
Diaryliodonium trifluoromethanesulfonate salt 140 (945 mg, 2.0 mmol, 1 eq.) was added to 
a round-bottomed flask equipped with a magnetic stirrer, dissolved in MeCN (3 mL) and 
stirred at RT for 5 min. To this was added a solution of NaSbF6 (1.55 g, 6.0 mmol, 3 eq.) in 
deionised water (20 mL) and the resultant mixture stirred vigorously for 30 min at RT. After 
30 min CH2Cl2 was added and the phases separated. The aqueous layer was then extracted 
three times with CH2Cl2 (3 × 50 mL). The organic layers were combined, dried over MgSO4, 
filtered and Et2O added to precipitate a white solid. This solid was filtered through a glass 
sinter and washed with Et2O before being dried in vacuo to afford the title compound as a 
white solid (1.05 g, 94%). 
M.P. 172–173 °C; 1H NMR (400 MHz, (CD3)2SO, δ): 8.02–7.94 (m, 2H), 7.67–7.59 (m, 1H), 
7.50 (ddd, J = 8.5, 7.5, 1.5 Hz, 2H), 7.26–7.18 (m, 2H), 2.60 (s, 6H), 2.29 (s, 3H); 13C NMR 
(101 MHz, (CD3)2SO, δ): 143.2, 141.6, 134.5, 131.9, 129.8, 122.6, 114.5, 26.3, 20.5; 19F (376 
MHz, (CD3)2SO, δ): −77.7; ESI–MS m/z (ion, %): 323 ([M−SbF6]+, 100); ESI–HRMS m/z: 
323.0294 [M−SbF6]+ (C15H16I requires 323.0291). 
Lab book reference number: AJR-4-338 
Counter-ion screen for the direct arylation of tryptophan 
 
To a microwave tube was added tryptophan 74 (50 mg, 0.192 mmol, 1 eq.), the appropriate 
diaryliodonium salt (0.384 mmol, 2 eq.), Pd(OAc)2 (2 mg, 9.6 μmol, 5 mol%) and EtOAc (5 
mL). The reaction mixture was stirred at 25 °C for 16 h. After 16 h the resulting reaction 
mixture was filtered through Celite then washed with sat. aq. NaHCO3. The organic layer 
was collected and dried over MgSO4, filtered and evaporated to give a brown solid, which 
was subsequently analysed by 1H NMR spectroscopy. 
Lab book reference number (−OTf): AJR-3-252 
Lab book reference number (−BF4): AJR-3-263 
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Lab book reference number (−PF6): AJR-3-264 
Lab book reference number (−SbF6): AJR-4-340 
Diphenyliodonium tosylate (132)199 
 
Diphenyliodonium tetrafluoroborate 233 (2.02 g, 5.49 mmol, 1 eq.) was added to a round-
bottomed flask equipped with a magnetic stirrer and dissolved in CH2Cl2 (25 mL). To this 
was added a solution of NaOTs (10.7 g, 55 mmol, 10 eq.) in deionised water (50 mL) and the 
resultant mixture stirred vigorously for 30 min at RT. After 30 min the phases were separated 
and the aqueous layer extracted three times with CH2Cl2. The organic layers were combined 
and evaporated, before being redissolved in CH2Cl2 (25 mL). To this was added a solution of 
NaOTs (10.7 g, 55 mmol, 10 eq.) in deionised water (50 mL) and the resultant mixture stirred 
vigorously for 30 min at RT. After 30 min the phases were separated and the aqueous layer 
extracted three times with CH2Cl2. The organic layers were combined and evaporated, then 
Et2O was added and the mixture kept at −18 °C overnight. The resultant precipitate was 
filtered through a glass sinter and washed with Et2O before being dried in vacuo to afford the 
title compound as an off-white solid (1.26 g, 51%). 
M.P. 152–155 °C (lit.200 160–161 °C); 1H NMR (400 MHz, (CD3)2SO, δ): 7.93 (d, J = 8.0 
Hz, 4H), 7.46 (t, J = 7.5 Hz, 2H), 7.41 (d, J = 8.0 Hz, 2H), 7.30 (t, J = 7.5 Hz, 4H), 6.97 (d, 
J = 8.0 Hz, 2H), 2.27 (s, 3H); 13C NMR (101 MHz, (CD3)2SO, δ): 142.7, 139.4, 135.4, 131.6, 
131.6, 128.6, 126.0, 115.7, 21.4; ESI–MS m/z (ion, %): 281 ([M−OTs]+, 100); ESI–HRMS 
m/z: 280.9827 [M−OTs]+ (C12H10I requires 280.9822). 
Lab book reference number: AJR-5-433 
Evaluation of Ackermann conditions in the direct arylation of tryptophan 
 
To an oven-dried Schlenk tube equipped with a magnetic stirrer bar was added tryptophan 
74 (65 mg, 0.25 mmol, 1 eq.) and diphenyliodonium salt 132 (170 mg, 0.375 mmol, 1.5 eq.). 
For entries 3 and 4, Pd(OAc)2 (2.8 mg, 12.5 μmol, 5 mol%) was also added at this stage. The 
Chapter 6: Experimental 
164 
 
Schlenk tube was then evacuated and backfilled with N2 (3 cycles) for entries 1 and 3; for 
entries 2 and 4 it was left open to air. Dry DMF (2 mL) was added and the reaction stirred at 
100 °C for 17 h. After 17 h the reaction was allowed to cool to RT, then those reactions 
containing Pd(OAc)2 (entries 3 and 4) were filtered through Celite with EtOAc. Deionised 
water (5 mL) was added and extracted into EtOAc (2 × 20 mL). The organic layers were then 
combined and dried over MgSO4, filtered and evaporated to give a brown solid, which was 
subsequently analysed by 1H NMR spectroscopy. 
Lab book reference number (entry 1): AJR-5-436 
Lab book reference number (entry 2): AJR-5-438 
Lab book reference number (entry 3): AJR-5-437 




Acid 148 (463 mg, 2 mmol, 1 eq.), amine 135 (560 mg, 2.2 mmol, 1.1 eq.) and DEPBT (718 
mg, 2.4 mmol, 1.2 eq.) were added to a round-bottomed flask which was fitted with a septum 
and flushed with argon from a balloon for 20 min. After 20 min dry, distilled DIPEA (1.4 
mL, 1.03 g, 8 mmol, 4 eq.) and dry CH2Cl2 (20 mL) were added via syringe to give a yellow 
solution and the reaction stirred at RT for 2 h. After 2 h the reaction mixture was washed 
with sat. aq. NH4Cl and extracted three times with CH2Cl2. The organic layers were 
combined, dried over MgSO4, filtered and evaporated to give a crude yellow residue. 
Purification by dry-loaded flash column chromatography (SiO2, petrol/EtOAc, 1:1, v/v) 
afforded the title compound as an off-white solid (473 mg, 55%). 
Rf 0.42 (petrol/EtOAc, 1:1, v/v); 1H NMR (400 MHz, CDCl3, δ): 8.26 (br s, 1H), 7.52 (d, J = 
8.0 Hz, 1H), 7.33 (d, J = 8.0 Hz, 1H), 7.17 (td, J = 8.0, 7.5, 1.0 Hz, 1H), 7.10 (td, J = 7.5, 
7.1, 1.0 Hz, 1H), 7.05–6.98 (m, 1H), 6.59 (d, J = 8.0 Hz, 1H), 4.95–4.79 (m, 2H), 4.11 (br s, 
1H), 3.65 (s, 3H), 3.31 (d, J = 5.0 Hz, 2H), 1.68–1.53 (m, 2H), 1.41 (s, 9H), 0.94–0.80 (m, 
5H); 13C NMR (101 MHz, CDCl3, δ): 172.4, 172.2, 155.7, 136.2, 127.7, 123.2, 122.3, 119.7, 
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118.7, 111.4, 109.9, 80.1, 53.3, 53.0, 52.5, 41.5, 28.4, 27.7, 24.8, 23.0, 22.0; ESI–MS m/z 
(ion, %): 432 ([M+H]+, 100), 454 ([M+Na]+, 100); ESI–HRMS m/z: 432.2494 [M+H]+ 
(C23H34N3O5 requires 432.2493). 




To a round-bottomed flask equipped with a magnetic stirrer bar was added N-Boc dipeptide 
149 (440 mg, 1.02 mmol, 1 eq.), which was then dissolved in a mixture of CH2Cl2 (8 mL) 
and trifluoroacetic acid (2 mL). Anisole (220 µL, 221 mg, 2.04 mmol, 2 eq.) was then added 
and the reaction stirred at RT for 2 h, during which time the solution turned dark red. After 2 
h the solvent was evaporated to afford a brown solid (338 mg, quant.) which was used in the 
next step without further purification or characterisation. 




Acid 151 (202 mg, 0.93 mmol, 1 eq.), amine 150 (338 mg, 1.02 mmol, 1.1 eq.) and DEPBT 
(335 mg, 1.12 mmol, 1.2 eq.) were added to a round-bottomed flask which was fitted with a 
septum and flushed with argon from a balloon for 20 min. After 20 min dry, distilled DIPEA 
(0.65 mL, 481 mg, 3.72 mmol, 4 eq.) and dry CH2Cl2 (9.3 mL) were added via syringe to 
give a yellow solution and the reaction stirred at RT for 2 h. After 2 h the reaction mixture 
was washed with sat. aq. NH4Cl and extracted three times with CH2Cl2. The organic layers 
were combined, dried over MgSO4, filtered and evaporated to give a crude yellow residue. 
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Purification by dry-loaded flash column chromatography (SiO2, petrol/EtOAc, 1:1, v/v) 
afforded the title compound as an off-white solid (266 mg, 54%). 
Rf 0.22 (petrol/EtOAc, 1:1, v/v); 1H NMR (400 MHz, CDCl3, δ): 8.44 (br s, 1H), 7.49 (dd, J 
= 8.0, 1.0 Hz, 1H), 7.33 (dt, J = 8.0, 1.0 Hz, 1H), 7.16 (ddd, J = 8.0, 7.0, 1.0 Hz, 1H), 7.09 
(ddd, J = 8.0, 7.0, 1.0 Hz, 1H), 7.01–6.95 (m, 1H), 6.64 (d, J = 8.0 Hz, 1H), 6.34 (d, J = 8.5 
Hz, 1H), 4.98 (d, J = 9.0 Hz, 1H), 4.86 (dt, J = 8.0, 5.5 Hz 1H), 4.46 (td, J = 9.0, 5.5 Hz, 1H), 
3.90 (t, J = 7.5 Hz, 1H), 3.65 (s, 3H), 3.29 (dd, J = 5.5, 3.0 Hz, 2H), 2.14–2.01 (m, 1H), 1.69–
1.53 (m, 2H), 1.44 (s, 9H), 0.94–0.76 (m, 11H); 13C NMR (101 MHz, CDCl3, δ): 172.1, 
171.8, 171.3, 136.2, 127.6, 123.4, 122.2, 119.7, 118.6, 111.5, 109.6, 80.5, 60.2, 52.8, 52.5, 
51.6, 40.8, 30.6, 28.4, 27.6, 24.7, 23.0, 22.0, 19.3, 17.5; ESI–MS m/z (ion, %): 531 ([M+H]+, 
60), 553 ([M+Na]+, 100); ESI–HRMS m/z: 553.3010 [M+Na]+ (C28H42N4NaO6 requires 
553.2997). 




To a round-bottomed flask equipped with a magnetic stirrer bar was added N-Boc tripeptide 
152 (240 mg, 0.45 mmol, 1 eq.), which was then dissolved in a mixture of CH2Cl2 (3.6 mL) 
and trifluoroacetic acid (0.9 mL). Anisole (100 µL, 97 mg, 0.90 mmol, 2 eq.) was then added 
and the reaction stirred at RT for 1 h. After 1 h the solvent was evaporated to afford a red 
solid (194 mg, quant.) which was used in the next step without further purification or 
characterisation. 
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Methyl (2R)-2-amino-4-methylpentanoate hydrochloride (155) 
 
Thionyl chloride (3.04 mL, 4.98 g, 41.9 mmol, 1.1 eq.) was added dropwise at 0 °C to a 
round-bottomed flask containing MeOH (30 mL). ʟ-Leucine 154 (5 g, 38.1 mmol, 1 eq.) was 
then added in three portions, resulting in a white suspension. The reaction mixture was 
warmed to 40 °C and stirred for 16 h. During this time a clear solution was formed. Water (5 
mL) was added to the reaction mixture and the solvent removed under reduced pressure to 
afford the title compound as an off-white solid (6.72 g, 97%). 
1H NMR (400 MHz, CD3OD, δ): 4.04 (t, J = 6.5 Hz, 1H), 3.84 (s, 3H), 1.87–1.65 (m, 3H), 
0.99 (dd, J = 6.0, 4.0 Hz, 6H); 13C NMR (101 MHz, CD3OD, δ): 171.5, 53.8, 52.5, 40.6, 25.5, 
22.5, 22.4; ESI–MS m/z (ion, %): 146 ([C7H16NO2]+, 100); ESI–HRMS m/z: 146.1176 
[C7H16NO2]+ (C7H16NO2 requires 146.1176). 
The analytical data obtained was in accordance with the literature.201 




Acid 148 (1 g, 4.32 mmol, 1 eq.), amine 155 (863 mg, 4.75 mmol, 1.1 eq.) and TBTU (1.66 
g, 5.18 mmol, 1.2 eq.) were added to a round-bottomed flask which was fitted with a septum 
and flushed with argon from a balloon for 20 min. After 20 min dry, distilled DIPEA (3 mL, 
2.2 g, 17.28 mmol, 4 eq.) and dry CH3CN (43 mL) were added via syringe to give a yellow 
solution and the reaction stirred at RT for 2 h. After 2 h the reaction mixture was washed 
with sat. aq. NH4Cl and extracted three times with CH2Cl2. The organic layers were 
combined, dried over MgSO4, filtered and evaporated to give a crude yellow residue. 
Purification by dry-loaded flash column chromatography (SiO2, petrol/EtOAc, 1:1, v/v) 
afforded the title compound as a white solid (1.37 g, 88%). 
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Rf 0.58 (petrol/EtOAc, 1:1, v/v); 1H NMR (400 MHz, CDCl3, δ): 6.43 (d, J = 8.5 Hz, 1H), 
4.93–4.79 (m, 1H), 4.61 (td, J = 8.5, 4.5 Hz, 1H), 4.16–4.02 (m, 1H), 3.72 (s, 3H), 1.73–1.60 
(m, 6H), 1.44 (s, 9H), 0.98–0.87 (m, 12H); 13C NMR (101 MHz, CDCl3, δ): 173.3, 173.3, 
172.3, 100.1, 52.4, 50.7, 28.4, 24.9, 24.8, 23.0, 21.9; ESI–MS m/z (ion, %): 359 ([M+H]+, 
50), 381 ([M+Na]+, 100); ESI–HRMS m/z: 359.2539 [M+H]+ (C18H35N2O5 requires 
359.2540). 




To a round-bottomed flask equipped with a magnetic stirrer bar was added O-Me dipeptide 
156 (800 mg, 2.23 mmol, 1 eq.) and LiOH·H2O (374 mg, 8.92 mmol, 4 eq.). MeOH (22 mL) 
was then added and the solution stirred at RT for 16 h. After 16 h the solution was acidified 
to pH 1 using 1M HCl, then extracted into CH2Cl2 three times. The organic layers were 
combined, dried over MgSO4, filtered and evaporated to afford a white solid (744 mg, 97%), 
which was used in the next step without further purification or characterisation. 





Acid 157 (141 mg, 0.41 mmol, 1 eq.), amine 153 (194 mg, 0.45 mmol, 1.1 eq.) and DEPBT 
(147 mg, 0.49 mmol, 1.2 eq.) were added to a round-bottomed flask which was fitted with a 
septum and flushed with argon from a balloon for 20 min. After 20 min dry, distilled DIPEA 
(0.29 mL, 212 mg, 1.64 mmol, 4 eq.) and dry CH3CN (4.1 mL) were added via syringe to 
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give a yellow solution and the reaction stirred at RT for 2 h. After 2 h the reaction mixture 
was washed with sat. aq. NH4Cl and extracted three times with CH2Cl2. The organic layers 
were combined, dried over MgSO4, filtered and evaporated to give a crude yellow residue. 
Purification by dry-loaded flash column chromatography (SiO2, petrol/EtOAc, 1:3, v/v) 
afforded the title compound as a brown solid (209 mg, 67%). 
Rf 0.50 (petrol/EtOAc, 1:3, v/v); 1H NMR (400 MHz, CD3OD, δ): 7.50 (dt, J = 8.0, 1.0 Hz, 
1H), 7.32 (dt, J = 8.0, 1.0 Hz, 1H), 7.11–7.05 (m, 2H), 7.00 (ddd, J = 8.0, 7.0, 1.0 Hz, 1H), 
4.70 (dd, J = 7.5, 6.0 Hz, 1H), 4.45 (ddt, J = 9.0, 6.0, 2.5 Hz, 2H), 4.13–4.04 (m, 2H), 3.63 
(s, 2H), 3.28–3.17 (m, 2H), 2.04–1.93 (m, 1H), 1.70–1.50 (m, 9H), 1.46–1.41 (m, 9H), 0.98–
0.79 (m, 24H); 13C NMR (101 MHz, CD3OD, δ): 175.6, 174.5, 174.4, 173.7, 173.3, 157.8, 
138.0, 128.7, 124.5, 122.4, 119.8, 119.1, 112.3, 110.4, 80.5, 60.1, 54.8, 54.7, 54.5, 53.2, 52.9, 
52.6, 52.6, 42.1, 42.0, 32.1, 30.1, 28.7, 28.5, 25.9, 25.8, 25.7, 23.5, 23.5, 23.4, 22.3, 22.1, 
19.8, 19.7, 18.9; ESI–MS m/z (ion, %): 757 ([M+H]+, 7), 775 ([M+NH4]+, 60), 779 ([M+Na]+, 
100); ESI–HRMS m/z: 779.4692 [M+Na]+ (C40H64N6NaO8 requires 779.4678). 





To a microwave tube was added peptide 158 (145 mg, 0.192 mmol, 1 eq.), aryliodonium salt 
140 (181 mg, 0.384 mmol, 2 eq.), Pd(OAc)2 (13 mg, 0.058 mmol, 30 mol%) and EtOAc (5 
mL). The reaction mixture was stirred at 25 °C for 16 h. After 16 h the resulting black reaction 
mixture was filtered through Celite then washed with sat. aq. NaHCO3. The organic layer 
was collected and dried over MgSO4, filtered and evaporated to give a brown solid. 
The title compound could not be isolated from starting material 158. 
ESI–MS m/z (ion, %): 855 ([M+Na]+, 20); ESI–HRMS m/z: 855.4980 [M+Na]+ 
(C46H68N6NaO8 requires 855.4996). 
Lab book reference number: AJR-4-341 






To a microwave tube was added dipeptide 149 (83 mg, 0.192 mmol, 1 eq.), phenylboronic 
acid 14 (47 mg, 0.384 mmol, 2 eq.), Cu(OAc)2 (3.5 mg, 0.0192 mmol, 10 mol%), Pd(OAc)2 
(2 mg, 9.6 μmol, 5 mol%) and AcOH (5 mL). The reaction mixture was stirred at 40 °C for 
16 h. After 16 h the resulting black reaction mixture was filtered through Celite and the 
solvent removed under reduced pressure to give a brown solid. This was dissolved in EtOAc 
(10 mL) then washed with sat. aq. NaHCO3. The organic layer was collected, dried over 
MgSO4, filtered and evaporated to give a brown solid. Purification by dry-loaded flash 
column chromatography (SiO2, petrol/EtOAc, 1.5:1, v/v) afforded the title compound as an 
off-white solid (30 mg, 31%). 
Rf 0.37 (petrol/EtOAc, 1.5:1, v/v); M.P. 55–58 °C; 1H NMR (400 MHz, CDCl3, δ): 8.24 (br 
s, 1H), 7.63–7.54 (m, 3H), 7.51–7.45 (m, 2H), 7.41–7.33 (m, 2H), 7.20 (ddd, J = 8.0, 7.0, 1.0 
Hz, 1H), 7.15 (ddd, J = 8.0, 7.0, 1.0 Hz, 1H), 6.35 (d, J = 7.5 Hz, 1H), 4.81 (d, J = 7.5 Hz, 
1H), 4.56–4.43 (m, 1H), 3.92 (s, 1H), 3.50 (d, J = 6.0 Hz, 2H), 3.30 (s, 3H), 1.57–1.47 (m, 
3H), 1.41 (s, 9H), 0.84 (dd, J = 6.5, 2.5 Hz, 6H); 13C NMR (101 MHz, CDCl3, δ): 172.2, 
172.0, 136.0, 135.8, 133.2, 129.7, 129.5, 129.3, 128.4, 128.3, 122.8, 120.2, 119.2, 115.5, 
111.1, 52.2, 41.6, 28.4, 27.2, 24.7, 23.2; ESI–MS m/z (ion, %): 508 ([M+H]+, 30), 530 
([M+Na]+, 100); ESI–HRMS m/z: 508.2814 [M+H]+ (C29H38N3O5 requires 508.2806); IR 
(solid-state, ATR, cm-1): 3395 (m, br), 3312 (m, br), 2956 (m), 2929 (m), 2870 (m), 2028 
(w), 1885 (w), 1696 (s), 1659 (s), 1604 (w), 1594 (w), 1501 (s), 1455 (s), 1367 (s), 1248 (m), 
1217 (m), 1164 (s), 1047 (w), 1021 (w), 910 (w), 741 (s), 698 (m); UV–vis (DMSO, nm): 
λmax 308 (ε = 12870 mol dm-3 cm-1). 
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Methyl (2S)-2-{[(tert-butoxy)carbonyl]amino}-3-(1H-indol-3-yl)propanoate (161)202 
 
To a round-bottomed flask containing a solution of tryptophan 135 (1 g, 3.9 mmol, 1 eq.) and 
K2CO3 (539 mg, 3.9 mmol, 1 eq.) in deionised water (10 mL) was added a solution of di-tert-
butyl dicarbonate (851 mg, 3.9 mmol, 1 eq.) in acetone (10 mL) at 0 °C with stirring. The 
solution was stirred for 2 h during which time it was allowed to warm to RT. After 2 h the 
acetone was removed under reduced pressure and deionised water added. This was extracted 
into EtOAc three times, dried over MgSO4, filtered and evaporated to afford the title 
compound as an off-white solid (1.06 g, 85%). 
[α]ᴅ = +43.1 (c 0.10, CHCl3); Mp 146–148 °C (lit.203 145–146 °C); 1H NMR (400 MHz, 
CDCl3, δ): 8.20 (br s, 1H), 7.55 (d, J = 8.0 Hz, 1H), 7.35 (dt, J = 8.0, 1.0 Hz, 1H), 7.19 (ddd, 
J = 8.0, 7.0, 1.0 Hz, 1H), 7.12 (ddd, J = 8.0, 7.0, 1.0 Hz, 1H), 6.99 (d, J = 8.0 Hz, 1H), 5.09 
(d, J = 8.0 Hz, 1H), 4.64 (dt, J = 8.0, 5.0 Hz, 1H), 3.68 (s, 3H), 3.31 (dd, J = 15.0, 5.0 Hz, 
1H), 3.29 (dd, J = 15.0, 5.0 Hz, 1H), 1.43 (s, 9H); 13C NMR (101 MHz, CDCl3, δ): 172.9, 
155.4, 136.3, 127.6, 123.0, 122.1, 119.5, 118.6, 111.4, 109.8, 80.0, 54.3, 52.3, 28.4, 28.0; 
ESI–MS m/z (ion, %): 319 ([M+H]+, 14), 341 ([M+Na]+, 100); ESI–HRMS m/z: 341.1465 
[M+Na]+ (C17H22N2NaO4 requires 341.1472). 




To a microwave tube was added tryptophan 161 (61 mg, 0.192 mmol, 1 eq.), diaryliodonium 
salt 140 (181 mg, 0.384 mmol, 2 eq.), Pd(OAc)2 (2 mg, 9.6 μmol, 5 mol%) and EtOAc (5 
mL). The reaction mixture was stirred at 25 °C for 16 h. After 16 h the resulting reaction 
mixture was filtered through Celite then washed with sat. aq. NaHCO3. The organic layer 
was collected and dried over MgSO4, filtered and evaporated to give a brown solid. 
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Attempted purification by dry-loaded flash column chromatography (SiO2, petrol/EtOAc, 
1:1, v/v) could not afford the title compound. 
Lab book reference number: AJR-4-315 
(2S)-2-Acetamido-4-methylpentanoic acid (163)204 
 
To a round-bottomed flask containing ʟ-Leucine 154 (1 g, 7.6 mmol, 1 eq.) was added a 
mixture of 1,4-dioxane and deionised water (26 mL, 1:1, v/v) to form a white suspension, 
then NaHCO3 (1.28 g, 15.2 mmol, 2 eq.) was added with stirring. Acetic anhydride (0.72 mL, 
776 mg, 7.6 mmol, 1 eq.) was added dropwise over 10 min then the reaction was heated to 
60 °C to form a clear solution. The solution was stirred at 60 °C for 16 h then evaporated. 
The resulting residue was redissolved in deionised water and acidified to pH 1.5 with 1M 
HCl. This was extracted into EtOAc three times, dried over MgSO4, filtered and evaporated 
to afford the title compound as a white solid (1.11 g, 84%). 
1H NMR (400 MHz, CD3OD, δ): 4.48–4.34 (m, 1H), 1.98 (s, 3H), 1.78–1.64 (m, 1H), 1.64–
1.54 (m, 2H), 0.97 (d, J = 6.5 Hz, 3H), 0.93 (d, J = 6.5 Hz, 3H); 13C NMR (101 MHz, CD3OD, 
δ): 176.1, 173.4, 52.1, 41.6, 26.1, 23.4, 22.3, 21.8; ESI–MS m/z (ion, %): 174 ([M+H]+, 10), 
196 ([M+Na]+, 100); ESI–HRMS m/z: 174.1124 [M+H]+ (C8H16NO3 requires 174.1125); 
Elemental anal.: C 55.69, H 8.72, N 8.05 (C8H15NO3 requires C 55.47, H 8.73, N 8.09). 




Acid 163 (200 mg, 1.15 mmol, 1 eq.), amine 135 (323 mg, 1.27 mmol, 1.1 eq.) and DEPBT 
(413 mg, 1.38 mmol, 1.2 eq.) were added to a round-bottomed flask which was fitted with a 
septum and flushed with argon from a balloon for 20 min. After 20 min dry, distilled DIPEA 
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(802 µL, 595 mg, 4.60 mmol, 4 eq.) and dry CH2Cl2 (12 mL) were added via syringe to give 
a yellow solution and the reaction stirred at RT for 2 h. After 2 h the reaction mixture was 
washed with sat. aq. NH4Cl and extracted three times with CH2Cl2. The organic layers were 
combined, dried over MgSO4, filtered and evaporated to give a crude yellow residue. 
Attempted purification by dry-loaded flash column chromatography (SiO2, EtOAc/MeOH, 
98:2, v/v) could not afford the title compound. 
Lab book reference number: AJR-4-311 
Methyl (2S)-3-(1H-indol-3-yl)-2-(trifluoroacetamido)propanoate (92) 
 
To a round-bottomed flask containing tryptophan 135 (1.27 g, 5 mmol, 1 eq.) was added 
triethylamine (0.75 mL, 0.54 g, 5 mmol, 1 eq.) and MeOH (2.5 mL) and the resulting 
suspension stirred for 5 min. After 5 min ethyl trifluoroacetate 165 (0.85 mL, 1.01 g, 6.35 
mmol, 1.27 eq.) was added and the mixture stirred at RT for 16 h, during which time a clear 
solution formed. After 16 h the solvent was evaporated and the resulting residue acidified 
with 2M HCl, before being extracted into EtOAc three times. The organic layers were 
combined then washed with brine, dried over MgSO4, filtered and evaporated to afford the 
title compound as an off-white solid (1.35 g, 90%). 
Rf 0.16 (petrol/EtOAc, 3:1, v/v); [α]ᴅ = +50.7 (c 0.10, CHCl3); M.P. 108–109 °C (lit.205 107–
109 °C); 1H NMR (400 MHz, CDCl3, δ): 8.25 (br s, 1H), 7.54–7.47 (m, 1H), 7.36 (dt, J = 
8.0, 1.0 Hz, 1H), 7.22 (ddd, J = 8.0, 7.0, 1.0 Hz, 1H), 7.15 (ddd, J = 8.0, 7.0, 1.0 Hz, 1H), 
6.96 (d, J = 8.0 Hz, 1H), 6.95 (s, 1H), 4.94 (dt, J = 8.0, 5.0 Hz, 1H), 3.73 (s, 3H), 3.42 (m, 
2H); 13C NMR (101 MHz, CDCl3, δ): 170.8, 156.9 (q, 2JC–F = 37.5), 136.2, 127.4, 123.1, 
122.6, 120.0, 118.3, 116.3 (q, 1JC–F = 287.0), 111.6, 108.8, 53.5, 53.0, 27.2; 19F NMR (376 
MHz, CDCl3, δ): −75.8; ESI–MS m/z (ion, %): 315 ([M+H]+, 50), 332 ([M+NH4]+, 40), 337 
([M+Na]+, 100), 353 ([M+K]+, 10); ESI–HRMS m/z: 315.0950 [M+H]+ (C14H14F3N2O3 
requires 315.0951). 
The analytical data obtained was in accordance with the literature.206 
Lab book reference number: AJR-4-343 
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(2R)-4-Methyl-2-(trifluoroacetamido)pentanoic acid (166) 
 
To a round-bottomed flask containing ʟ-Leucine 154 (1 g, 7.6 mmol, 1 eq.) was added 
triethylamine (1.06 mL, 769 mg, 7.6 mmol, 1 eq.) and MeOH (7.6 mL) and the resulting 
suspension stirred for 5 min. After 5 min ethyl trifluoroacetate 165 (1.13 mL, 1.35 g, 9.5 
mmol, 1.25 eq.) was added and the mixture stirred at RT for 16 h, during which time a clear 
solution formed. After 16 h the solvent was evaporated and the resulting residue acidified 
with 2M HCl, before being extracted into EtOAc three times. The organic layers were 
combined then washed with brine, dried over MgSO4, filtered and evaporated to afford the 
title compound as an off-white solid (1.67 g, 97%). 
[α]ᴅ = +31.6 (c 0.10, CHCl3); M.P. 75–77 °C (lit.207 76–77 °C dec.); 1H NMR (400 MHz, 
CD3OD, δ): 4.48 (dd, J = 10.0, 5.0 Hz, 1H), 1.81–1.60 (m, 3H), 0.97 (d, J = 6.0 Hz, 3H), 0.94 
(d, J = 6.0 Hz, 3H); 13C NMR (101 MHz, CD3OD, δ):174.4, 158.9 (q, 2JC–F = 38.0 Hz), 117.5 
(q, 1JC–F = 287.0 Hz), 52.4, 40.7, 26.1, 23.3, 21.5; 19F NMR (376 MHz, CD3OD, δ): −77.0; 
ESI–MS m/z (ion, %): 250 ([M+Na]+, 100); ESI–HRMS m/z: 250.0665 [M+Na]+ 
(C8H12F3NNaO3 requires 250.0661). 
The analytical data obtained was in accordance with the literature.208 




Acid 166 (500 mg, 2.2 mmol, 1 eq.), amine 135 (616 mg, 2.42 mmol, 1.1 eq.) and DEPBT 
(790 mg, 2.64 mmol, 1.2 eq.) were added to a round-bottomed flask which was fitted with a 
septum and flushed with argon from a balloon for 20 min. After 20 min dry, distilled DIPEA 
(1.5 mL, 1.14 g, 8.8 mmol, 4 eq.) and dry CH2Cl2 (22 mL) were added via syringe to give a 
yellow solution and the reaction stirred at RT for 2 h. After 2 h the reaction mixture was 
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washed with sat. aq. NH4Cl and extracted three times with CH2Cl2. The organic layers were 
combined, dried over MgSO4, filtered and evaporated to give a crude yellow residue. 
Purification by dry-loaded flash column chromatography (SiO2, petrol/EtOAc, 1:1, v/v) 
afforded the title compound as an off-white solid (568 mg, 60%). 
Rf 0.48 (petrol/EtOAc, 1:1, v/v); [α]ᴅ = +33.9 (c 0.10, CHCl3); M.P. 129–131 °C; 1H NMR 
(400 MHz, CDCl3, δ): 8.19 (br s, 1H), 7.48 (d, J = 8.0 Hz, 1H), 7.36–7.33 (m, 1H), 7.23–
7.08 (m, 2H), 6.98 (d, J = 2.0 Hz, 1H), 6.45 (d, J = 8.0 Hz, 1H), 4.97–4.84 (m, 1H), 4.51–
4.36 (m, 1H), 3.70 (s, 3H), 3.38–3.25 (m, 2H), 1.68 (s, 1H), 1.62–1.41 (m, 3H), 1.29–1.18 
(m, 3H), 0.89–0.75 (m, 6H); 19F NMR (376 MHz, CDCl3, δ): −75.6; 13C NMR (101 MHz, 
CDCl3, δ): 172.0, 170.4, 157.1 (q, 2JC–F = 37.5 Hz), 136.2, 127.5, 123.3, 122.5, 120.0, 118.4, 
116.6 (q, 1JC–F = 288.0 Hz), 111.5, 109.3, 53.2, 52.7, 52.2, 41.5, 27.6, 24.7, 22.7, 22.1; ESI–
MS m/z (ion, %): 428 ([M+H]+, 75), 450 ([M+Na]+, 100); ESI–HRMS m/z: 450.1612 
[M+Na]+ (C20H24F3N3NaO4 requires 450.1611); IR (solid-state, ATR, cm-1): 3277 (w, br), 
3084 (w), 2959 (w), 2933 (w), 2873 (w), 1714 (s), 1652 (s), 1551 (m), 1439 (m), 1341 (m), 
1209 (s), 1184 (s), 1156 (s), 1094 (w), 1010 (w), 988 (w), 742 (s), 719 (m), 652 (m), 632 (m), 
521 (m); UV–vis (DMSO, nm): λmax 282 (ε = 5734 mol dm-3 cm-1). 
Lab book reference number: AJR-4-344 
2-(Trifluoroacetamido)acetic acid (169) 
 
To a round-bottomed flask containing glycine 168 (826 mg, 11 mmol, 1 eq.) was added 
triethylamine (1.5 mL, 1.11 g, 11 mmol, 1 eq.) and MeOH (5.5 mL) and the resulting 
suspension stirred for 5 min. After 5 min ethyl trifluoroacetate 165 (1.7 mL, 1.99 g, 14 mmol, 
1.27 eq.) was added and the mixture stirred at RT for 16 h, during which time a clear solution 
formed. After 16 h the solvent was evaporated and the resulting residue acidified with 2M 
HCl, before being extracted into EtOAc three times. The organic layers were combined then 
washed with brine, dried over MgSO4, filtered and evaporated to afford the title compound 
as a white solid (1.68 g, 89%). 
M.P. 119–121 °C (lit.209 118–119 °C dec.); 1H NMR (400 MHz, CD3OD, δ): 4.00 (s, 2H); 
13C NMR (101 MHz, CD3OD, δ): 171.5, 159.4 (q, 2JC–F = 37.5 Hz), 117.4 (q, 1JC–F = 286.0 
Hz), 41.7; 19F NMR (376 MHz, CD3OD, δ): −77.3; ESI–MS m/z (ion, %): 194 ([M+Na]+, 
100); ESI–HRMS m/z: 194.0033 [M+Na]+ (C4H4F3NNaO3 requires 194.0035). 
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The analytical data obtained was in accordance with the literature.210 
Lab book reference number: AJR-4-342 
Methyl (2S)-3-(1H-indol-3-yl)-2-[2-(trifluoroacetamido)acetamido]propanoate (170) 
 
Acid 169 (100 mg, 0.58 mmol, 1 eq.), amine 135 (163 mg, 0.64 mmol, 1.1 eq.) and TBTU 
(225 mg, 0.70 mmol, 1.2 eq.) were added to a round-bottomed flask which was fitted with a 
septum and flushed with argon from a balloon for 20 min. After 20 min dry, distilled DIPEA 
(0.4 mL, 300 mg, 2.32 mmol, 4 eq.) and dry CH3CN (5.8 mL) were added via syringe to give 
a yellow solution and the reaction stirred at RT for 2 h. After 2 h the reaction mixture was 
washed with sat. aq. NH4Cl and extracted three times with CH2Cl2. The organic layers were 
combined, dried over MgSO4, filtered and evaporated to give a crude yellow residue. 
Purification by dry-loaded flash column chromatography (SiO2, petrol/EtOAc, 1:3, v/v) 
afforded the title compound as an off-white solid (201 mg, 93%). 
Rf 0.52 (petrol/EtOAc, 1:3, v/v); [α]ᴅ = +40.7 (c 0.10, CHCl3); M.P. 53–55 °C; 1H NMR (400 
MHz, CDCl3, δ): 8.28–8.18 (br s, 1H), 7.50–7.44 (m, 1H), 7.38 (t, J = 5.0 Hz, 1H), 7.30 (dt, 
J = 8.0, 1.0 Hz, 1H), 7.18 (ddd, J = 8.0, 7.0, 1.2 Hz, 1H), 7.11 (ddd, J = 8.0, 7.0, 1.0 Hz, 1H), 
6.94 (d, J = 2.5 Hz, 1H), 6.57 (d, J = 8.0 Hz, 1H), 4.93 (dt, J = 8.0, 5.5 Hz, 1H), 3.85–3.74 
(m, 2H), 3.73 (s, 3H), 3.37–3.24 (m, 2H); 13C NMR (101 MHz, CDCl3, δ): 172.3, 166.8, 
157.3 (q, 2JC–F = 38.0 Hz), 136.2, 127.4, 123.2, 122.5, 120.0, 118.3, 116.6 (q, 1JC–F = 287.0 
Hz), 111.6, 109.4, 53.2, 52.8, 42.5, 27.5; 19F NMR (376 MHz, CDCl3, δ): −75.6; ESI–MS 
m/z (ion, %): 372 ([M+H]+, 10), 394 ([M+Na]+, 100); ESI–HRMS m/z: 394.0988 [M+Na]+ 
(C16H16F3N3NaO4 requires 394.0985); IR (solid-state, ATR, cm-1): 3391 (m), 3341 (m), 1729 
(m), 1704 (s), 1654 (m), 1560 (m), 1532 (m), 1445 (m), 1351 (m), 1215 (s), 1184 (s), 1150 
(s), 1005 (m), 968 (m), 742 (s), 608 (s), 536 (s), 428 (s); UV–vis (DMSO, nm): λmax 284 (ε = 
10138 mol dm-3 cm-1). 
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Methyl (2S)-3-(2-phenyl-1H-indol-3-yl)-2-(trifluoroacetamido)propanoate (171) 
 
To a microwave tube was added tryptophan 92 (58 mg, 0.192 mmol, 1 eq.), aryliodonium 
salt 140 (181 mg, 0.384 mmol, 2 eq.), Pd(OAc)2 (2 mg, 9.6 µmol, 5 mol%) and EtOAc (5 
mL). The reaction mixture was stirred at 25 °C for 16 h. After 16 h the resulting black reaction 
mixture was filtered through Celite then washed with sat. aq. NaHCO3. The organic layer 
was collected and dried over MgSO4, filtered and evaporated to give a brown solid. 
Purification by dry-loaded flash column chromatography (SiO2, petrol/EtOAc, 3:1, v/v) 
afforded the title compound as an off-white solid (59 mg, 82%). 
Rf 0.32 (petrol/EtOAc, 3:1, v/v); [α]ᴅ = +42.4 (c 0.10, CHCl3); M.P. 155–156 °C; 1H NMR 
(400 MHz, CDCl3, δ): 8.15 (br s, 1H), 7.58–7.52 (m, 3H), 7.50 (dd, J = 8.0, 7.0 Hz, 2H), 
7.44–7.36 (m, 2H), 7.23 (ddd, J = 8.0, 7.0, 1.0 Hz, 1H), 7.19–7.14 (m, 1H), 6.64 (d, J = 8.0 
Hz, 1H), 4.83 (dt, J = 8.0, 5.5 Hz, 1H), 3.61 (dd, J = 5.5, 1.0 Hz, 2H), 3.35 (s, 3H); 13C NMR 
(101 MHz, CDCl3, δ): 170.7, 156.7 (q, 2JC–F = 37.5), 136.5, 135.8, 132.6, 129.3, 129.1, 128.5, 
128.4, 122.9, 120.4, 118.7, 114.9 (q, 1JC–F = 288.0 Hz), 111.2, 105.6, 53.4, 52.6, 26.5; 19F 
NMR (376 MHz, CDCl3, δ): −75.9; ESI–MS m/z (ion, %): 391 ([M+H]+, 10), 408 
([M+NH4]+, 35), 413 ([M+Na]+, 100), 429 ([M+K]+, 10); ESI–HRMS m/z: 413.1074 
[M+Na]+ (C20H17F3N2NaO3 requires 413.1083). 
The analytical data obtained was in accordance with the literature.211 




Method A: Title compound was isolated as an off-white solid side product from the synthesis 
of 171 (14 mg, 17%). 
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Method B: To a microwave tube was added tryptophan 92 (60 mg, 0.192 mmol, 1 eq.), 
aryldiazonium salt 196 (45 mg, 0.192 mmol, 1 eq.), Pd(OAc)2 (2 mg, 9.6 μmol, 5 mol%) and 
EtOAc (5 mL). The reaction mixture was stirred at RT for 16 h. After 16 h the resulting 
brown reaction mixture was filtered through Celite then washed with sat. aq. NaHCO3. The 
organic layer was collected and dried over MgSO4, filtered and evaporated to give a brown 
solid. Purification by dry-loaded flash column chromatography (SiO2, petrol/EtOAc, 3:1, v/v) 
afforded the title compound as an off-white solid (54 mg, 65%). 
Rf 0.42 (petrol/EtOAc, 3:1, v/v); [α]ᴅ = +34.4 (c 0.10, CHCl3); M.P. 58–60 °C; 1H NMR (400 
MHz, CDCl3, δ): 8.00 (br s, 1H), 7.59 (dd, J = 8.0, 1.0 Hz, 1H), 7.39–7.34 (m, 1H), 7.22 
(ddd, J = 8.0, 7.0, 1.0 Hz, 1H), 7.17 (ddd, J = 8.0, 7.0, 1.0 Hz, 1H), 6.99 (d, J = 2.5 Hz, 2H), 
6.58 (d, J = 7.5 Hz, 1H), 4.76 (td, J = 7.0, 5.5 Hz, 1H), 3.50 (s, 3H), 3.26 (dd, J = 15.0, 5.5 
Hz, 1H), 3.13 (dd, J = 15.0, 7.0 Hz, 1H), 2.36 (s, 3H), 2.10 (s, 3H), 2.09 (s, 3H); 13C NMR 
(101 MHz, CDCl3, δ): 170.8, 157.0 (q, 2JC–F = 38.0 Hz), 139.0, 138.1, 135.9, 135.2, 128.7, 
128.3, 128.0, 122.2, 120.0, 118.4 (q, 1JC–F = 288.0 Hz), 111.1, 106.7, 53.5, 52.7, 27.0, 21.2, 
20.1; 19F NMR (376 MHz, CDCl3, δ): −75.7; ESI–MS m/z (ion, %): 433 ([M+H]+, 5), 450 
([M+NH4]+, 40), 455 ([M+Na]+, 100), 471 ([M+K]+, 5); ESI–HRMS m/z: 455.1547 [M+Na]+ 
(C23H23F3N2NaO3 requires 455.1553); IR (solid-state, ATR, cm-1): 3391 (w, br), 2955 (w), 
2919 (w), 2851 (w), 1712 (s), 1614 (w), 1543 (w), 1458 (m), 1439 (m), 1378 (w), 1344 (w), 
1292 (m), 1206 (s), 1163 (s), 1011 (w), 909 (m), 853 (w), 731 (s), 510 (m); UV–vis (DMSO, 
nm): λmax 288 (ε = 9725 mol dm-3 cm-1). 
Lab book reference number (method A): AJR-4-346 




Method A: To a microwave tube was added dipeptide 167 (82 mg, 0.192 mmol, 1 eq.), 
diaryliodonium salt 140 (181 mg, 0.384 mmol, 2 eq.), Pd(OAc)2 (2 mg, 9.6 µmol, 5 mol%) 
and EtOAc (5 mL). The reaction mixture was stirred at 25 °C for 16 h. After 16 h the resulting 
black reaction mixture was filtered through Celite then washed with sat. aq. NaHCO3. The 
organic layer was collected and dried over MgSO4, filtered and evaporated to give a brown 
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solid. Purification by dry-loaded flash column chromatography (SiO2, petrol/EtOAc, 3:1, v/v) 
afforded the title compound as a yellow solid (63 mg, 65%). 
Method B: To a microwave tube equipped with magnetic stirrer bar was added dipeptide 167 
(43 mg, 0.10 mmol, 1 eq.), diaryliodonium salt 233 (74 mg, 0.20 mmol, 2 eq.), Pd/C (5 wt%, 
11 mg, 5 mol%) and AcOH (1 mL). The vial was sealed with a septum and the reaction stirred 
at 60 °C for 16 h. After 16 h the reaction mixture was allowed to cool to RT, filtered through 
a silica pad with EtOAc and evaporated to give a brown residue, which was subsequently 
analysed by 1H NMR spectroscopy. 
Rf 0.19 (petrol/EtOAc, 3:1, v/v); [α]ᴅ = +43.8 (c 0.10, CHCl3); M.P. 83–85 °C dec; 1H NMR 
(400 MHz, CDCl3, δ): 8.18 (br s, 1H), 7.57–7.53 (m, 3H), 7.49 (ddt, J = 8.0, 6.5, 1.0 Hz, 2H), 
7.42–7.35 (m, 2H), 7.25–7.19 (m, 1H), 7.15 (ddd, J = 8.0, 7.0, 1.0 Hz, 1H), 6.91–6.84 (m, 
1H), 5.93–5.83 (m, 1H), 4.79 (dq, J = 7.5, 5.5, 5.0 Hz, 1H), 3.96 (td, J = 8.0, 5.0 Hz, 1H), 
3.65–3.48 (m, 2H), 3.38 (s, 3H), 1.54–1.34 (m, 3H), 0.82–0.75 (m, 6H); 13C NMR (101 MHz, 
CDCl3, δ): 171.7, 170.1, 156.6 (q, 2JC–F = 37.5 Hz), 136.2, 135.8, 132.9, 129.3, 129.2, 129.1, 
128.4, 128.3, 128.2, 122.8, 120.2, 118.6 (q, 1JC–F = 287.5 Hz), 111.2, 106.2, 53.3, 52.3, 51.8, 
42.0, 26.6, 24.6, 22.7, 22.1; 19F NMR (376 MHz, CDCl3, δ): −72.4; ESI–MS m/z (ion, %): 
504 ([M+H]+, 5), 521 ([M+NH4]+, 15), 526 ([M+Na]+, 100), 542 ([M+K]+, 5); ESI–HRMS 
m/z: 526.1925 [M+Na]+ (C26H28F3N3NaO4 requires 526.1924); IR (solid-state, ATR, cm-1): 
3337 (w, br), 3061 (w), 2958 (w), 2930 (w), 2873 (w), 1715 (m), 1658 (s), 1530 (m), 1448 
(m), 1209 (s), 1155 (s), 742 (s), 698 (s); UV–vis (DMSO, nm): λmax 308 (ε = 20467 mol dm-
3 cm-1). 
Lab book reference number (method A): AJR-4-348 




Title compound was isolated as a yellow solid side product from the synthesis of 173 (13 mg, 
12%). 
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Rf 0.29 (petrol/EtOAc, 3:1, v/v); [α]ᴅ = +31.1 (c 0.10, CHCl3); 1H NMR (400 MHz, CDCl3, 
δ): 7.87 (br s, 1H), 7.61–7.56 (m, 1H), 7.39–7.34 (m, 1H), 7.22 (td, J = 8.0, 7.5, 1.0 Hz, 1H), 
7.17 (td, J = 7.5, 1.0 Hz, 1H), 7.03 (d, J = 3.5 Hz, 2H), 6.91–6.85 (m, 1H), 5.67 (d, J = 7.0 
Hz, 1H), 4.69 (td, J = 7.5, 4.5 Hz, 1H), 4.19–4.08 (m, 1H), 3.54 (s, 3H), 3.23 (dd, J = 15.0, 
5.0 Hz, 1H), 3.01 (dd, J = 15.0, 7.5 Hz, 1H), 2.35 (s, 3H), 2.12 (s, 3H), 2.08 (s, 3H), 1.54–
1.41 (m, 3H), 0.96–0.64 (m, 6H); 13C NMR (101 MHz, CDCl3, δ): 171.8, 170.3, 156.7 (q, 
2JC–F = 37.5 Hz), 139.4, 138.3, 137.9, 135.8, 134.7, 129.00, 128.9, 128.4, 128.0, 122.4, 120.1, 
118.4, 116.5 (q, 1JC–F = 288.0 Hz), 111.1, 107.6, 53.5, 52.5, 51.8, 42.6, 29.6, 27.1, 24.6, 22.8, 
22.3, 21.2, 20.3; 19F NMR (376 MHz, CDCl3, δ): −75.8; ESI–MS m/z (ion, %): 546 ([M+H]+, 
2), 563 ([M+NH4]+, 15), 568 ([M+Na]+, 100), 584 ([M+K]+, 2); ESI–HRMS m/z: 568.2384 
[M+Na]+ (C29H34F3N3NaO4 requires 568.2394); IR (solid-state, ATR, cm-1): 3391 (w), 3341 
(w, br), 2957 (w), 2927 (w), 1710 (m), 1661 (s), 1529 (m), 1458 (m), 1439 (m), 1353 (w), 
1210 (s), 1155 (s), 1008 (s), 909 (w), 853 (w), 731 (s); UV–vis (DMSO, nm): λmax 290 (ε = 
8712 mol dm-3 cm-1). 




Method A: To a microwave tube was added dipeptide 170 (71 mg, 0.192 mmol, 1 eq.), 
diaryliodonium salt 140 (181 mg, 0.384 mmol, 2 eq.), Pd(OAc)2 (2 mg, 9.6 µmol, 5 mol%) 
and EtOAc (5 mL). The reaction mixture was stirred at 25 °C for 16 h. After 16 h the resulting 
black reaction mixture was filtered through Celite then washed with sat. aq. NaHCO3. The 
organic layer was collected and dried over MgSO4, filtered and evaporated to give a brown 
solid. Purification by dry-loaded flash column chromatography (SiO2, petrol/EtOAc, 1.5:1, 
v/v) afforded the title compound as an off-white solid (41 mg, 48%). 
Method B: To a microwave tube equipped with magnetic stirrer bar was added dipeptide 170 
(74 mg, 0.20 mmol, 1 eq.), diaryliodonium salt 233 (147 mg, 0.40 mmol, 2 eq.), Pd/C (5 
wt%, 21 mg, 5 mol%) and AcOH (2 mL). The vial was sealed with a septum and the reaction 
stirred at 60 °C for 16 h. After 16 h the reaction mixture was allowed to cool to RT, filtered 
through a silica pad with EtOAc and evaporated to give a brown residue, which was 
subsequently analysed by 1H NMR spectroscopy. 
Chapter 6: Experimental 
181 
 
Rf 0.28 (petrol/EtOAc, 1.5:1, v/v); [α]ᴅ = +51.0 (c 0.10, CHCl3); M.P. 82–84 °C; 1H NMR 
(400 MHz, CDCl3, δ): 8.22 (br s, 1H), 7.55–7.49 (m, 3H), 7.46 (dd, J = 8.0, 7.0 Hz, 2H), 
7.40–7.33 (m, 2H), 7.22 (ddd, J = 8.0, 7.0, 1.0 Hz, 1H), 7.12 (ddd, J = 8.0, 7.0, 1.0 Hz, 1H), 
6.93 (br s, 1H), 6.00 (d, J = 7.5 Hz, 1H), 4.83 (dt, J = 7.5, 5.0, 1H), 3.70–3.60 (m, 2H), 3.42 
(s, 3H), 3.30–3.20 (m, 2H); 13C NMR (101 MHz, CDCl3, δ): 171.6, 166.1, 156.7 (q, 2JC–F = 
37.5 Hz), 141.9, 136.3, 135.8, 133.2, 129.4, 129.2, 128.3, 128.3, 128.1, 122.9, 120.3, 118.7, 
114.9 (q, 1JC–F = 287.0 Hz), 111.2, 106.2, 53.3, 52.6, 42.0, 26.3; 19F NMR (376 MHz, CDCl3, 
δ): −75.7; ESI–MS m/z (ion, %): 470 ([M+Na]+, 100); ESI–HRMS m/z: 470.1292 [M+Na]+ 
(C22H20F3N3NaO4 requires 470.1298); IR (solid-state, ATR, cm-1): 3340 (w, br), 3061 (w), 
2954 (w), 2930 (w), 1722 (m), 1666 (m), 1528 (m), 1441 (m), 1351 (m), 1211 (s), 1153 (s), 
1074 (w), 1004 (m), 908 (m), 730 (m), 698 (s), 515 (s); UV–vis (DMSO, nm): λmax 308 (ε = 
20684 mol dm-3 cm-1). 
Lab book reference number (method A): AJR-4-349 




Method A: Title compound was isolated as an off-white solid side product from the synthesis 
of 175 (4 mg, 4%). 
Method B: To a microwave tube was added dipeptide 170 (71 mg, 0.192 mmol, 1 eq.), 
aryldiazonium salt 196 (45 mg, 0.192 mmol, 1 eq.), Pd(OAc)2 (2 mg, 9.6 μmol, 5 mol%) and 
EtOAc (5 mL). The reaction mixture was stirred at RT for 24 h. After 24 h the resulting 
brown reaction mixture was filtered through Celite then washed with sat. aq. NaHCO3. The 
organic layer was collected and dried over MgSO4, filtered and evaporated to give a brown 
solid. Purification by dry-loaded flash column chromatography (SiO2, petrol/EtOAc, 1:1, v/v) 
afforded the title compound as an off-white solid (43 mg, 46%). 
Rf 0.57 (petrol/EtOAc, 1:1, v/v); [α]ᴅ = +33.3 (c 0.10, CHCl3); M.P. 90–92 °C; 1H NMR (400 
MHz, CDCl3, δ): 7.87 (br s, 1H), 7.56 (dd, J = 8.0, 1.0 Hz, 1H), 7.36 (dt, J = 8.0, 1.0 Hz, 1H), 
7.22 (ddd, J = 8.0, 7.0, 1.0 Hz, 1H), 7.16 (ddd, J = 8.0, 7.0, 1.0 Hz, 1H), 7.05–7.00 (m, 2H), 
6.89 (d, J = 1.0 Hz, 1H), 5.74 (d, J = 7.5 Hz, 1H), 4.76 (dt, J = 7.5, 5.5 Hz, 1H), 3.74 (dd, J 
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= 17.0, 4.5 Hz, 1H), 3.57 (dd, J = 17.0, 4.5 Hz, 1H), 3.50 (s, 3H), 3.18 (d, J = 5.5 Hz, 2H), 
2.36 (s, 3H), 2.14 (s, 3H), 2.10 (s, 3H); 13C NMR (101 MHz, CDCl3, δ): 171.7, 166.2, 156.0 
(q, 2JC–F = 37.5 Hz), 139.3, 138.2, 138.1, 135.8, 134.7, 128.9, 128.8, 128.6, 128.6, 122.3, 
120.0, 118.4, 115.7 (q, 1JC–F = 287.0 Hz), 111.1, 107.4, 53.5, 52.5, 42.1, 27.0, 21.2, 20.3, 20.2; 
19F NMR (376 MHz, CDCl3, δ): −75.7; ESI–MS m/z (ion, %): 512 ([M+Na]+, 100); ESI–
HRMS m/z: 512.1773 [M+Na]+ (C25H26F3N3NaO4 requires 512.1768); IR (solid-state, ATR, 
cm-1): 3339 (w, br), 2959 (w), 2919 (w), 2850 (w), 1718 (m), 1670 (m), 1523 (m), 1458 (m), 
1437 (m), 1260 (s), 1157 (s), 1006 (m), 853 (m), 800 (m), 744 (s), 517 (m); UV–vis (DMSO, 
nm): λmax 288 (ε = 12188 mol dm-3 cm-1). 
Lab book reference number (method A): AJR-4-349 
Lab book reference number (method B): AJR-5-429 
Benzenediazonium tetrafluoroborate (48) 
 
Method A: Synthesised using general procedure A from phenylamine 177 (0.91 mL, 931 mg, 
10 mmol, 1 eq.) in deionised water (5.5 mL) to afford the title compound as a white solid 
(1.25 g, 65%). 
Method B: Synthesised using general procedure B from phenylamine 177 (0.91 mL, 931 mg, 
10 mmol, 1 eq.) in EtOH (3 mL) to afford the title compound as a white solid (1.92 g, quant.). 
M.P. 103–105 °C (lit.212 101 °C dec.); 1H NMR (400 MHz, (CD3)2SO, δ): 8.67 (dd, J = 8.5, 
1.0 Hz, 2H), 8.26 (tt, J = 7.5, 1.0 Hz, 1H), 7.98 (ddt, J = 8.5, 7.5, 1.0 Hz, 2H); 13C NMR (101 
MHz, (CD3)2SO, δ): 140.8, 132.7, 131.2, 116.1; 11B NMR (128 MHz, (CD3)2SO, δ): −2.3; 
19F NMR (376 MHz, (CD3)2SO, δ): −148.1 (m, 1JF–10B, 4F), −148.1 (m, 
1J
F–11B
, 4F); ESI–MS 
m/z (ion, %): 105 ([M−BF4]+, 100); ESI–HRMS m/z: 105.0480 [M−BF4]+ (C6H5N2 requires 
105.0447). 
The analytical data obtained was in accordance with the literature.212 
Lab book reference number (Method A): AJR-4-360 
Lab book reference number (Method B): LAH-1-78 (reaction conducted by A. Hammarback) 
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4-Methylbenzene-1-diazonium tetrafluoroborate (192) 
 
Synthesised using general procedure B from 4-amino-1-methylbenzene 178 (1.07 g, 10 
mmol, 1 eq.) in EtOH (3 mL) to afford the title compound as a white solid (1.78 g, 86%). 
M.P. 106–107 °C (lit.213 101–102 °C); 1H NMR (400 MHz, (CD3)2SO, δ): 8.58–8.51 (m, 2H), 
7.83–7.75 (m, 2H), 2.57 (s, 3H); 13C NMR (101 MHz, (CD3)2SO, δ): 153.94, 132.7, 131.8, 
112.0, 22.4; 11B NMR (128 MHz, (CD3)2SO, δ): −2.3; 19F NMR (376 MHz, (CD3)2SO, δ): 
−148.0 (m, 1JF–10B, 4F), −148.1 (m, 1JF–11B, 4F); ESI–MS m/z (ion, %): 119 ([M−BF4]+, 100); 
ESI–HRMS m/z: 119.0603 [M−BF4]+ (C7H7N2 requires 119.0604). 
The analytical data obtained was in accordance with the literature.213 
Lab book reference number: THS-1-3 (reaction conducted by T. Sheridan) 
4-tert-butylbenzene-1-diazonium tetrafluoroborate (193) 
 
Synthesised using general procedure B from 4-tert-butylaniline 179 (0.8 mL, 746 mg, 5 
mmol, 1 eq.) in EtOH (1.5 mL) to afford the title compound as a white solid (963 mg, 78%). 
M.P. 93–94 °C (lit.214 91 °C); 1H NMR (400 MHz, (CD3)2SO, δ): 8.62–8.56 (m, 2H), 8.06–
8.00 (m, 2H), 1.35 (s, 9H); 13C NMR (101 MHz, (CD3)2SO, δ): 165.5, 132.8, 128.5, 112.2, 
36.5, 30.2; 11B NMR (128 MHz, (CD3)2SO, δ): −2.3; 19F NMR (376 MHz, (CD3)2SO, δ): 
−148.1 (m, 1JF–10B, 4F), −148.1 (m, 1JF–11B, 4F); ESI–MS m/z (ion, %): 161 ([M−BF4]+, 100); 
ESI–HRMS m/z: 161.1070 [M−BF4]+ (C10H13N2 requires 161.1073). 
The analytical data obtained was in accordance with the literature.214 
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1-Naphthalene-1-diazonium tetrafluoroborate (194) 
 
Synthesised using general procedure B from 1-naphthylamine 180 (0.48 g, 3.33 mmol, 1 eq.) 
in EtOH (1.7 mL) to afford the title compound as a brown solid (0.75 g, 93%). 
M.P. 104–106 °C (lit.215 105–107 °C); 1H NMR (400 MHz, (CD3)2SO, δ): 9.20 (dd, J = 8.0, 
1.0 Hz, 1H), 8.94 (dt, J = 8.5, 1.0 Hz, 1H), 8.51 (dq, J = 8.5, 1.0 Hz, 1H), 8.43 (ddd, J = 8.0, 
1.0, 0.5 Hz, 1H), 8.12 (ddd, J = 8.5, 7.0, 1.5 Hz, 1H), 8.06 (t, J = 8.0 Hz, 1H), 7.97 (ddd, J = 
8.0, 7.0, 1.0 Hz, 1H); 13C NMR (101 MHz, (CD3)2SO, δ): 142.6, 137.2, 132.6, 132.2, 130.3, 
129.9, 127.1, 126.4, 122.4, 111.1; 11B NMR (128 MHz, (CD3)2SO, δ): −2.3; 19F NMR (376 
MHz, (CD3)2SO, δ): −148.1 (m, 1JF–10B, 4F), −148.1 (m, 1JF–11B, 4F); ESI–MS m/z (ion, %): 
155 ([M−BF4]+, 100); ESI–HRMS m/z: 155.0607 [M−BF4]+ (C10H7N2 requires 155.0604). 
The analytical data obtained was in accordance with the literature.216 
Lab book reference number: LAH-1-39 (reaction conducted by A. Hammarback) 
4-Phenylbenzene-1-diazonium tetrafluoroborate (195) 
 
Synthesised using general procedure B from 4-phenylaniline 181 (846 mg, 5 mmol, 1 eq.) in 
EtOH (1.5 mL) to afford the title compound as a brown solid (870 mg, 65%). 
M.P. 118–119 °C (lit.217 111–112 °C); 1H NMR (400 MHz, (CD3)2SO, δ): 8.76–8.70 (m, 2H), 
8.36–8.29 (m, 2H), 7.95–7.88 (m, 2H), 7.65–7.56 (m, 3H); 13C NMR (101 MHz, (CD3)2SO, 
δ): 151.5, 136.4, 133.5, 130.8, 129.6, 129.0, 128.0, 113.3; 11B NMR (128 MHz, (CD3)2SO, 
δ): −2.3; 19F NMR (376 MHz, (CD3)2SO, δ): −148.1 (m, 1JF–10B, 4F), −148.1 (m, 1JF–11B, 4F); 
EI–MS m/z (ion, %): 154 ([M−BF4−N2]+, 100); EI–HRMS m/z: 154.0782 [M−BF4−N2]+ 
(C12H10 requires 154.0783). 
The analytical data obtained was in accordance with the literature.218 
Lab book reference number: AJR-8-717 
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2,4,6-Trimethylbenzene-1-diazonium tetrafluoroborate (196) 
 
Method A: Synthesised using general procedure A from 2,4,6-trimethylphenylamine 182 (1.4 
mL, 1.35 g, 10 mmol, 1 eq.) in deionised water (5.5 mL) to afford the title compound as a 
white solid (1.09 g, 47%). 
Method B: Synthesised using general procedure B from 2,4,6-trimethylphenylamine 182 (1.4 
mL, 1.35 g, 10 mmol, 1 eq.) in EtOH (3 mL) to afford the title compound as a white solid 
(2.34 g, quant.). 
M.P. 84–85 °C; 1H NMR (400 MHz, (CD3)2SO, δ): 7.40 (s, 2H), 2.57 (s, 6H), 2.39 (s, 3H); 
13C NMR (101 MHz, (CD3)2SO, δ): 153.4, 143.7, 130.7, 112.0, 22.1, 18.1; 11B NMR (128 
MHz, (CD3)2SO, δ): −2.3; 19F NMR (376 MHz, (CD3)2SO, δ): −148.1 (m, 1JF–10B, 4F), −148.2 
(m, 1J
F–11B
, 4F); ESI–MS m/z (ion, %): 147 ([M−BF4]+, 100); ESI–HRMS m/z: 147.0916 
[M−BF4]+ (C9H11N2 requires 147.0917). 
The analytical data obtained was in accordance with the literature.219 
Lab book reference number (Method A): AJR-5-376 
Lab book reference number (Method B): LAH-1-38 (reaction conducted by A. Hammarback) 
4-Methoxybenzene-1-diazonium tetrafluoroborate (197) 
 
Method A: Synthesised using general procedure A from 4-methoxyaniline 183 (1.23 g, 10 
mmol, 1 eq.) in deionised water (5.5mL) to afford the title compound as a white solid (182 
mg, 8%). 
Method B: Synthesised using general procedure B from 4-methoxyaniline 183 (1.23 g, 10 
mmol, 1 eq.) in EtOH (3 mL) to afford the title compound as a white solid (2.16 g, 98%). 
M.P. 145–147 °C (lit.220 143 °C); 1H NMR (400 MHz, (CD3)2SO, δ): 8.64–8.58 (m, 2H), 
7.51–7.45 (m, 2H), 4.04 (s, 3H); 13C NMR (101 MHz, (CD3)2SO, δ): 168.8, 136.2, 117.3, 
103.4, 57.5; 11B NMR (128 MHz, (CD3)2SO, δ): −2.3; 19F NMR (376 MHz, (CD3)2SO, δ): 





, 4F), −148.1 (m, 1J
F–11B
, 4F); ESI–MS m/z (ion, %): 135 ([M−BF4]+, 100); 
ESI–HRMS m/z: 135.0548 [M−BF4]+ (C7H7N2O requires 135.0553). 
The analytical data obtained was in accordance with the literature.212 
Lab book reference number (Method A): AJR-5-406 
Lab book reference number (Method B): LAH-1-34 (reaction conducted by A. Hammarback) 
4-Phenoxybenzene-1-diazonium tetrafluoroborate (198) 
 
Synthesised using general procedure B from 4-phenoxyaniline 184 (1.85 g, 10 mmol, 1 eq.) 
in EtOH (3 mL) to afford the title compound as an off-white solid (2.71 g, 95%). 
M.P. 167–170 °C (lit.213 177–178 °C); 1H NMR (400 MHz, (CD3)2SO, δ): 8.67–8.60 (m, 2H), 
7.61–7.54 (m, 2H), 7.45–7.37 (m, 3H), 7.33–7.27 (m, 2H); 13C NMR (101 MHz, (CD3)2SO, 
δ): 167.1, 152.7, 136.6, 131.0, 126.9, 121.0, 118.7, 106.0; 11B NMR (128 MHz, (CD3)2SO, 
δ): −2.3; 19F NMR (376 MHz, (CD3)2SO, δ): −148.1 (m, 1JF–10B, 4F), −148.1 (m, 1JF–11B, 4F); 
ESI–MS m/z (ion, %): 197 ([M−BF4]+, 100); ESI–HRMS m/z: 197.0706 [M−BF4]+ 
(C12H9N2O requires 197.0709). 
The analytical data obtained was in accordance with the literature.213 
Lab book reference number: AJR-8-722 
4-Fluorobenzene-1-diazonium tetrafluoroborate (199) 
 
Method A: Synthesised using general procedure A from 4-aminofluorobenzene 185 (0.95 mL, 
1.11 g, 10 mmol, 1 eq.) in deionised water (5.5 mL) to afford the title compound as a white 
solid (1.10 g, 52%). 
Method B: Synthesised using general procedure B from 4-aminofluorobenzene 185 (0.95 mL, 
1.11 g, 10 mmol, 1 eq.) to afford the title compound as a white solid (2.05 g, 98%). 
M.P. 164–165 °C (lit.212 161–162 °C); 1H NMR (400 MHz, (CD3)2SO, δ): 8.83–8.77 (m, 2H), 
7.93–7.85 (m, 2H); 13C NMR (101 MHz, (CD3)2SO, δ): 168.4 (d, J = 267.0 Hz), 137.0 (d, J 
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= 12.0 Hz), 119.4 (d, J = 25 .0 Hz), 111.9 (d, J = 3.0 Hz); 11B NMR (128 MHz, (CD3)2SO, 




, 4F); ESI–MS m/z (ion, %): 123 ([M−BF4]+, 100); ESI–HRMS m/z: 123.0353 [M−BF4]+ 
(C6H4FN2 requires 123.0353). 
The analytical data obtained was in accordance with the literature.212 
Lab book reference number (Method A): AJR-5-415 
Lab book reference number (Method B): LAH-1-25 (reaction conducted by A. Hammarback) 
4-Bromobenzene-1-diazonium tetrafluoroborate (200) 
 
Method A: Synthesised using general procedure A from 4-aminobromobenzene 186 (1.72 g, 
10 mmol, 1 eq.) in deionised water (5.5 mL) to afford the title compound as a white solid 
(887 mg, 33%). 
Method B: Synthesised using general procedure B from 4-aminobromobenzene 186 (1.72 g, 
10 mmol, 1 eq.) in EtOH (3 mL) to afford the title compound as a white solid (2.52 g, 93%). 
M.P. 138–140 °C (lit.213 138 °C dec.); 1H NMR (400 MHz, (CD3)2SO, δ): 8.60–8.55 (m, 2H), 
8.29–8.24 (m, 2H); 13C NMR (101 MHz, (CD3)2SO, δ): 136.6, 134.5, 134.0, 115.2; 11B NMR 
(128 MHz, (CD3)2SO, δ): −2.3; 19F NMR (376 MHz, (CD3)2SO, δ): −148.1 (m, 1JF–10B, 4F), 
−148.2 (m, 1J
F–11B
, 4F); ESI–MS m/z (ion, %): 183 ([M−BF4]+, 100); ESI–HRMS m/z: 
182.9556 [M−BF4]+ (C6H4BrN2 requires 182.9552). 
The analytical data obtained was in accordance with the literature.212 
Lab book reference number (Method A): AJR-5-373 
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3-Bromobenzene-1-diazonium tetrafluoroborate (201) 
 
Method A: Synthesised using general procedure A from 3-aminobromobenzene 187 (1.09 
mL, 1.72 g, 10 mmol, 1 eq.) in deionised water (5.5 mL) to afford the title compound as a 
white solid (1.18 g, 44%). 
Method B: Synthesised using general procedure B from 3-aminobromobenzene 187 (1.09 
mL, 1.72 g, 10 mmol, 1 eq.) in EtOH (3 mL) to afford the title compound as a white solid 
(2.71 g, quant.). 
M.P. 140–142 °C (lit.213 145 °C); 1H NMR (400 MHz, (CD3)2SO, δ): 8.96 (dd, J = 2.0, 2.0 
Hz, 1H), 8.69 (ddd, J = 8.5, 2.0, 1.0 Hz, 1H), 8.49 (ddd, J = 8.5, 2.0, 1.0 Hz, 1H), 7.92 (dd, 
J = 8.5, 8.5 Hz, 1H); 13C NMR (101 MHz, (CD3)2SO, δ): 143.8, 134.3, 132.8, 131.9, 122.3, 
117.8; 11B NMR (128 MHz, (CD3)2SO, δ): −2.3; 19F NMR (376 MHz, (CD3)2SO, δ): −148.0 
(m, 1J
F–10B
, 4F), −148.0 (m, 1J
F–11B
, 4F); ESI–MS m/z (ion, %): 183 ([M−BF4]+, 100); ESI–
HRMS m/z: 182.9548 [M−BF4]+ (C6H4BrN2 requires 182.9552). 
The analytical data obtained was in accordance with the literature.213  
Lab book reference number (Method A): AJR-5-390 
Lab book reference number (Method B): LAH-1-31 (reaction conducted by A. Hammarback) 
4-Chlorobenzene-1-diazonium tetrafluoroborate (202) 
 
Method A: Synthesised using general procedure A from 4-aminochlorobenzene 188 (1.28 g, 
10 mmol, 1 eq.) in deionised water (5.5 mL) to afford the title compound as a white solid 
(556 mg, 25%). 
Method B: Synthesised using general procedure B from 4-aminochlorobenzene 188 (1.28 g, 
10 mmol, 1 eq.) in EtOH (3 mL) to afford the title compound as a white solid (2.15 g, 95%). 
M.P. 138–139 °C (lit.212 134 °C dec.); 1H NMR (400 MHz, (CD3)2SO, δ): 8.73–8.64 (m, 2H), 
8.15–8.07 (m, 2H); 13C NMR (101 MHz, (CD3)2SO, δ): 146.5, 134.4, 131.6, 114.8; 11B NMR 
(128 MHz, (CD3)2SO, δ): −2.3; 19F NMR (376 MHz, (CD3)2SO, δ): −148.0 (m, 1JF–10B, 4F), 
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−148.0 (m, 1JF–11B, 4F); ESI–MS m/z (ion, %): 139 ([M−BF4]+, 100); ESI–HRMS m/z: 
139.0054 [M−BF4]+ (C6H4ClN2 requires 139.0058). 
The analytical data obtained was in accordance with the literature.212 
Lab book reference number (Method A): AJR-5-375 
Lab book reference number (Method B): LAH-1-24 (reaction conducted by A. Hammarback) 
3-Chlorobenzene-1-diazonium tetrafluoroborate (203) 
 
Method A: Synthesised using general procedure A from 3-aminochlorobenzene 189 (1.10 
mL, 1.28 g, 10 mmol, 1 eq.) in deionised water (5.5 mL) to afford the title compound as a 
white solid (1.06 g, 47%). 
Method B: Synthesised using general procedure B from 3-aminochlorobenzene 189 (1.10 
mL, 1.28 g, 10 mmol, 1 eq.) in EtOH (3 mL) to afford the title compound as a white solid 
(2.26 g, quant.). 
M.P. 147–148 °C (lit.219 148 °C dec.); 1H NMR (400 MHz, (CD3)2SO, δ): 8.85 (dd, J = 2.0, 
2.0 Hz, 1H), 8.67 (ddd, J = 8.5, 2.0, 1.0 Hz, 1H), 8.37 (ddd, J = 8.5, 2.0, 1.0 Hz, 1H), 8.01 
(dd, J = 8.5, 8.5 Hz, 1H); 13C NMR (101 MHz, (CD3)2SO, δ): 141.1, 134.6, 132.9, 131.7, 
131.6, 117.8; 11B NMR (128 MHz, (CD3)2SO, δ): −2.2; 19F NMR (376 MHz, (CD3)2SO, δ): 
−148.0 (m, 1J
F–10B
, 4F), −148.0 (m, 1J
F–11B
, 4F); ESI–MS m/z (ion, %): 139 ([M−BF4]+, 100); 
ESI–HRMS m/z: 139.0055 [M−BF4]+ (C6H4ClN2 requires 139.0058). 
The analytical data obtained was in accordance with the literature.216 
Lab book reference number (Method A): AJR-5-382 
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4-(Trifluoromethyl)benzene-1-diazonium tetrafluoroborate (54) 
 
Method A: Synthesised using general procedure A from 4-aminobenzotrifluoride 190 (0.63 
mL, 805 mg, 5 mmol, 1 eq.) in deionised water (2.75 mL) to afford the title compound as a 
white solid (416 mg, 32%). 
Method B: Synthesised using general procedure A from 4-aminobenzotrifluoride 190 (1.26 
mL, 1.61 mg, 10 mmol, 1 eq.) in EtOH (3 mL) to afford the title compound as a white solid 
(2.38 g, 92%). 
M.P. 118–119 °C (lit.221 105–106 °C);  1H NMR (400 MHz, (CD3)2SO, δ): 8.91 (d, J = 8.5 
Hz, 2H), 8.42 (d, J = 8.5 Hz, 2H); 13C NMR (101 MHz, (CD3)2SO, δ): 113.8, 128.3, 122.3 
(q, J = 274.0 Hz), 121.3, 110.5; 11B NMR (128 MHz, (CD3)2SO, δ): −2.3; 19F NMR (376 
MHz, (CD3)2SO, δ): −62.5, −148.0 (m, 1JF–10B, 4F), −148.1 (m, 
1J
F–11B
, 4F); ESI–MS m/z (ion, 
%): 173 ([M−BF4]+, 100); ESI–HRMS m/z: 173.0325 [M−BF4]+ (C7H4F3N2 requires 
173.0321). 
The analytical data obtained was in accordance with the literature.221 
Lab book reference number (Method A): AJR-4-368 
Lab book reference number (Method B): LAH-1-44 (reaction conducted by A. Hammarback) 
4-Nitrobenzene-1-diazonium tetrafluoroborate (204) 
 
Synthesised using general procedure A from 4-nitroaniline 191 (1.38 g, 10 mmol, 1 eq.) in 
EtOH (3 mL) to afford the title compound as a white solid (2.24 g, 95%). 
M.P. 148–151 °C (lit.212 155 °C dec.); 1H NMR (400 MHz, (CD3)2SO, δ): 8.95–8.90 (m, 2H), 
8.75–8.69 (m, 2H); 13C NMR (101 MHz, (CD3)2SO, δ): 153.3, 134.6, 126.1, 121.9; 11B NMR 
(128 MHz, (CD3)2SO, δ): −2.3; 19F NMR (376 MHz, (CD3)2SO, δ): −148.1 (m, 1JF–10B, 4F), 
−148.1 (m, 1JF–11B, 4F); ESI–MS m/z (ion, %): 150 ([M−BF4]+, 100); ESI–HRMS m/z: 
150.0304 [M−BF4]+ (C6H4N3O2 requires 150.0298). 
The analytical data obtained was in accordance with the literature.212 
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Lab book reference number: LAH-1-41 (reaction conducted by A. Hammarback) 
Methyl (2S)-3-[2-(4-methylphenyl)-1H-indol-3-yl]-2-acetamidopropanoate (76) 
 
Method A: Synthesised using general procedure C with aryldiazonium salt 192 (40 mg, 0.192 
mmol, 1 eq.) to afford the title compound as a brown solid (67 mg, quant.). 
Method B: Synthesised as in method A using Pd(OTs)2(MeCN)2 215 (5.1 mg, 9.6 µmol, 5 
mol%) in place of Pd(OAc)2 to afford the title compound as a brown solid (67 mg, quant.). 
Rf 0.32 (petrol/EtOAc, 1:1, v/v); [α]ᴅ = +51.9 (c 0.10, CHCl3); M.P. 97–99 °C; 1H NMR (400 
MHz, CDCl3, δ): 8.14 (br s, 1H), 7.56 (d, J = 8.0 Hz, 1H), 7.49–7.43 (m, 2H), 7.38–7.33 (m, 
1H), 7.31–7.27 (m, 2H), 7.20 (ddd, J = 8.0, 7.0, 1.0 Hz, 1H), 7.13 (ddd, J = 8.0, 7.0, 1.0 Hz, 
1H), 5.77 (d, J = 8.0 Hz, 1H), 4.82 (dt, J = 8.0, 5.5 Hz, 1H), 3.54 (dd, J = 15.0, 5.5 Hz, 1H), 
3.52 (dd, J = 15.0, 5.5 Hz, 1H), 3.33 (s, 3H), 2.41 (s, 3H), 1.66 (s, 3H); 13C NMR (101 MHz, 
(CDCl3, δ): 172.4, 169.7, 138.2, 136.2, 135.7, 130.3, 130.0, 129.6, 128.3, 122.5, 120.1, 118.9, 
111.0, 106.6, 52.9, 52.2, 26.8, 23.0, 21.4; ESI–MS m/z (ion, %): 351 ([M+H]+, 10), 373 
([M+Na]+, 100); ESI–HRMS m/z: 373.1524 [M+Na]+ (C21H22N2NaO3 requires 373.1523). 
The analytical data obtained was in accordance with the literature.114 
Lab book reference number (method A): AJR-8-715 
Lab book reference number (method B): THS-1-64 (reaction conducted by T. Sheridan) 
Methyl (2S)-3-[2-(4-tert-butylphenyl)-1H-indol-3-yl]-2-acetamidopropanoate (205) 
 
Method A: Synthesised using general procedure C with aryldiazonium salt 193 (48 mg, 0.192 
mmol, 1 eq.) to afford the title compound as a brown solid (75 mg, quant.). 
Method B: Synthesised as in method A using Pd(OTs)2(MeCN)2 215 (5.1 mg, 9.6 µmol, 5 
mol%) in place of Pd(OAc)2 to afford the title compound as a brown solid (75 mg, quant.). 
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Rf 0.30 (petrol/EtOAc, 1:1.5, v/v); [α]ᴅ = +68.6 (c 0.10, CHCl3); M.P. 153–155 °C; 1H NMR 
(400 MHz, CDCl3, δ): 8.14 (br s, 1H), 7.56 (d, J = 8.0 Hz, 1H), 7.50 (s, 4H), 7.36 (d, J = 8.0 
Hz, 1H), 7.19 (ddd, J = 8.0, 7.0, 1.0 Hz, 1H), 7.13 (ddd, J = 8.0, 7.0, 1.0 Hz, 1H), 5.77 (d, J 
= 8.0 Hz, 1H), 4.84 (dt, J = 8.0, 5.5 Hz, 1H), 3.56 (app d, J = 5.5 Hz, 2H), 3.28 (s, 3H), 1.64 
(s, 3H), 1.36 (s, 9H); 13C NMR (101 MHz, (CDCl3, δ): 172.3, 169.7, 151.3, 136.1, 135.7, 
130.4, 129.6, 128.1, 126.2, 122.5, 120.1, 118.9, 111.0, 106.5, 52.9, 52.1, 34.9, 31.4, 26.6, 
23.0; ESI–MS m/z (ion, %): 393 ([M+H]+, 10), 415 ([M+Na]+, 100); ESI–HRMS m/z: 
393.2169 [M+Na]+ (C24H29N2O3 requires 393.2173); IR (solid-state ATR, cm-1): 3282 (w, 
br), 2960 (m), 1738 (m), 1660 (m), 1518 (m), 1436 (m), 1372 (m), 1260 (m), 1214 (m), 1013 
(m), 837 (m), 799 (m), 741 (s), 588 (m). 
Lab book reference number (method A): AJR-8-718 
Lab book reference number (method B): THS-1-65 (reaction conducted by T. Sheridan) 
Methyl (2S)-2-acetamido-3-[2-(1-naphthylphenyl)-1H-indol-3-yl]propanoate (206) 
 
Method A: Synthesised using general procedure C with aryldiazonium salt 194 (50 mg, 0.192 
mmol, 1 eq.) to afford the title compound as a brown solid (74 mg, quant.). 
Method B: Synthesised as in method A using Pd(OTs)2(MeCN)2 215 (5.1 mg, 9.6 µmol, 5 
mol%) in place of Pd(OAc)2 to afford the title compound as a brown solid (74 mg, quant.). 
Rf 0.15 (petrol/EtOAc, 1:1, v/v); M.P. 78–79 °C dec.; 1H NMR (400 MHz, CDCl3, δ): 8.45 
(br s, 1H), 7.94 (d, J = 8.0 Hz, 2H), 7.80 (d, J = 8.0 Hz, 1H), 7.64 (d, J = 8.0 Hz, 1H), 7.58–
7.45 (m, 4H), 7.37 (d, J = 8.0 Hz, 1H), 7.24 (ddd, J = 7.5, 1.0 Hz, 1H), 7.19 (ddd, J = 7.5, 
1.0 Hz, 1H), 5.58 (d, J = 8.0 Hz, 1H), 4.68 (dt, J = 8.0, 5.0 Hz, 1H), 3.50–2.98 (m, 5H), 1.26 
(br s, 3H); 13C NMR (101 MHz, (CDCl3, δ): 172.2, 169.6, 136.0, 134.8, 134.0, 132.4, 130.3, 
129.2, 128.8, 128.7, 128.7, 127.2, 126.5, 125.7, 125.6, 122.6, 120.1, 119.0, 111.1, 108.8, 
52.9, 52.0, 26.8, 22.6; ESI–MS m/z (ion, %): 387 ([M+H]+, 20), 409 ([M+Na]+, 100); ESI–
HRMS m/z: 387.1695 [M+H]+ (C24H23N2O3 requires 387.1703); IR (solid-state, ATR, cm-1): 
3254 (w, br), 1734 (m), 1653 (s), 1506 (m), 1435 (m), 1371 (s), 1214 (s), 1011 (s), 908 (m), 
804 (m), 779 (m), 727 (m), 494 (w). 
Chapter 6: Experimental 
193 
 
Lab book reference number (method A): LAH-2-110 (reaction conducted by A. 
Hammarback) 
Lab book reference number (method B): AJR-7-679 
Methyl (2S)-2-acetamido-3-[2-(4-phenylphenyl)-1H-indol-3-yl]propanoate (207) 
 
Method A: Synthesised using general procedure C with aryldiazonium salt 195 (52 mg, 0.192 
mmol, 1 eq.) to afford the title compound as a brown solid (79 mg, quant.). 
Method B: Synthesised as in method A using Pd(OTs)2(MeCN)2 215 (5.1 mg, 9.6 µmol, 5 
mol%) in place of Pd(OAc)2 to afford the title compound as a brown solid (79 mg, quant.). 
Rf 0.27 (petrol/EtOAc, 1:1.5, v/v); [α]ᴅ = +94.8 (c 0.10, CHCl3); M.P. 205–206 °C; 1H NMR 
(400 MHz, CDCl3, δ): 8.32 (br s, 1H), 7.74–7.67 (m, 2H), 7.66–7.61 (m, 4H), 7.60–7.56 (m, 
1H), 7.52–7.44 (m, 2H), 7.43–7.35 (m, 2H), 7.21 (ddd, J = 8.0, 7.0, 1.0 Hz, 1H), 7.15 (ddd, 
J = 8.0, 7.0, 1.0 Hz, 1H), 5.84 (d, J = 8.0 Hz, 1H), 4.87 (dt, J = 8.0, 5.5 Hz, 1H), 3.62 (dd, J 
= 15.0, 5.5 Hz, 1H), 3.59 (dd, J = 15.0, 5.5 Hz, 1H), 3.32 (s, 3H), 1.66 (s, 3H); 13C NMR 
(101 MHz, (CDCl3, δ): 172.3, 169.7, 140.9, 140.3, 135.9, 135.7, 132.2, 129.7, 129.1, 128.7, 
127.9, 127.1, 122.8, 120.2, 119.0, 111.1, 107.2, 100.1, 53.0, 52.2, 26.8, 23.0; ESI–MS m/z 
(ion, %): 413 ([M+H]+, 10), 435 ([M+Na]+, 100); ESI–HRMS m/z: 413.1871 [M+H]+ 
(C26H25N2O3 requires 413.1860); IR (solid-state, ATR, cm-1): 3406 (w), 3378 (w), 1746 (m), 
1655 (s), 1460 (m), 1449 (m), 1374 (m), 1314 (m), 1184 (m), 1008 (w), 982 (w), 842 (w), 
767 (m), 743 (s), 734 (m), 697 (m), 535 (s), 512 (m). 
Lab book reference number (method A): AJR-8-719 





Chapter 6: Experimental 
194 
 
Methyl (2S)-2-acetamido-3-[2-(4-methoxyphenyl)-1H-indol-3-yl]propanoate (77) 
 
Method A: Synthesised using general procedure C (with a reaction time of 24 h) with 
aryldiazonium salt 197 (43 mg, 0.192 mmol, 1 eq.) to afford the title compound as a brown 
solid (70 mg, quant.). 
Method B: Synthesised as in method A using Pd(OTs)2(MeCN)2 215 (5.1 mg, 9.6 µmol, 5 
mol%) in place of Pd(OAc)2 to afford the title compound as a brown solid (70 mg, quant.). 
Method C: Reaction conducted as in method B using Pd(OTs)2(MeCN)2 215 (2.5 mg, 4.8 
µmol, 2.5 mol%) to afford a crude brown solid. 1H NMR spectroscopic analysis indicated 
49% conversion to the title compound, which was not purified. 
Method D: Reaction conducted as in method B using Pd(OTs)2(MeCN)2 215 (1 mg, 1.92 
µmol, 1 mol%) to afford a crude brown solid. 1H NMR spectroscopic analysis indicated 40% 
conversion to the title compound, which was not purified. 
Rf 0.15 (petrol/EtOAc, 1:1, v/v); [α]ᴅ = +34.9 (c 0.10, CHCl3); M.P. 202–205 °C; 1H NMR 
(400 MHz, CDCl3, δ): 8.56 (br s, 1H), 7.54 (d, J = 8.0 Hz, 1H), 7.49–7.44 (m, 2H), 7.33 (d, 
J = 8.0 Hz, 1H), 7.17 (ddd, J = 8.0, 7.0, 1.5 Hz, 1H), 7.12 (ddd, J = 8.0, 7.0, 1.5 Hz, 1H), 
6.95–6.90 (m, 2H), 5.85 (d, J = 8.0 Hz, 1H), 4.81 (dt, J = 8.0, 5.5 Hz, 1H), 3.81 (s, 3H), 3.52 
(dd, J = 15.0, 5.5 Hz, 1H), 3.48 (dd, J = 15.0, 5.5 Hz, 1H), 3.34 (s, 3H), 1.66 (s, 3H); 13C 
NMR (101 MHz, (CDCl3, δ): 172.4, 169.8, 159.5, 136.1, 135.7, 129.6, 129.5, 125.6, 122.2, 
119.9, 118.6, 114.6, 111.1, 105.9, 55.5, 53.0, 52.2, 26.7, 23.0; ESI–MS m/z (ion, %): 367 
([M+H]+, 50), 389 ([M+Na]+, 100); ESI–HRMS m/z: 389.1458 [M+Na]+ (C21H22N2NaO4 
requires 389.1472). 
The analytical data obtained was in accordance with the literature.114 
Lab book reference number (method A): AJR-5-410 
Lab book reference number (method B): AJR-7-653 
Lab book reference number (method C): AJR-7-638 
Lab book reference number (method D): AJR-7-627 
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Methyl (2S)-2-acetamido-3-[2-(4-phenoxyphenyl)-1H-indol-3-yl]propanoate (208) 
 
Method A: Synthesised using general procedure C with aryldiazonium salt 198 (55 mg, 0.192 
mmol, 1 eq.) to afford the title compound as a brown solid (82 mg, quant.). 
Method B: Synthesised as in method A using Pd(OTs)2(MeCN)2 215 (5.1 mg, 9.6 µmol, 5 
mol%) in place of Pd(OAc)2 to afford the title compound as a brown solid (82 mg, quant.). 
Rf 0.29 (petrol/EtOAc, 1:1.5, v/v); [α]ᴅ = +85.3 (c 0.10, CHCl3); M.P. 72–74 °C; 1H NMR 
(400 MHz, CDCl3, δ): 8.32 (br s, 1H), 7.56 (d, J = 8.0 Hz, 1H), 7.52–7.47 (m, 2H), 7.42–
7.36 (m, 2H), 7.35–7.32 (m, 1H), 7.22–7.16 (m, 2H), 7.15–7.11 (m, 1H), 7.10–7.04 (m, 4H), 
5.85 (d, J = 8.0 Hz, 1H), 4.84 (dt, J = 8.0, 5.5 Hz, 1H), 3.52 (dd, J = 15.0, 5.5 Hz, 1H), 3.49 
(dd, J = 15.0, 5.5 Hz, 1H), 3.38 (s, 3H), 1.72 (s, 3H); 13C NMR (101 MHz, (CDCl3, δ): 172.4, 
169.7, 157.6, 156.5, 135.8, 135.7, 130.1, 129.8, 129.5, 127.9, 124.1, 122.6, 120.1, 119.6, 
119.0, 118.9, 111.1, 106.6, 53.0, 52.2, 26.8, 23.1; ESI–MS m/z (ion, %): 429 ([M+H]+, 20), 
451 ([M+Na]+, 100); ESI–HRMS m/z: 451.1622 [M+Na]+ (C26H24N2NaO4 requires 
451.1628); IR (solid-state, ATR, cm-1): 3266 (w, br), 2961 (w), 1736 (m), 1654 (m), 1588 
(w), 1487 (s), 1458 (m), 1436 (m), 1372 (w), 1229 (s), 1012 (m), 869 (m), 840 (m), 795 (m), 
743 (s), 692 (m), 486 (w). 
Lab book reference number: AJR-8-723 
Lab book reference number (method B): THS-1-67 (reaction conducted by T. Sheridan) 
Methyl (2S)-3-[2-(4-fluorophenyl)-1H-indol-3-yl]-2-acetamidopropanoate (120) 
 
Method A: Synthesised using general procedure C with aryldiazonium salt 199 (40 mg, 0.192 
mmol, 1 eq.) to afford the title compound as a brown solid (68 mg, quant.). 
Method B: Synthesised as in method A using Pd(OTs)2(MeCN)2 215 (5.1 mg, 9.6 µmol, 5 
mol%) in place of Pd(OAc)2 to afford the title compound as a brown solid (68 mg, quant.). 
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Rf 0.23 (petrol/EtOAc, 1:1, v/v); [α]ᴅ = +54.4 (c 0.10, CHCl3); M.P. 213–216 °C dec.; 1H 
NMR (400 MHz, CDCl3, δ): 8.18 (br s, 1H), 7.56 (ddt, J = 8.0, 1.5, 1.0 Hz, 1H), 7.54–7.48 
(m, 2H), 7.34 (dt, J = 8.0, 1.0 Hz, 1H), 7.20 (ddd, J = 8.0, 7.0, 1.0 Hz, 1H), 7.17–7.12 (m, 
3H), 5.84 (d, J = 8.0 Hz, 1H), 4.83 (dt, J = 8.0, 5.5 Hz, 1H), 3.51 (dd, J = 15.0, 5.5 Hz, 1H), 
3.46 (dd, J = 15.0, 5.5 Hz, 1H), 3.33 (s, 3H), 1.70 (s, 3H); 13C NMR (101 MHz, (CDCl3, δ): 
172.3, 169.7, 162.9 (q, 1JC–F = 249.0 Hz), 135.8, 135.1, 130.3 (d, 3JC–F = 8.0 Hz), 129.5, 129.4 
(d, 4JC–F = 3.5 Hz), 122.8, 120.3, 119.0, 116.3 (d, 2JC–F = 21.5 Hz), 111.1, 107.0, 52.9, 52.2, 
26.8, 23.1; 19F NMR (376 MHz, CDCl3, δ): −112.8–−112.9 (m); ESI–MS m/z (ion, %): 355 
([M+H]+, 60), 377 ([M+Na]+, 100); ESI–HRMS m/z: 355.1442 [M+H]+ (C20H20FN2O3 
requires 355.1452). 
The analytical data obtained was in accordance with the literature.211 
Lab book reference number (method A): AJR-5-417 
Lab book reference number (method B): AJR-7-655 
Methyl (2S)-3-[2-(4-bromophenyl)-1H-indol-3-yl]-2-acetamidopropanoate (79) 
 
Method A: Synthesised using general procedure C with aryldiazonium salt 200 (52 mg, 0.192 
mmol, 1 eq.) to afford the title compound as a brown solid (80 mg, quant.). 
Method B: Synthesised as in method A using Pd(OTs)2(MeCN)2 215 (5.1 mg, 9.6 µmol, 5 
mol%) in place of Pd(OAc)2 to afford the title compound as a brown solid (80 mg, quant.). 
Rf 0.31 (petrol/EtOAc, 1:1, v/v); [α]ᴅ = +44.0 (c 0.10, CHCl3); M.P. 74–75 °C dec.; 1H NMR 
(400 MHz, CDCl3, δ): 8.36 (br s, 1H), 7.60–7.54 (m, 3H), 7.44–7.39 (m, 2H), 7.34 (dt, J = 
8.0, 1.0 Hz, 1H), 7.21 (ddd, J = 8.0, 7.0, 1.0 Hz, 1H), 7.14 (ddd, J = 8.0, 7.0, 1.0 Hz, 1H), 
5.85 (d, J = 8.0 Hz, 1H), 4.83 (dt, J = 8.0, 5.5 Hz, 1H), 3.52 (dd, J = 15.0, 5.5 Hz, 1H), 3.47 
(dd, J = 15.0, 5.5 Hz, 1H), 3.33 (s, 3H), 1.70 (s, 3H); 13C NMR (101 MHz, (CDCl3, δ): 172.3, 
169.8, 135.9, 134.8, 132.4, 132.2, 129.9, 129.5, 123.0, 122.2, 120.3, 119.1, 111.2, 107.4, 
53.0, 52.2, 26.9, 23.1; ESI–MS m/z (ion, %): 415 ([M+H]+, 30), 437 ([M+Na]+, 100); ESI–
HRMS m/z: 437.0474 [M+Na]+ (C20H19BrN2NaO3 requires 437.0471). 
The analytical data obtained was in accordance with the literature.114 
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Lab book reference number (method A): AJR-5-401 
Lab book reference number (method B): AJR-7-656 
Methyl (2S)-3-[2-(3-bromophenyl)-1H-indol-3-yl]-2-acetamidopropanoate (209) 
 
Method A: Synthesised using general procedure C with aryldiazonium salt 201 (43 mg, 0.192 
mmol, 1 eq.) to afford the title compound as a brown solid (80 mg, quant.). 
Method B: Synthesised as in method A using Pd(OTs)2(MeCN)2 215 (5.1 mg, 9.6 µmol, 5 
mol%) in place of Pd(OAc)2. Purification by dry-loaded flash column chromatography (SiO2, 
petrol/EtOAc, 1:1, v/v) afforded the title compound as a brown solid (55 mg, 69%). 
Rf 0.28 (petrol/EtOAc, 1:1, v/v); [α]ᴅ = +50.5 (c 0.10, CHCl3); M.P. 82–84 °C dec.; 1H NMR 
(400 MHz, CDCl3, δ): 8.27 (br s, 1H), 7.71 (t, J = 1.5 Hz, 1H), 7.58 (ddt, J = 8.0, 1.5, 1.0 Hz, 
1H), 7.53–7.48 (m, 2H), 7.38–7.32 (m, 2H), 7.22 (ddd, J = 8.0, 7.0, 1.0 Hz, 1H), 7.15 (ddd, 
J = 8.0, 7.0, 1.0 Hz, 1H), 5.84 (d, J = 8.0 Hz, 1H), 4.85 (dt, J = 8.0, 5.5 Hz, 1H), 3.53 (dd, J 
= 15.0, 5.5 Hz, 1H), 3.48 (dd, J = 15.0, 5.5 Hz, 1H), 3.34 (s, 3H), 1.72 (s, 3H); 13C NMR 
(101 MHz, CDCl3, δ): 172.3, 169.7, 135.9, 135.3, 134.4, 131.2, 131.1, 130.8, 129.4, 127.1, 
123.2, 123.1, 120.4, 119.2, 111.2, 107.9, 52.9, 52.2, 26.8, 23.1; ESI–MS m/z (ion, %): 415 
([M+H]+, 50), 437 ([M+Na]+, 100); ESI–HRMS m/z: 415.0658 [M+H]+ (C20H20BrN2O3 
requires 415.0652); IR (solid-state, ATR, cm-1): 3264 (w, br), 3057 (w), 2951 (w), 2924 (w), 
2850 (w), 1732 (m), 1651 (s), 1596 (m), 1518 (m), 1435 (s), 1372 (m), 1261 (m), 1214 (s), 
1010 (m), 787 (m), 741 (s), 687 (s), 594 (m), 507 (m), 437 (m); UV–vis (DMSO, nm): λmax 
312 (ε = 19398 mol dm-3 cm-1). 
Lab book reference number (method A): AJR-5-407 
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Methyl (2S)-3-[2-(4-chlorophenyl)-1H-indol-3-yl]-2-acetamidopropanoate (210) 
 
Method A: Synthesised using general procedure C with aryldiazonium salt 202 (43 mg, 0.192 
mmol, 1 eq.). Purification by dry-loaded flash column chromatography (SiO2, petrol/EtOAc, 
1:1, v/v) afforded the title compound as a brown solid (52 mg, 73%). 
Method B: Synthesised as in method A using Pd(OTs)2(MeCN)2 215 (5.1 mg, 9.6 µmol, 5 
mol%) in place of Pd(OAc)2. Purification by dry-loaded flash column chromatography (SiO2, 
petrol/EtOAc, 1:1, v/v) afforded the title compound as a brown solid (57 mg, 80%). 
Rf 0.39 (petrol/EtOAc, 1:1, v/v); [α]ᴅ = +45.6 (c 0.10, CHCl3); M.P. 202 °C dec.; 1H NMR 
(400 MHz, CDCl3, δ): 8.19 (br s, 1H), 7.57 (dt, J = 8.0, 1.0, 1.0 Hz, 1H), 7.53–7.48 (m, 2H), 
7.47–7.43 (m, 2H), 7.38–7.33 (m, 1H), 7.22 (ddd, J = 8.0, 7.0, 1.0 Hz, 1H), 7.15 (ddd, J = 
8.0, 7.0, 1.0 Hz, 1H), 5.82 (d, J = 8.0 Hz, 1H), 4.84 (dt, J = 8.0, 5.5 Hz, 1H), 3.51 (dd, J = 
15.0, 5.5 Hz, 1H), 3.46 (dd, J = 15.0, 5.5 Hz, 1H), 3.33 (s, 3H), 1.71 (s, 3H); 13C NMR (101 
MHz, (CDCl3, δ): 172.3, 169.7, 135.9, 134.8, 134.2, 131.7, 129.6, 129.5, 129.5, 123.0, 120.4, 
119.1, 111.2, 107.5, 53.0, 52.2, 26.9, 23.1; ESI–MS m/z (ion, %): 371 ([M+H]+, 30), 393 
([M+Na]+, 100); ESI–HRMS m/z: 371.1166 [M+H]+ (C20H20ClN2O3 requires 371.1157). 
Crystals suitable for X-ray diffraction were grown by slow diffusion from a solution of 
CH2Cl2. 
The analytical data obtained was in accordance with the literature.211 
Lab book reference number (method A): AJR-5-405 
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Methyl (2S)-3-[2-(3-chlorophenyl)-1H-indol-3-yl]-2-acetamidopropanoate (211) 
 
Method A: Synthesised using general procedure C with aryldiazonium salt 203 (43 mg, 0.192 
mmol, 1 eq.). Purification by dry-loaded flash column chromatography (SiO2, petrol/EtOAc, 
1:1, v/v) afforded the title compound as a brown solid (45 mg, 63%). 
Method B: Synthesised as in method A using Pd(OTs)2(MeCN)2 215 (5.1 mg, 9.6 µmol, 5 
mol%) in place of Pd(OAc)2. Purification by dry-loaded flash column chromatography (SiO2, 
petrol/EtOAc, 1:1, v/v) afforded the title compound as a brown solid (57 mg, 80%). 
Rf 0.26 (petrol/EtOAc, 1:1, v/v); [α]ᴅ = +54.4 (c 0.10, CHCl3); M.P. 78–79 °C dec.; 1H NMR 
(400 MHz, CDCl3, δ): 8.19 (br s, 1H), 7.61–7.54 (m, 2H), 7.47 (dt, J = 7.5, 1.5 Hz, 1H), 
7.45–7.39 (m, 1H), 7.36 (ddd, J = 7.5, 2.5, 1.5 Hz, 2H), 7.22 (ddd, J = 8.0, 7.0, 1.0 Hz, 1H), 
7.15 (ddd, J = 8.0, 7.0, 1.0 Hz, 1H), 5.83 (d, J = 8.0 Hz, 1H), 4.85 (dt, J = 8.0, 5.5 Hz, 1H), 
3.54 (dd, J = 15.0, 5.5 Hz, 1H), 3.51 (dd, J = 15.0, 5.5 Hz, 1H), 3.34 (s, 3H), 1.72 (s, 3H); 
13C NMR (101 MHz, (CDCl3, δ): 172.3, 169.7, 135.9, 135.2, 135.1, 134.5, 130.6, 129.5, 
128.3, 128.2, 126.6, 123.2, 120.4, 119.3, 111.2, 107.9, 52.9, 52.2, 26.9, 23.1; ESI–MS m/z 
(ion, %): 371 ([M+H]+, 90), 393 ([M+Na]+, 100); ESI–HRMS m/z: 393.0963 [M+Na]+ 
(C20H19ClN2NaO3 requires 393.0976); IR (solid-state, ATR, cm-1): 3271 (w, br), 3059 (w), 
2952 (w), 2852 (w), 1733 (m), 1651 (s), 1597 (m), 1520 (m), 1436 (m), 1372 (s), 1214 (s), 
788 (s), 737 (s), 688 (m); UV–Vis (DMSO, nm): λmax 312 (ε = 15639 mol dm-3 cm-1). 
Lab book reference number (method A): AJR-5-408 
Lab book reference number (method B): AJR-7-667 
Bis(acetonitrile)palladium ditosylate (215)222 
 
Pd(OAc)2 (500 mg, 2.23 mmol, 1 eq.) was added to a Schlenk tube equipped with a magnetic 
stirrer which was then sealed, evacuated and purged with N2 three times. Dry MeCN (45 mL) 
was added with stirring to give an orange–brown solution. To this was added a solution of 
para-toluenesulfonic acid (2.07 g, 12.04 mmol, 5.4 eq.) in dry MeCN (30 mL) via cannula, 
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which resulted in a yellow solution. Dry Et2O (50 mL) was then added to precipitate a yellow 
solid and the mixture left to stand for 20 min with no stirring. After 20 min the excess Et2O 
was removed by filter cannula and the resulting solid washed with dry Et2O (20 mL), which 
was then removed by filter cannula. The resulting solid was dried briefly under vacuum to 
afford the title compound as a cream solid (944 mg, 80%). 
Note: Dissociation of MeCN ligands is facile in solution, the ratio of complexed p-
TsOH:complexed MeCN:free MeCN by 1H NMR was measured as 1:0.6:1.3. 
Mp 130–135 °C dec; 1H NMR (400 MHz, CD3OD, δ): 7.72 (d, J = 8.0 Hz, 4H), 7.25 (d, J = 
8.0 Hz, 4H), 2.56 (s, complexed MeCN, 2H), 2.38 (s, 6H), 2.03 (s, free MeCN, 4H); 13C 
NMR (125 MHz, CD3OD, δ): 142.6, 137.6, 130.0, 127.0, 21.3; IR (solid-state, ATR, cm-1): 
3007, 2992, 2929, 2337, 1595, 1491, 1398, 1348, 1283, 1177, 1142, 1097, 1028, 1015, 947, 
814, 712, 675, 642, 629, 554, 507, 438. 
Lab book reference number (method A): AJR-6-532 
Effect of MeCN on direct arylation of tryptophan 
 
To a microwave tube was added tryptophan 74 (50 mg, 0.192 mmol, 1 eq.), aryldiazonium 
salt 48 (37 mg, 0.192 mmol, 1 eq.), Pd(OAc)2 (2 mg, 9.6 μmol, 5 mol%), MeCN (1 µL, 789 
µg, 19.2 μmol, 10 mol%) and EtOAc (5 mL). The reaction mixture was stirred at RT for 16 
h. After 16 h the resulting brown reaction mixture was filtered through Celite then washed 
with sat. aq. NaHCO3. The organic layer was collected and dried over MgSO4, filtered and 
evaporated to afford the title compound as an off-white solid (64 mg, quant.). 
Lab book reference number: AJR-7-681 
Attempted direct arylation of indole 
 
To a microwave tube was added phenyldiazonium salt 48 (58 mg, 0.30 mmol, 1 eq.) and 
Pd(OAc)2 (3.4 mg, 15 μmol, 5 mol%). Indole 45 (35 mg, 0.30 mmol, 1 eq.) was then added. 
Upon addition phenyldiazonium salt 48 visibly darkened to red, followed by black. This 
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heated up rapidly and began visibly smoking, which subsided after 2 min. EtOAc (3 mL) was 
added to give a dark red solution which was stirred at 60 °C for 16 h. After 16 h TLC analysis 
of the reaction mixture indicated a large number of species, so the reaction was abandoned. 
Lab book reference number: AJR-5-453 
Attempted direct arylation of methylindole 
 
To a microwave tube was added 1-methylindole 33 (37 µL, 39 mg, 0.30 mmol, 1 eq.), 
phenyldiazonium salt 48 (58 mg, 0.30 mmol, 1 eq.), Pd(OAc)2 (3.4 mg, 15 μmol, 5 mol%) 
and EtOAc (3 mL). The mixture was then stirred at 60 °C for 16 h. After 16 h TLC (SiO2, 
petrol/EtOAc, 4:1, v/v) analysis of the reaction mixture indicated a large number of species. 
The resulting dark red reaction mixture was filtered through Celite then washed with sat. aq. 
NaHCO3. The organic layer was collected and dried over MgSO4, filtered and evaporated to 
give a brown residue. Analysis by 1H NMR spectroscopic analysis indicated a large number 
of species, so the reaction was abandoned. 
Lab book reference number: AJR-5-454 
Attempted direct arylation of indazole 
 
To a microwave tube was added indazole 222 (35 mg, 0.30 mmol, 1 eq.), phenyldiazonium 
salt 48 (58 mg, 0.30 mmol, 1 eq.), Pd(OAc)2 (3.4 mg, 15 μmol, 5 mol%) and EtOAc (3 mL). 
The mixture was then stirred at 60 °C for 16 h. After 16 h the reaction mixture was filtered 
through Celite then washed with sat. aq. NaHCO3. The organic layer was collected and dried 
over MgSO4, filtered and evaporated to give a brown residue. Analysis by 1H NMR 
spectroscopic analysis indicated only starting material. Purification by dry-loaded flash 
column chromatography (SiO2, petrol/EtOAc, 1:1, v/v) afforded the starting material as an 
off-white solid (35 mg, quant.). 
Lab book reference number: AJR-6-468 
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Attempted direct arylation of 7-azaindole at 60 °C 
 
To a microwave tube was added 7-azaindole 223 (35 mg, 0.30 mmol, 1 eq.), 
phenyldiazonium salt 48 (58 mg, 0.30 mmol, 1 eq.), Pd(OAc)2 (3.4 mg, 15 μmol, 5 mol%) 
and EtOAc (3 mL). The mixture was then stirred at 60 °C for 16 h. After 16 h TLC (SiO2, 
petrol/EtOAc, 1:1, v/v) analysis of the reaction mixture indicated a large number of species. 
The reaction mixture was filtered through Celite then washed with sat. aq. NaHCO3. The 
organic layer was collected and dried over MgSO4, filtered and evaporated to give a brown 
residue. Analysis by 1H NMR spectroscopic analysis indicated a large number of species, so 
the reaction was abandoned. 
Lab book reference number: AJR-6-469 
Attempted direct arylation of 7-azaindole at 40 °C 
 
To a microwave tube was added 7-azaindole 223 (35 mg, 0.30 mmol, 1 eq.), 
phenyldiazonium salt 48 (58 mg, 0.30 mmol, 1 eq.), Pd(OAc)2 (3.4 mg, 15 μmol, 5 mol%) 
and EtOAc (3 mL). The mixture was then stirred at 40 °C for 16 h. After 16 h TLC (SiO2, 
petrol/EtOAc, 1:1, v/v) analysis of the reaction mixture indicated no conversion of starting 
material, so the reaction was abandoned. 
Lab book reference number: AJR-6-477 
Attempted direct arylation of 7-azaindole at RT 
 
To a microwave tube was added 7-azaindole 223 (35 mg, 0.30 mmol, 1 eq.), 
phenyldiazonium salt 48 (58 mg, 0.30 mmol, 1 eq.), Pd(OAc)2 (3.4 mg, 15 μmol, 5 mol%) 
and EtOAc (3 mL). The mixture was then stirred at RT for 16 h. After 16 h TLC (SiO2, 
petrol/EtOAc, 1:1, v/v) analysis of the reaction mixture indicated no conversion of starting 
material, so the reaction was abandoned. 
Lab book reference number: AJR-6-473 





To a round-bottomed flask equipped with a magnetic stirrer bar was added indazole 222 (1 
g, 8.46 mmol, 1 eq.). This was dissolved in acetone (10 mL) with stirring, before being cooled 
to 0 °C. KOH (1.42 g, 25.4 mmol, 3 eq.) was then added, the flask was sealed with a septum 
and flushed with N2 from a balloon. The reaction mixture was then stirred at 0 °C for 1 h, 
then MeI (0.8 mL, 1.8 g, 12.7 mmol, 1.5 eq.) was added dropwise at 0 °C. After complete 
addition the reaction was allowed to warm to RT with stirring for 1 h. After 1 h the KOH was 
filtered off using a glass sinter and the solvent evaporated. Purification by wet-loaded flash 
column chromatography (SiO2, petrol/EtOAc, 4:1, v/v) afforded the title compound as a white 
solid (810 mg, 72%). 
Rf 0.55 (petrol/EtOAc, 4:1, v/v); M.P. 60–61 °C (lit.152 58–59 °C); 1H NMR (400 MHz, 
CDCl3, δ): 7.99 (s, 1H), 7.73 (dt, J = 8.0, 1.0 Hz, 1H), 7.41–7.38 (m, 2H), 7.18–7.12 (m, 1H), 
4.08 (s, 3H); 13C NMR (101 MHz, CDCl3, δ): 140.0, 132.8, 126.3, 124.1, 121.2, 120.5, 109.0, 
35.6; EI–GC–MS m/z (ion): 132 [C8H8N2]+; EI–HRMS m/z: 132.0688 [C8H8N2]+ (C8H8N2 
requires 132.0687). 
Lab book reference number: AJR-6-498 
Attempted direct arylation of 1-methylindazole (225) 
 
To a microwave tube was added 1-methylindazole 224 (40 mg, 0.30 mmol, 1 eq.), 
phenyldiazonium salt 48 (58 mg, 0.30 mmol, 1 eq.), Pd(OAc)2 (3.4 mg, 15 μmol, 5 mol%) 
and EtOAc (3 mL). The mixture was then stirred at 60 °C for 16 h. After 16 h TLC (SiO2, 
petrol/EtOAc, 1:1, v/v) analysis of the reaction mixture indicated no conversion of starting 
material, so the reaction was abandoned. 
Lab book reference number: AJR-8-758 
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Attempted Tfa-protection of 1-methylindazole (226) 
 
To a round-bottomed flask equipped with magnetic stirrer bar was added indazole 222 (100 
mg, 0.85 mmol, 1 eq.). The flask was sealed with a septum and flushed with nitrogen from a 
balloon for 10 mins, then Et3N (131 µL, 95 mg, 0.94 mmol, 1.1 eq.) and solvent (0.85 mL) 
were added via syringe. The mixture was cooled to 0 °C, then ethyl trifluoroacetate 165 (112 
µL, 134 mg, 0.94 mmol, 1.1 eq.) was added dropwise. After complete addition the reaction 
was allowed to warm to RT and stirred for 20 h. No conversion of starting material was 
observed. 
Lab book reference number (MeCN): AJR-6-495 
Lab book reference number (THF): AJR-6-501 
Boc-protection of 1-methylindazole (227)153 
 
To a round-bottomed flask equipped with magnetic stirrer bar was added indazole 222 (591 
mg, 5 mmol, 1 eq.) and DMAP (12 mg, 0.1 mmol, 2 mol%). The flask was sealed with a 
septum and flushed with nitrogen from a balloon for 10 mins, then dry MeCN (7 mL) was 
added via syringe. To this mixture was added a solution of Boc2O (1.31 g, 6 mmol, 1.2 eq.) 
in dry MeCN (3 mL) to give a clear solution. This was stirred at RT for 3 h. After 3 h the 
solvent was evaporated and the residue redissolved in Et2O. Deionised water was added and 
the mixture extracted into Et2O three times. The organic layers were collected and dried over 
MgSO4, filtered and evaporated to give an orange oil. Purification by wet-loaded flash 
column chromatography (SiO2, petrol/Et2O, 2:1, v/v) afforded an inseparable mixture of the 
title compound and 228 as a clear oil (1.0 g, 98%). 
Lab book reference number: AJR-6-487 
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Attempted Ac-protection of 1-methylindazole (229) 
 
To a round-bottomed flask equipped with magnetic stirrer bar was added indazole 222 (100 
mg, 0.85 mmol, 1 eq.). The flask was sealed with a septum and flushed with nitrogen from a 
balloon for 10 mins, then Et3N (131 µL, 95 mg, 0.94 mmol, 1.1eq.) and MeCN (0.85 mL) 
were added via syringe. The mixture was cooled to 0 °C, then Ac2O (89 µL, 96 mg, 0.94 
mmol, 1.1 eq.) was added dropwise. After complete addition the reaction was allowed to 
warm to RT and stirred for 20 h. After 3 h deionised water was added and the mixture 
extracted into EtOAc three times. The organic layers were collected and washed with 1M 
HCl and brine, then dried over MgSO4, filtered and evaporated to give a clear oil. Purification 
by wet-loaded flash column chromatography (SiO2, petrol/EtOAc, 4:1, v/v) afforded an 
inseparable mixture of the title compound and 230 as a white solid (107 mg, 79%). 
Lab book reference number: AJR-6-494 
1-Methyl-7-azaindole (231)154 
 
To a round-bottomed flask equipped with a magnetic stirrer bar was added 7-azaindole 223 
(1 g, 8.46 mmol, 1 eq.). This was dissolved in DMF (5 mL) with stirring, before being cooled 
to 0 °C. The flask was sealed with a septum and flushed with N2 from a balloon for 10 mins, 
then NaH (244 mg, 10.15 mmol, 1.2 eq.) was added and the reaction stirred at 0 °C for 1 h. 
After 1 h MeI (0.58 mL, 1.32 g, 9.31 mmol, 1.1 eq.) was added dropwise at 0 °C. After 
complete addition the reaction was allowed to warm to RT with stirring for 1 h. After 1 h ice-
cold deionised water was added to quench the reaction, which was then extracted into EtOAc 
three times. The organic layers were combined and washed five times with deionised water, 
then washed with brine, dried over MgSO4, filtered and evaporated to give an orange oil. 
This was purified directly by filtration through a silica plug (SiO2, EtOAc) to afford the title 
compound as a yellow oil (0.98 g, 88%). 
1H NMR (400 MHz, CDCl3, δ): 8.34 (dd, J = 5.0, 1.0 Hz, 1H), 7.91 (dt, J = 8.0, 1.0 Hz, 1H), 
7.18 (d, J = 3.5 Hz, 1H), 7.05 (ddd, J = 8.0, 5.0, 1.0 Hz, 1H), 6.45 (dd, J = 3.5, 1.0 Hz, 1H), 
3.90 (d, J = 1.0 Hz, 3H); 13C NMR (101 MHz, CDCl3, δ): 147.9, 142.9, 129.2, 128.9, 120.7, 
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115.6, 99.4, 31.4; ESI–MS m/z (ion, %): 133 ([M+H]+, 100); ESI–HRMS m/z: 133.0763 
[M+H]+ (C8H9N2 requires 133.0760). 
Lab book reference number: AJR-6-480 
1-methyl-2-phenyl-7-azaindole (232) 
 
Method A: To a microwave tube equipped with magnetic stirrer bar was added 1-methyl-7-
azaindole 231 (40 mg, 0.30 mmol, 1 eq.), aryldiazonium salt 48 (58 mg, 0.30 mmol, 1 eq.), 
Pd(OAc)2 (3.4 mg, 15 μmol, 5 mol%) and EtOH (3 mL). The reaction mixture was stirred at 
40 °C for 22 h. After 22 h the reaction mixture was filtered through Celite with EtOAc then 
washed with sat. aq. NaHCO3. The organic layer was collected and dried over MgSO4, 
filtered and evaporated to give a brown solid, which was subsequently analysed by 1H NMR 
spectroscopy. 
Method B: To a microwave tube equipped with magnetic stirrer bar was added 1-methyl-7-
azaindole 231 (100 mg, 0.76 mmol, 1 eq.), diaryliodonium salt 233 (390 mg, 1.06 mmol, 1.4 
eq.), Pd(OAc)2 (8.4 mg, 37.5 μmol, 5 mol%) and EtOH (3.8 mL). The vial was sealed with a 
septum and the reaction stirred at 60 °C for 22 h. After 22 h the reaction mixture was allowed 
to cool to RT, then filtered through Celite with EtOAc, washed with sat. aq. NaHCO3, dried 
over MgSO4, filtered and evaporated to give a brown residue. Purification by dry-loaded flash 
column chromatography (SiO2, petrol/Et2O, 1:1, v/v) to afford the title compound as a yellow 
oil (125 mg, 79%). 
Rf 0.26 (petrol/Et2O, 1:1, v/v); 1H NMR (400 MHz, CDCl3, δ): 8.36 (dd, J = 5.0, 1.5 Hz, 1H), 
7.91 (dd, J = 8.0, 1.5 Hz, 1H), 7.58–7.54 (m, 2H), 7.52–7.47 (m, 2H), 7.46–7.41 (m, 1H), 
7.09 (dd, J = 8.0, 5.0 Hz, 1H), 6.52 (s, 1H), 3.89 (s, 3H); 13C NMR (101 MHz, CDCl3, δ): 
149.4, 142.8, 142.0, 132.5, 129.3, 128.8, 128.4, 128.3, 120.8, 116.2, 99.5, 30.0; ESI–MS m/z 
(ion, %): 209 ([M+H]+, 100); ESI–HRMS m/z: 209.1074 [M+H]+ (C14H13N2 requires 
209.1073). 
Lab book reference number (method A): AJR-6-520 
Lab book reference number (method B): AJR-6-489 
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Diphenyliodonium tetrafluoroborate (233)155 
 
To a round-bottomed flask equipped with a magnetic stirrer bar was added mCPBA (≤77%, 
7.39 g, 33 mmol, 1.1 eq.), which was then dissolved in CH2Cl2 (100 mL). Iodobenzene 1 (3.4 
mL, 6.12 g, 30 mmol, 1 eq.) was added to this solution, then BF3·OEt2 (9.2 mL, 10.6 g, 75 
mmol, 2.5 eq.) was added dropwise. The resultant solution was stirred at RT for 30 min, then 
cooled to 0 °C. PhB(OH)2 14 (4.02 g, 33 mmol, 1.1 eq.) was then added at 0 °C. After 
complete addition, the reaction was allowed to warm to RT with stirring over 15 min. After 
15 min the crude reaction mixture was filtered through a silica pad, first eluting with CH2Cl2, 
then CH2Cl2/MeOH (20:1, v/v). The second fraction was collected and concentrated in vacuo. 
Et2O was added to precipitate an off-white solid, which was filtered through a glass sinter 
and washed with further Et2O, before being dried in vacuo to afford the title compound as an 
off-white solid (7.82 g, 71%). 
M.P. 136–138 °C (lit.223 136–138 °C); 1H NMR (400 MHz, (CD3)2SO, δ): 8.25 (dd, J = 8.0, 
1.0 Hz, 4H), 7.73–7.62 (m, 2H), 7.57–7.51 (m, 4H); 13C NMR (101 MHz, (CD3)2SO, δ): 
135.2, 132.1, 131.8, 116.5; ESI-MS m/z (ion, rel. %): 281 ([C12H10I]+, 100); ESI-HRMS m/z: 
280.9824 [C12H10I]+ (C12H10I requires 280.9822). 
Lab book reference number: AJR-8-727 
2-Phenylindole (234) 
 
To a microwave tube equipped with magnetic stirrer bar was added indole 45 (35 mg, 0.30 
mmol, 1 eq.), diaryliodonium salt 233 (155 mg, 0.42 mmol, 1.4 eq.), Pd(OAc)2 (3.4 mg, 15 
μmol, 5 mol%) and EtOH (1.5 mL). The vial was sealed with a septum and the reaction stirred 
at 60 °C for 22 h. After 22 h the reaction mixture was allowed to cool to RT and purified 
directly by wet-loaded flash column chromatography (SiO2, pentane/EtOAc, 9:1, v/v) to 
afford the title compound as a white solid (32 mg, 55%). 
Rf 0.46 (pentane/EtOAc, 9:1, v/v); 1H NMR (400 MHz, CDCl3, δ): 8.33 (br s, 1H), 7.70–7.64 
(m, 3H), 7.49–7.40 (m, 3H), 7.38–7.31 (m, 1H), 7.22 (m, 1H), 7.15 (m, 1H), 6.85 (s, 1H); 
13C NMR (101 MHz, CDCl3, δ): 138.0, 136.9, 132.5, 129.4, 129.2, 127.9, 125.3, 122.5, 120.8, 
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120.4, 111.0, 100.1; ESI–MS m/z (ion, %): 194 ([M+H]+, 100); ESI–HRMS m/z: 194.0968 
[M+H]+ (C14H12N requires 194.0964). 
Lab book reference number: AJR-7-641 
Attempted direct arylation of indazole 
 
To a microwave tube equipped with magnetic stirrer bar was added indazole 222 (35 mg, 
0.30 mmol, 1 eq.), diaryliodonium salt 233 (155 mg, 0.42 mmol, 1.4 eq.), Pd(OAc)2 (3.4 mg, 
15 μmol, 5 mol%) and EtOH (1.5 mL). The vial was sealed with a septum and the reaction 
stirred at 60 °C for 22 h. After 22 h analysis of the crude reaction mixture by TLC (SiO2, 
petrol/EtOAc, 1:1:, v/v) indicated no conversion of starting material, so the reaction was 
abandoned. 
Lab book reference number: AJR-6-470 
Attempted direct arylation of 7-azaindole 
 
To a microwave tube equipped with magnetic stirrer bar was added 7-azaindole 223 (35 mg, 
0.30 mmol, 1 eq.), diaryliodonium salt 233 (155 mg, 0.42 mmol, 1.4 eq.), Pd(OAc)2 (3.4 mg, 
15 μmol, 5 mol%) and EtOH (1.5 mL). The vial was sealed with a septum and the reaction 
stirred at 60 °C for 22 h. After 22 h analysis of the crude reaction mixture by TLC (SiO2, 
petrol/EtOAc, 1:1, v/v) indicated no conversion of starting material, so the reaction was 
abandoned. 
Lab book reference number: AJR-6-471 
Attempted direct arylation of pyridazine 
 
To a microwave tube equipped with magnetic stirrer bar was added pyridazine 235 (36 mg, 
0.30 mmol, 1 eq.), diaryliodonium salt 233 (155 mg, 0.42 mmol, 1.4 eq.), Pd(OAc)2 (3.4 mg, 
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15 μmol, 5 mol%) and EtOH (1.5 mL). The vial was sealed with a septum and the reaction 
stirred at 60 °C for 4 days. After 4 days analysis of the crude reaction mixture by TLC (SiO2, 
petrol/EtOAc, 4:1, v/v) indicated no conversion of starting material, so the reaction was 
abandoned. 
Lab book reference number: AJR-6-479 
Attempted direct arylation of 1-methylindazole (225) 
 
To a microwave tube equipped with magnetic stirrer bar was added 1-methylindazole 224 
(40 mg, 0.30 mmol, 1 eq.), diaryliodonium salt 233 (155 mg, 0.42 mmol, 1.4 eq.), Pd(OAc)2 
(3.4 mg, 15 μmol, 5 mol%) and EtOH (1.5 mL). The vial was sealed with a septum and the 
reaction stirred at 60 °C for 4 days. After 4 days analysis of the crude reaction mixture by 
TLC (SiO2, petrol/EtOAc, 4:1, v/v) indicated no conversion of starting material, so the 
reaction was abandoned. 
Lab book reference number: AJR-6-478 
Catalyst screening for 1-methyl-2-phenyl-7-azaindole (232) 
 
To a microwave tube equipped with magnetic stirrer bar was added 1-methyl-7-azaindole 
231 (40 mg, 0.30 mmol, 1 eq.), diaryliodonium salt 233 (155 mg, 0.42 mmol, 1.4 eq.), Pd 
catalyst (5 mol%) and EtOH (1.5 mL). The vial was sealed with a septum and the reaction 
stirred at 60 °C for 22 h. After 22 h the reaction mixture was allowed to cool to RT, then 
filtered through Celite with EtOAc, washed with sat. aq. NaHCO3, dried over MgSO4, filtered 
and evaporated to give a brown residue, which was subsequently analysed by 1H NMR 
spectroscopy. 
Lab book reference number (Pd/C, 5 wt%): AJR-6-511 
Lab book reference number (Pd/C, 10 wt%): AJR-6-517 
Lab book reference number (Pd/charcoal): AJR-6-512 
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Lab book reference number (Pd black): AJR-6-516 
Lab book reference number (Lindlar): AJR-6-515 
Lab book reference number (Pearlman’s): AJR-6-513 
Lab book reference number (PdO): AJR-6-514 
PVP–Pd (13) 
To a three-necked round-bottomed flask fitted with a mechanical stirrer and reflux condenser 
was added PdCl2 (255 mg, 1.44 mmol, 1 eq.), HCl (0.2 M, 14.4 mL) and deionised water 
(706 mL). The reaction mixture was stirred for 1 h to give an orange solution. PVP 12 (3.2 
g, 28.3 mmol, 14 eq.), deionised water (672 mL) and EtOH (1000 mL) were added and the 
reaction heated to reflux with stirring for 4.5 h. The mixture was cooled to ambient 
temperature and the solvent removed under reduced pressure to give a brittle, glassy black 
solid. This was crushed with a pestle and mortar then dried in vacuo to give the product as a 
black crystalline solid (3.40 g). 
IR (solid-state ATR, cm-1): 2953 (w, br), 1640 (s), 1421 (s), 1288 (s). 
Lab book reference number: AJR-1-33, AJR-8-709 
DMF-stabilised PdNPs (236) 
To a 250 mL two-necked round-bottomed flask equipped with a magnetic stirrer bar and 
reflux condenser was added DMF (15 ml). This was heated to 140 °C before a suspension of 
PdCl2 (2.6 mg, 15 µmol) in deionised water (150 µL) was added. The resulting solution was 
heated at 140 °C for 6 h to yield the product as a clear yellow solution. Often the product 
could not be obtained, and a black particulate solution was seen instead. 
Lab book reference number: AJR-5-463, AJR-5-464 
Diphenyliodonium trifluoromethanesulfonate (38)124 
 
Aryliodonium salt 22 (1 g, 3.1 mmol, 1 eq.) and benzene 237 (303 µL, 266 mg, 3.41 mmol, 
1.1 eq.) were added to a round-bottomed flask and dissolved in CH2Cl2 (6 mL) with stirring. 
The mixture was cooled to 0 °C then trifluoromethanesulfonic acid (301 µL, 512 mg, 3.41 
mmol, 1.1 eq.) was added dropwise with stirring. After complete addition the reaction was 
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stirred for 2 h over which time it was allowed to warm to RT. After 2 h the mixture was 
evaporated to give an orange-white residue to which Et2O was added to precipitate a white 
solid. This was filtered through a glass sinter and washed on the filter with further Et2O until 
the filtrate ran clear. This was then dried in vacuo at 100 °C to afford the title compound as 
an off-white solid (1.02 g, 76%). 
M.P. 174–176 °C (lit.224 175–177 °C); 1H NMR (400 MHz, (CD3)2SO, δ):8.28–8.22 (m, 4H), 
7.70–7.64 (m, 2H), 7.57–7.50 (m, 4H); 13C NMR (101 MHz, (CD3)2SO, δ): 135.2, 132.1, 
131.8, 116.5; 19F NMR (376 MHz, CDCl3, δ): −77.7; ESI–MS m/z (ion, %): 280 ([M−OTf]+, 
100); ESI–HRMS m/z: 280.9830 [M−OTf]+ (C12H10I requires 280.9822). 
Lab book reference number: AJR-8-726 
Screening for the direct arylation of tryptophan (75) 
 
To a microwave tube equipped with magnetic stirrer bar was added tryptophan 74 (52 mg, 
0.20 mmol, 1 eq.), diaryliodonium triflate salt 38 (172 mg, 0.40 mmol, 2 eq.) or 
diaryliodonium tetrafluoroborate salt 233 (147 mg, 0.40 mmol, 2 eq.), Pd catalyst (5 mol%) 
and solvent (2 mL). The vial was sealed with a septum and the reaction stirred at 60 °C for 
16 h. After 16 h the reaction mixture was allowed to cool to RT, filtered through a silica pad 
with EtOAc and evaporated to give a brown residue, which was subsequently analysed by 1H 
NMR spectroscopy. 
Lab book reference number (entry 1): AJR-8-712 
Lab book reference number (entry 2): AJR-8-729 
Lab book reference number (entry 3): AJR-8-730 
Lab book reference number (entry 4): AJR-8-720 
Lab book reference number (entry 5): AJR-8-714 
Lab book reference number (entry 6): AJR-8-728 
Lab book reference number (entry 7): AJR-8-725 
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Lab book reference number (entry 8): AJR-8-735 
Lab book reference number (entry 9): AJR-8-733 
Lab book reference number (entry 10): AJR-8-734 
1-Methyl-2-phenylindole (34) 
 
Method A: The initial kinetics for formation of the title compound were recorded using 
general procedure D (temperature decreased to 50 °C) with Pd/C (64 mg), PVP–Pd 13 (40 
mg), Pd(OAc)2 (6.7 mg) or Pd2(dba)3 238 (15.5 mg). 
Method B: The initial kinetics for formation of the title compound were recorded using 
general procedure D with Pd/C (64 mg), PVP–Pd 13 (40 mg), Pd(OAc)2 (6.7 mg) or Pd2(dba)3 
238 (15.5 mg). 
1H NMR (400 MHz, CDCl3, δ): 7.64 (d, J = 8.0 Hz, 1H), 7.56–7.46 (m, 4H), 7.45–7.36 (m, 
2H), 7.28–7.23 (m, 1H), 7.18–7.12 (m, 1H), 6.57 (s, 1H), 3.76 (s, 3H); 13C NMR (101 MHz, 
CDCl3, δ): 141.7, 138.5, 133.0, 129.5, 128.6, 128.1, 128.0, 121.8, 120.6, 120.0, 109.7, 101.8, 
31.3. 
Lab book reference number (method A, Pd/C): ln_1a_07 (reaction conducted by L. Neumann) 
Lab book reference number (method A, PVP–Pd): ln_1c_04 (reaction conducted by L. 
Neumann) 
Lab book reference number (method A, Pd(OAc)2): ln_1f_05 (reaction conducted by L. 
Neumann) 
Lab book reference number (method A, Pd2(dba)3): ln_1g_05 (reaction conducted by L. 
Neumann) 
Lab book reference number (method B, Pd/C): ln_1a_06 (reaction conducted by L. Neumann) 
Lab book reference number (method B, PVP–Pd): ln_1c_02_new (reaction conducted by L. 
Neumann) 
Lab book reference number (method B, Pd(OAc)2): ln_1f_03 (reaction conducted by L. 
Neumann) 
Chapter 6: Experimental 
213 
 
Lab book reference number (method B, Pd2(dba)3): ln_1g_02 (reaction conducted by L. 
Neumann) 
Comparison of PVP–Pd batches using 1-Methyl-2-phenylindole 
The initial kinetics for formation of the title compound were recorded using general 
procedure D with PVP–Pd 13 (40 mg). 
Lab book reference number: ln_1c_02_old (reaction conducted by L. Neumann) 
Lab book reference number: ln_1c_02_new (reaction conducted by L. Neumann) 
2-phenylbenzofuran (240) 
 
The initial kinetics for formation of the title compound were recorded using general 
procedure D with Pd/C (64 mg), PVP–Pd 13 (40 mg), Pd(OAc)2 (6.7 mg) or Pd2(dba)3 238 
(15.5 mg). 
To a microwave tube equipped with magnetic stirrer bar was added benzofuran 239 (33 µL, 
35 mg, 0.30 mmol, 1 eq.), diaryliodonium salt 233 (155 mg, 0.42 mmol, 1.4 eq.), Pd(OAc)2 
(3.4 mg, 0.015 mmol, 5 mol%) and EtOH (1.5 mL). The vial was sealed with a septum and 
the reaction stirred at 60 °C for 22 h. After 22 h the reaction mixture was allowed to cool to 
RT, filtered through a silica pad with EtOAc and evaporated to give a brown residue, which 
was purified directly by wet-loaded flash column chromatography (SiO2, petrol) to afford the 
title compound as a white solid (18 mg, 31%). 
1H NMR (400 MHz, CDCl3, δ): 7.92–7.87 (m, 2H), 7.63–7.59 (m, 1H), 7.57–7.53 (m, 1H), 
7.50–7.44 (m, 2H), 7.40–7.35 (m, 1H), 7.31 (ddd, J = 8.0, 7.0, 1.5 Hz, 1H), 7.26 (ddd, J = 
8.0, 7.0, 1.5 Hz, 1H), 7.05 (d, J = 1.0 Hz, 1H); 13C NMR (101 MHz, CDCl3, δ): 156.0, 155.0, 
130.6, 129.3, 128.9, 128.7, 125.1, 124.4, 123.1, 121.0, 111.3, 101.4; EI–GC–MS m/z (ion): 
194 [C14H10O]+; EI–HRMS m/z: 194.0720 [C14H10O]+ (C14H10O requires 194.0732). 
Lab book reference number (Pd/C): ln_3a (reaction conducted by L. Neumann) 
Lab book reference number (PVP–Pd): ln_3c (reaction conducted by L. Neumann) 
Lab book reference number (Pd(OAc)2): ln_3f (reaction conducted by L. Neumann) 
Lab book reference number (Pd2(dba)3): ln_3g (reaction conducted by L. Neumann) 
Chapter 6: Experimental 
214 
 
Lab book reference number: AJR-7-642 
4-n-butyl-2-phenylthiophene (242) 
 
The initial kinetics for formation of the title compound were recorded using general 
procedure D with Pd/C (64 mg), PVP–Pd 13 (40 mg), Pd(OAc)2 (6.7 mg) or Pd2(dba)3 238 
(15.5 mg). 
Method A: To a microwave tube equipped with magnetic stirrer bar was added 2-n-
butylthiophene 241 (42 mg, 0.30 mmol, 1 eq.), diaryliodonium salt 233 (155 mg, 0.42 mmol, 
1.4 eq.), Pd(OAc)2 (3.4 mg, 0.015 mmol, 5 mol%) and EtOH (1.5 mL). The vial was sealed 
with a septum and the reaction stirred at 60 °C for 22 h. After 22 h the reaction mixture was 
allowed to cool to RT, filtered through a silica pad with EtOAc and evaporated to give a 
brown residue, which was purified directly by wet-loaded flash column chromatography 
(SiO2, petrol) to afford the title compound as a clear oil (32 mg, 49%). 
Method B: Synthesised as in method A using PVP–Pd 13 (20 mg, 0.015 mmol, 5 mol%) in 
place of Pd(OAc)2. Purification by wet-loaded flash column chromatography (SiO2, petrol) 
afforded the title compound as a clear oil (45 mg, 69%). 
1H NMR (400 MHz, CDCl3, δ): 7.61–7.56 (m, 2H), 7.42–7.36 (m, 2H), 7.31–7.25 (m, 1H), 
7.24 (d, J = 1.5 Hz, 1H), 7.09 (dt, J = 1.5, 1.0 Hz, 1H), 2.87 (t, J = 7.5 Hz, 2H), 1.77–1.67 
(m, 2H), 1.50–1.38 (m, 2H), 0.97 (t, J = 7.5 Hz, 3H); 13C NMR (101 MHz, CDCl3, δ): 146.8, 
141.9, 136.4, 128.8, 127.0, 126.4, 123.5, 117.9, 33.9, 30.0, 22.4, 14.0; ESI–MS m/z (ion): 
217 [C14H17S]+; ESI–HRMS m/z: 217.1024 [C14H17S]+ (C14H17S requires 217.1045). 
Lab book reference number (Pd/C): ln_5a (reaction conducted by L. Neumann) 
Lab book reference number (PVP–Pd): ln_5c (reaction conducted by L. Neumann) 
Lab book reference number (Pd(OAc)2): ln_5f (reaction conducted by L. Neumann) 
Lab book reference number (Pd2(dba)3): ln_5g (reaction conducted by L. Neumann) 
Lab book reference number (method A): AJR-7-643 
Lab book reference number (method B): AJR-7-731 





The initial kinetics for formation of the title compound were recorded using general 
procedure D with Pd/C (64 mg), PVP–Pd 13 (40 mg), Pd(OAc)2 (6.7 mg) or Pd2(dba)3 238 
(15.5 mg). 
The initial kinetics were also studied using procedure D, with the temperature increased to 
70 °C over 10 h, using Pd/C (64 mg). 
Method A: To a microwave tube equipped with magnetic stirrer bar was added 2-n-butylfuran 
243 (42 µL, 37 mg, 0.30 mmol, 1 eq.), diaryliodonium salt 233 (155 mg, 0.42 mmol, 1.4 eq.), 
PVP–Pd 13 (20 mg, 0.015 mmol, 5 mol%) and EtOH (1.5 mL). The vial was sealed with a 
septum and the reaction stirred at 60 °C for 22 h. After 22 h the reaction mixture was allowed 
to cool to RT, filtered through a silica pad with EtOAc and evaporated to give a brown 
residue, which was purified directly by dry-loaded flash column chromatography (SiO2, 
petrol) to afford the title compound as a clear oil (27 mg, 45%). 
Method B: Synthesised as in method B using Pd/C (32 mg, 0.015 mmol, 5 mol%) in place of 
PVP–Pd 13. Purification by dry-loaded flash column chromatography (SiO2, petrol) to afford 
an inseparable mixture of the title compound and biphenyl as a clear oil (45 mg). 
1H NMR (400 MHz, CDCl3, δ): 7.68–7.63 (m, 2H), 7.40–7.34 (m, 2H), 7.23 (tt, J = 7.5, 1.0 
Hz, 1H), 6.56 (d, J = 3.0 Hz, 1H), 6.08 (dt, J = 3.0, 1.0 Hz, 1H), 2.70 (app t, J = 7.5 Hz, 2H), 
1.70 (tt, J = 7.5, 6.5 Hz, 2H), 1.44 (app sext, J = 7.5 Hz, 2H), 0.97 (t, J = 7.5 Hz, 3H); 13C 
NMR (101 MHz, CDCl3, δ): 156.6, 152.2, 131.4, 128.7, 126.8, 123.4, 107.0, 105.8, 30.4, 
28.0, 22.4, 14.0; EI–GC–MS m/z (ion): 200 [C14H16O]+; EI–HRMS m/z: 200.1202 [C14H16O]+ 
(C14H16O requires 200.1201). 
Lab book reference number (Pd/C): ln_6a (reaction conducted by L. Neumann) 
Lab book reference number (PVP–Pd): ln_6c (reaction conducted by L. Neumann) 
Lab book reference number (Pd(OAc)2): ln_6f (reaction conducted by L. Neumann) 
Lab book reference number (Pd2(dba)3): ln_6g (reaction conducted by L. Neumann) 
Lab book reference number: AJR-8-743 
Lab book reference number (method A): AJR-8-732 
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Lab book reference number (method B): AJR-8-739, AJR-8-740, AJR-8-742 
(1E,4E)-1,5-diphenylpenta-1,4-dien-3-one (247) 
 
To a round-bottomed flask equipped with a magnetic stirrer was added NaOH (4.7 g, 117 
mmol, 2.5 eq.), deionised water (91 mL) and EtOH (66 mL), before being cooled to 0 °C. 
Acetone (3.45 mL, 2.73 g, 47 mmol, 1 eq.) and benzaldehyde (9.60 mL, 9.98 g, 94 mmol, 1 
eq.) were then added dropwise with stirring over 15 min. After complete addition the reaction 
was allowed to warm to RT over 40 min with stirring, during which time a yellow precipitate 
formed. After 40 min this was filtered through a glass sinter and washed with deionised water 
(3 × 25 mL). The resultant solid was dissolved in a minimum amount of hot (70 °C) ethyl 
acetate and then rapidly cooled to 0°C using an ice bath to produce yellow crystals. These 
were dried in vacuo to afford the title compound as a yellow crystalline solid (6.86 g, 62%). 
M.P. 111–112 °C (lit.225 110–112 °C); 1H NMR (400 MHz, CDCl3, δ): 7.75 (d, J = 16.0 Hz, 
2H), 7.65–7.58 (m, 4H), 7.45–7.38 (m, 6H), 7.09 (d, J = 16.0 Hz, 2H); 13C NMR (101 MHz, 
CDCl3, δ): 189.3, 143.7, 135.2, 130.9, 129.4, 128.8, 125.8; ESI–MS m/z (ion, %): 235 
([M+H]+, 100), 257 ([M+Na]+, 40); ESI–HRMS m/z: 235.1110 [M+H]+ (C17H15O requires 
235.1117); IR (solid-state ATR, cm-1): 1649 (m), 1588 (m), 1446 (m), 979 (s), 753 (s), 691 
(s); Elemental anal.: C 87.20, H 6.04 (C17H14O requires C 87.15, H 6.02). 
Lab book reference number: AJR-1-3 
Tris((1E,4E)-1,5-diphenylpenta-1,4-dien-3-one)dipalladium(0)·CHCl3 (238)170 
 
Method A: To a round-bottomed flask equipped with a magnetic stirrer was added Pd(OAc)2 
(100 mg, 0.45 mol, 1 eq.), dba 247 (209 mg, 0.89 mmol, 2 eq.), NaOAc (365 mg, 4.45 mol, 
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10 eq.) and MeOH (10 mL). The reaction was stirred at 40 °C for 3 h. After 3 h the resultant 
dark precipitate was filtered through a glass sinter and washed with MeOH (2 × 5 mL), 
deionised water (3 × 5 mL) then MeOH (2 × 5 mL). The dark purple residue was rinsed 
through the sinter with dry, freshly distilled CHCl3 (30 mL) and the solvent removed to yield 
a purple residue. This was redissolved in a minimum amount of dry, freshly distilled CHCl3 
(7 mL), then dry, freshly distilled acetone (20 mL) was added and the solution kept at −18 
°C for 18 h. After 18 h the dark purple precipitate formed was filtered through a glass sinter 
and washed with cold (5 °C) dry, freshly distilled acetone (2 × 5 mL) then dried in vacuo at 
40 °C for 30 min to afford the title compound as a purple crystalline solid (188 mg, 82%). 
The purity was subsequently measured by 1H NMR spectroscopic analysis as 84%. 
Method B: To a Schlenk tube equipped with a magnetic stirrer bar was added Pd(OAc)2 (100 
mg, 0.45 mol, 1 eq.), dba 247 (209 mg, 0.89 mmol, 2 eq.) and NaOAc (365 mg, 4.45 mol, 10 
eq.). The Schlenk tube was placed under vacuum and refilled with nitrogen three times, then 
dry MeOH (10 mL) was added and the mixture stirred at 40 °C for 3 h. After 3 h the solvent 
was removed by filter cannula and the residue washed with dry MeOH (2 × 5 mL). The 
resulting residue was then redissolved in dry CHCl3 (20 mL) and the solution transferred to 
a clean Schlenk tube under N2 via filter cannula. The reaction Schlenk tube was then rinsed 
with dry CHCl3 (10 mL) and this was transferred under N2 via filter cannula to the CHCl3 
solution. This solvent was then removed to give a dark purple residue, which was redissolved 
in dry CHCl3 (20 mL). Dry acetone (80 mL) was then added and the solution kept at −18 °C 
for 16 h. After 16 h the solvent was removed via filter cannula and the dark purple precipitate 
washed with cold (5 °C) dry acetone (2 × 5 mL) then dried in vacuo to afford the title 
compound as a purple crystalline solid (128 mg, 55%). The purity was subsequently 
measured by 1H NMR spectroscopic analysis as 91%. 
Note: the integrals for multiplets in the 1H NMR data have not been reported due to the 
coincidence of multiple environments from both isomers and dissociated free ligand 
rendering such assignment extraneous. Signals corresponding to the minor isomer have been 
denoted with an asterisk. 
M.P. 120–122 °C dec. (lit.168 120–122 °C dec.); 1H NMR (500 MHz, CDCl3, δ): 7.75 (d, J = 
16.0 Hz, 1H,), 7.65–7.60* (m), 7.45–6.92* (m), 6.83–6.31* (m), 6.15 (d, J = 13.0 Hz, 1H), 
6.03* (d, J = 12.5 Hz, 1H), 6.00–5.90* (m, 3H), 5.87 (d, J = 12.5 Hz, 1H), 5.65* (d, J = 14.0 
Hz, 1H), 5.33 (d, J = 12.5 Hz, 1H), 5.13 (d, J = 13.0 Hz, 1H), 5.03* (d, J = 13.0 Hz, 1H), 
4.96 (app t, J = 13.0 Hz, 2 H), 4.90–4.80* (m, 3 H); LIFDI–MS m/z (ion, %): 235 ([C17H15O]+, 
100), 915 ([M+H]+, 10); IR (solid-state ATR, cm-1): 1609 (m), 1574 (m), 1539 (m), 1484 
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(m), 1442 (m), 1332 (m), 1184 (m), 974 (w), 757 (s), 696 (s), 557 (m); Elemental anal.: C 
60.25, H 4.30 (Pd2C52H43O3Cl3 requires C 60.34, H 4.19). 
Crystals suitable for X-ray diffraction were grown by layering of a saturated CHCl3 solution 
with n-hexane to afford the Pd2(dba)3·CHCl3 adduct 238. Crystals of the Pd2(dba)3·CH2Cl2 
249 and Pd2(dba)3·C6H6 250 adducts were grown by slow evaporation from saturated 
solutions of CH2Cl2 and benzene, respectively. 
Lab book reference number (Method A): AJR-8, pp. 91–92 
Lab book reference number (Method B): AJR-4-335 
N, N-dimethylanilinium tetrafluoroborate (252) 
 
To Schlenk tube fitted with a magnetic stirrer was added aniline 251 (1 mL, 1 g, 8.25 mmol, 
1 eq.). The Schlenk tube was then evacuated and backfilled with N2 three times, before dry 
Et2O (5 mL) was added with stirring. HBF4·OEt2 (1.2 mL, 1.42 g, 9.08 mmol, 1.1 eq.) was 
then added dropwise and after complete addition a biphasic mixture was formed, consisting 
of a cloudy upper Et2O layer and a lower brown oil layer. The Et2O layer was removed via 
cannula and the brown oil evaporated to form an off-white solid. This was redissolved in dry 
CH2Cl2 (5 mL), then dry Et2O (5 mL) was added with stirring which formed the same brown 
oil as before. The Et2O layer was removed via cannula and the brown oil evaporated to form 
an off-white solid. This was redissolved in dry CH2Cl2 (5 mL), then dry Et2O (5 mL) was 
added with stirring, which caused an off-white solid to precipitate. The Et2O was removed 
via cannula, then the solid with washed with fresh dry Et2O (5 mL). This was removed via 
cannula then the solid was dried in vacuo to afford the title compound as an off-white solid 
(1.54 g, 89%). 
M.P. 48–51 °C; 1H NMR (400 MHz, CD2Cl2, δ): 9.51 (br s, 1H), 7.65–7.50 (m, 5H), 3.33 (d, 
J = 5.0 Hz, 6H); 13C NMR (101 MHz, (CD2Cl2, δ): 142.3, 131.5, 120.6, 85.3, 48.6; 11B NMR 
(128 MHz, CD2Cl2, δ): −1.9; 19F NMR (376 MHz, CD2Cl2, δ): −151.1 (m, 1JF–10B, 4F), −151.1 
(m, 1JF–11B, 4F); ESI–MS m/z (ion, %): 122 ([M−BF4]+, 100); ESI–HRMS m/z: 122.0965 
[M−BF4]+ (C8H12N requires 122.0964). 
Lab book reference number: AJR-7-680 
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Behaviour of 238 in dry, degassed CDCl3 under anhydrous conditions 
To a Young’s NMR tube handled in a dry glove box was added complex 238 (5 mg, 4.4 
µmol, 1 eq.) dissolved in dry, degassed CDCl3 (0.5 mL). 1H NMR spectra were then recorded 
at 500 MHz 10 min after dissolution, then every 30 min for 24 h. 
Lab book reference number: AJR-2-132 
Behaviour of 238 in reagent grade CDCl3 
To an NMR tube was added complex 238 (5 mg, 4.4 µmol, 1 eq.) dissolved in CDCl3 (0.5 
mL). 1H NMR spectra were then recorded at 500 MHz 10 min after dissolution, then every 
30 min for 24 h. 
Lab book reference number: AJR-2-128 
Behaviour of 238 under anhydrous conditions with 1 eq. acid 252 
In a dry glove box, acid 252 (0.92 mg, 4.4 µmol, 1 eq.) was dissolved in dry, degassed CDCl3 
(0.5 mL). This solution was then added to complex 238 (5 mg, 4.4 µmol, 1 eq.) and the 
resultant solution transferred to a Young’s NMR tube. 1H NMR spectra were then recorded 
at 500 MHz 10 min after dissolution, then every 30 min for 24 h. 
Lab book reference number: AJR-2-138 
Behaviour of 238 under anhydrous conditions with 3 eq. acid 252 
In a dry glove box, acid 252 (2.8 mg, 13.2 µmol, 1 eq.) was dissolved in dry, degassed CDCl3 
(0.5 mL). This solution was then added to complex 238 (5 mg, 4.4 µmol, 1 eq.) and the 
resultant solution transferred to a Young’s NMR tube. 1H NMR spectra were then recorded 
at 500 MHz 10 min after dissolution, then every 30 min for 24 h. 
Lab book reference number: AJR-2-141 
Behaviour of 238 under anhydrous conditions with 10 eq. AcOH 
To a Young’s NMR tube handled in a dry glove box was added complex 238 (5 mg, 4.4 
µmol, 1 eq.) dissolved in dry, degassed CDCl3 (0.5 mL). This was removed from the glove 
box and AcOH (2.5 µL, 2.6 mg, 44 µmol, 10 eq.) was added under a flow of nitrogen. 1H 
NMR spectra were then recorded at 500 MHz 10 min after dissolution, then every 30 min for 
16 h. No degradation of the complex was observed during this period. 
Lab book reference number: AJR-7-639 
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Behaviour of 238 under anhydrous conditions with 359 eq. AcOH 
To a Young’s NMR tube handled in a dry glove box was added complex 238 (5 mg, 4.4 
µmol, 1 eq.) dissolved in dry, degassed CDCl3 (0.5 mL). This was removed from the glove 
box and AcOH (100 µL, 95 mg, 1.58 mmol, 359 eq.) was added under a flow of nitrogen. 1H 
NMR spectra were then recorded at 500 MHz 10 min after dissolution, then every 30 min for 
16 h. No degradation of the complex was observed during this period. 
Lab book reference number: AJR-7-677 
Behaviour of 238 under anhydrous conditions with 10 eq. TFA 
To a Young’s NMR tube handled in a dry glove box was added complex 238 (5 mg, 4.4 
µmol, 1 eq.) dissolved in dry, degassed CDCl3 (0.5 mL). This was removed from the glove 
box and TFA (3.4 µL, 5 mg, 44 µmol, 10 eq.) was added under a flow of nitrogen. 1H NMR 
spectra were then recorded at 500 MHz 10 min after dissolution, then every 30 min for 16 h.  
Lab book reference number: AJR-7-670 
Behaviour of 238 under anhydrous conditions with 298 eq. TFA 
To a Young’s NMR tube handled in a dry glove box was added complex 238 (5 mg, 4.4 
µmol, 1 eq.) dissolved in dry, degassed CDCl3 (0.5 mL). This was removed from the glove 
box and TFA (100 µL, 149 mg, 1.31 mmol, 298 eq.) was added under a flow of nitrogen. 
Visible decomposition to Pd black was observed within seconds. A 1H NMR spectra was 
recorded at 500 MHz 10 min after dissolution, which matched that of the free ligand 247. 
Lab book reference number: AJR-7-675 
Behaviour of 238 under anhydrous conditions with HBF4·OEt2 
To a Young’s NMR tube handled in a dry glove box was added complex 238 (5 mg, 4.4 
µmol, 1 eq.) dissolved in dry, degassed CDCl3 (0.5 mL). This was removed from the 
glovebox and HBF4·OEt2 (0.6 µL, 0.7 mg, 4.4 µmol, 1 eq.) was added under a flow of 
nitrogen. Visible decomposition to Pd black was observed within seconds. A 1H NMR spectra 
was recorded at 500 MHz 10 min after dissolution, which matched that of the free ligand 247. 
Lab book reference number: AJR-7-637 
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ESI–MS study of complex 238 
To a microwave tube equipped with a magnetic stirrer was added complex 238 (10 mg, 8.8 
µmol, 1 eq.) and CHCl3 (0.5 mL). In a separate microwave vial, acid 252 (1.8 mg, 8.8 µmol, 
1 eq.) was dissolved in CHCl3 (0.5 mL). The latter solution was then added to the solution 
containing complex 238, the microwave vial was sealed and the reaction stirred at RT for 5 
h. After 5 h an aliquot (4 µL) was removed and diluted 100-fold with a solution of 
CH2Cl2:MeOH (400 µL, 2:1, v/v). This was then analysed by ESI–MS with a carrier gas flow 
rate of 1200 µL h-1. 
Lab book reference number: AJR-7-688 
ESI–MS study of complex 238 over eight hours 
In a glove (dry) box, complex 238 (100 mg, 0.09 mmol, 1 eq.) was dissolved in dry, degassed 
CHCl3 (5 mL) in a microwave vial equipped with magnetic stirrer. In a separate microwave 
vial, acid 252 (18 mg, 0.09 mmol, 1 eq.) was dissolved in dry, degassed CHCl3 (5 mL). The 
latter solution was then added to the solution containing complex 238, the microwave vial 
was sealed and the reaction stirred at RT for 5 min. After 5 min an aliquot (10 µL) was 
removed, then 4 µL of this solution was diluted 100-fold with a solution of CH2Cl2:MeOH 
(400 µL, 2:1, v/v). This was then analysed by ESI–MS with a carrier gas flow rate of 1200 
µL h-1. This sampling process was repeated every 30 min for 8 h. 
Lab book reference number: AJR-8-705 
ESI–MS study of complex 238 over 30 minutes 
In a glove (dry) box, complex 238 (100 mg, 0.09 mmol, 1 eq.) was dissolved in dry, degassed 
CHCl3 (5 mL) in a microwave vial equipped with magnetic stirrer. After complete 
dissolution, an aliquot (10 µL) was removed, then 4 µL of this solution was diluted 100-fold 
with a solution of CH2Cl2:MeOH (400 µL, 2:1, v/v). This was then analysed by ESI–MS with 
a carrier gas flow rate of 1200 µL h-1. In a separate microwave vial, acid 252 (18 mg, 0.09 
mmol, 1 eq.) was dissolved in dry, degassed CHCl3 (5 mL). This solution was then added to 
the solution containing complex 238, the microwave vial was sealed and the reaction stirred 
at RT for 2 min. After 2 min an aliquot (10 µL) was removed, then 4 µL of this solution was 
diluted 100-fold with a solution of CH2Cl2:MeOH (400 µL, 2:1, v/v). This was then analysed 
by ESI–MS with a carrier gas flow rate of 1200 µL h-1. This sampling process was repeated 
every 2 min for 30 min. 
Lab book reference number: AJR-8-707 
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Appendix 2: X-Ray Diffraction Data 
Crystallographic data for compound 75 
 
Figure 51 Single crystal X-ray diffraction structure of 75. Thermal ellipsoids shown with 50% 
probability and hydrogen atoms removed for clarity. Selected bond lengths (Å): C(3)–C(4): 1.500(3), 
C(4)–C(11): 1.375(3), N(2)–C(11): 1.388(2), C(11)–C(12): 1.475(3). Selected bond angles (°): C(4)–
C(11)–C(12): 131.75(18), N(2)–C(11)–C(12): 118.71(17).  
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Table 16 Crystal data and structure refinement for ijsf1413 (compound 75). 
Identification code  
Empirical formula 
Formula weight 
Temperature / K 
Crystal system 
Space group 
a / Å 
b / Å 
c / Å 
α / Å 
β / Å 
γ / Å 
Volume / Å3 
No. of formula units per unit cell, Z 
ρcalc mg / mm3 
m / mm-1 
F(000) 
Crystal size / mm3 
Radiation 





Goodness-of-fit on F2 
Final R indexes [I>=2σ (I)] 
Final R indexes [all data] 


















0.2757 × 0.1814 × 0.1572 
MoKα (λ = 0.71073) 
5.966 to 64.01 
−23 ≤ h ≤ 31, −26 ≤ k ≤ 25, −15 ≤ l ≤ 13 
6369 
4199 [Rint = 0.0191] 
4199/1/236 
1.049 
R1 = 0.0363, wR2 = 0.0863 
R1 = 0.0404, wR2 = 0.0901 
0.28/-0.22 
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Crystallographic data for compound 142 
 
Figure 52 Single crystal X-ray diffraction structure of 142. Thermal ellipsoids shown with 50% 
probability and hydrogen atoms removed for clarity. Selected bond lengths (Å): C(7)–C(9): 1.506(3), 
C(7)–C(8): 1.378(3), N(1)–C(8): 1.378(3), C(8)–C(12): 1.484(3). Selected bond angles (°): C(7)–
C(8)–C(12): 128.9(2), N(1)–C(8)–C(12): 121.8(2).  
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Table 17 Crystal data and structure refinement for ijsf1488 (compound 142). 
Identification code  
Empirical formula 
Formula weight 
Temperature / K 
Crystal system 
Space group 
a / Å 
b / Å 
c / Å 
α / Å 
β / Å 
γ / Å 
Volume / Å3 
No. of formula units per unit cell, Z 
ρcalc mg / mm3 
µ / mm-1 
F(000) 
Crystal size / mm3 
Radiation 





Goodness-of-fit on F2 
Final R indexes [I>=2σ (I)] 
Final R indexes [all data] 


















0.2485 × 0.1431 × 0.0656 
CuKα (λ = 1.54184) 
10.268 to 134.116 
−9 ≤ h ≤ 10, −16 ≤ k ≤ 16, −10 ≤ l ≤ 10 
6691 
3634 [Rint = 0.0256, Rsigma = 0.0341] 
3634/1/357 
1.029 
R1 = 0.0334, wR2 = 0.0865 
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Crystallographic data for compound 210 
 
Figure 53 Single crystal X-ray diffraction structure of 210. Thermal ellipsoids shown with 50% 
probability and absolute stereochemistry established by anomalous dispersion. Selected bond lengths 
(Å): C(7)–C(15): 1.500(2), C(7)–C(8): 1.369(3), N(1)–C(8): 1.382(3), C(8)–C(9): 1.475(3), C(12)–
Cl(1): 1.743(2). Selected bond angles (°): C(7)–C(8)–C(9): 131.44(17), N(1)–C(8)–C(9): 119.04(16).  
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Table 18 Crystal data and structure refinement for ijsf1487 (compound 210). 
Identification code  
Empirical formula 
Formula weight 
Temperature / K 
Crystal system 
Space group 
a / Å 
b / Å 
c / Å 
α / Å 
β / Å 
γ / Å 
Volume / Å3 
No. of formula units per unit cell, Z 
ρcalc mg / mm3 
µ / mm-1 
F(000) 
Crystal size / mm3 
Radiation 





Goodness-of-fit on F2 
Final R indexes [I>=2σ (I)] 
Final R indexes [all data] 


















0.183 × 0.1321 × 0.0705 
CuKα (λ = 1.54184) 
8.51 to 134.026 
−24 ≤ h ≤ 24, −24 ≤ k ≤ 24, −13 ≤ l ≤ 13 
19066 
3300 [Rint = 0.0214, Rsigma = 0.0128] 
3300/1/245 
1.051 
R1 = 0.0217, wR2 = 0.0550 
R1 = 0.0219, wR2 = 0.0552 
0.16/−0.23 
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Crystallographic data for compound 238 
 
Figure 54 Single crystal X-ray diffraction structure of complex 238 (major isomer). Thermal 
ellipsoids shown with 50% probability, hydrogen atoms and solvating chloroform removed for 
clarity. Selected bond lengths (Å): Pd(1)–C(7): 2.303(3), Pd(1)–C(8): 2.248(3), C(7)–C(8): 1.358(4), 
Pd(1)–C(24): 2.279(4), Pd(1)–C(25): 2.251(4), C(24)–C(25): 1.364(6), Pd(1)–C(41): 2.202(3), 
Pd(1)–C(42): 2.220(3), C(41)–C(42): 1.393(5), Pd(2)–C(10): 2.222(3), Pd(2)–C(11): 2.244(3), 
C(10)–C(11): 1.395(4), Pd(2)–C(27): 2.244(4), Pd(2)–C(28): 2.241(4), C(27)–C(28): 1.392(6), 
Pd(2)–C(44): 2.244(3), Pd(2)–C(45): 2.280(3), C(44)–C(45): 1.359(5). Pd(1)–Pd(2) bond distance: 
3.244 Å. 
 
Figure 55 Single crystal X-ray diffraction structure of complex 238 (minor isomer). Thermal 
ellipsoids shown with 50% probability, hydrogen atoms and solvating chloroform removed for 
clarity. Selected bond lengths (Å): Pd(1)–C(7A): 2.275(11), Pd(1)–C(8A): 2.297(11), C(7A)–C(8A): 
1.368(19), Pd(1)–C(24A): 2.243(6), Pd(1)–C(25A): 2.254(6), C(24A)–C(25A): 1.390(9), Pd(1)–
C(41A): 2.211(7), Pd(1)–C(42A): 2.207(7), C(41A)–C(42A): 1.339(10), Pd(2)–C(10A): 2.192(11), 
Pd(2)–C(11A): 2.272(10), C(10A)–C(11A): 1.332(9), Pd(2)–C(27A): 2.274(6), Pd(2)–C(28A): 
2.242(6), C(27A)–C(28A): 1.352(9), Pd(2)–C(44A): 2.267(7), Pd(2)–C(45A): 2.311(7), C(44A)–
C(45A): 1.394(10). Pd(1)–Pd(2) bond distance: 3.244 Å.  
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Table 19 Crystal data and structure refinement for ijsf1227 (compound 238). 
Identification code  
Empirical formula 
Formula weight 
Temperature / K 
Crystal system 
Space group 
a / Å 
b / Å 
c / Å 
α / Å 
β / Å 
γ / Å 
Volume / Å3 
No. of formula units per unit cell, Z 
ρcalc mg / mm3 
m / mm-1 
F(000) 
Crystal size / mm3 





Goodness-of-fit on F2 
Final R indexes [I>=2σ (I)] 
Final R indexes [all data] 


















0.1342 × 0.1177 × 0.1018 
5.9 to 60.16 
−9 ≤ h ≤ 18, −16 ≤ k ≤ 18, −34 ≤ l ≤ 28 
25517 
12430 [Rint = 0.0250] 
12430/26/631 
1.073 
R1 = 0.0333, wR2 = 0.0720 
R1 = 0.0464, wR2 = 0.0796 
0.84/−0.61 
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Crystallographic data for compound 249 
 
Figure 56 Single crystal X-ray diffraction structure of complex 249 (major isomer). Thermal 
ellipsoids shown with 50% probability, hydrogen atoms and solvating methylene chloride removed 
for clarity. 
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Table 20 Crystal data and structure refinement for ijsf1232 (compound 249). 
Identification code  
Empirical formula 
Formula weight 
Temperature / K 
Crystal system 
Space group 
a / Å 
b / Å 
c / Å 
α / Å 
β / Å 
γ / Å 
Volume / Å3 
No. of formula units per unit cell, Z 
ρcalc mg / mm3 
m / mm-1 
F(000) 
Crystal size / mm3 





Goodness-of-fit on F2 
Final R indexes [I>=2σ (I)] 
Final R indexes [all data] 


















0.3172 × 0.1571 × 0.0798 
5.94 to 64.28 
−17 ≤ h ≤ 18, −18 ≤ k ≤ 18, −21 ≤ l ≤ 22 
37706 
13493 [Rint = 0.0487] 
13493/21/635 
1.086 
R1 = 0.0395, wR2 = 0.0907 
R1 = 0.0531, wR2 = 0.1009 
1.06/−1.34 
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Crystallographic data for compound 250 
 
Figure 57 Single crystal X-ray diffraction structure of complex 250 (major isomer). Thermal 
ellipsoids shown with 50% probability, hydrogen atoms and solvating benzene removed for clarity. 
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Table 21 Crystal data and structure refinement for ijsf1302 (compound 250). 
Identification code  
Empirical formula 
Formula weight 
Temperature / K 
Crystal system 
Space group 
a / Å 
b / Å 
c / Å 
α / Å 
β / Å 
γ / Å 
Volume / Å3 
No. of formula units per unit cell, Z 
ρcalc mg / mm3 
m / mm-1 
F(000) 
Crystal size / mm3 





Goodness-of-fit on F2 
Final R indexes [I>=2σ (I)] 
Final R indexes [all data] 


















0.0881 × 0.0626 × 0.0492 
5.7 to 50.7 
−15 ≤ h ≤ 16, −24 ≤ k ≤ 28, −18 ≤ l ≤ 12 
17380 
8075 [Rint = 0.0377] 
8075/15/662 
1.062 
R1 = 0.0440, wR2 = 0.0953 
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Appendix 3: UV–Visible Spectroscopic Data 
 
 
Figure 58 UV–visible spectroscopic analysis for compound 142. 
  





Figure 59 UV–visible spectroscopic analysis for compound 160. 
  





Figure 60 UV–visible spectroscopic analysis for compound 167. 
  





Figure 61 UV–visible spectroscopic analysis for compound 170. 
  





Figure 62 UV–visible spectroscopic analysis for compound 172. 
  





Figure 63 UV–visible spectroscopic analysis for compound 173. 
  





Figure 64 UV–visible spectroscopic analysis for compound 174. 
  





Figure 65 UV–visible spectroscopic analysis for compound 175. 
  





Figure 66 UV–visible spectroscopic analysis for compound 176. 
  





Figure 67 UV–visible spectroscopic analysis for compound 209. 
  





Figure 68 UV–visible spectroscopic analysis for compound 211. 
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Appendix 4: HPLC Data 
Arylation Products of 136 
Method A 
 
Figure 69 HPLC–ESI–MS chromatogram (BPC) of the crude reaction material (arylated tryptophan 
donated Trp*, diarylated tryptophans donated Trp**, dihydroxylated byproducts donated Trp‡). 
 
Figure 70 ESI–MS of dihydroxylated side products from arylation of 136. 
 
Ac-AlaTrp*Ala-OH, m/z 465, 54% Ac-AlaTrp
‡Ala-OH, m/z 497, 37% 
Ac-AlaTrp**Ala-OH, 
m/z 541, 8% 




Figure 71 ESI–MS of arylation product 137. 
 
Figure 72 ESI–MS of diarylated side products from arylation of 136. 
  





Figure 73 HPLC–ESI–MS chromatogram (BPC) of the crude reaction material (arylated tryptophan 
donated Trp*, starting material donated Trp).  
 
Figure 74 ESI–MS of starting material 136. 
 
Ac-AlaTrpAla-OH, 
m/z 465, 52% 
Ac-AlaTrp*Ala-OH, m/z 465, 48% 
[PhMesI]+, m/z 323 




Figure 75 ESI–MS of arylation product 137. 




Figure 76 ESI–MS of starting material 140. 
  





Figure 77 HPLC–ESI–MS chromatogram (BPC) of the crude reaction material. 
 
Figure 78 ESI–MS of arylation product 137. 
 
Ac-AlaTrp(Ph)Ala-OH, 
m/z 465, 69% 
Ac-AlaTrp(Ph)Ala-OiPr, 
m/z 507, 31% 




Figure 79 ESI–MS of iPr-ester formed during workup from arylation product 137. 
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Arylation Products of 138 
Method A 
 
Figure 80 HPLC–ESI–MS chromatogram (BPC) of the crude reaction material (arylated tryptophan 
donated Trp*, dihydroxylated byproducts donated Trp‡). 
 
Figure 81 ESI–MS of dihydroxylated side products from arylation of 138. 
 
Figure 82 ESI–MS of arylation product 139.  
Ac-SerGlyTrp‡Ala-OH, 
m/z 570, 57% 
Ac-SerGlyTrp*Ala-OH, m/z 560, 42% 





Figure 83 HPLC–ESI–MS chromatogram (BPC) of the crude reaction material (arylated tryptophan 
donated Trp*, starting material donated Trp).  
 
Figure 84 ESI–MS of starting material 138. 
 
Ac-SerGlyTrpAla-OH, 
m/z 560, 44% 
Ac-SerGlyTrp*Ala-OH, m/z 560, 56% 
[PhMesI]+, m/z 323 




Figure 85 ESI–MS of arylation product 139. 
  




Figure 86 ESI–MS of starting material 140. 
  





Figure 87 HPLC–ESI–MS chromatogram (BPC) of the crude reaction material. 
 
Figure 88 ESI–MS of arylation product 139. 
 
Ac-SerGlyTrp(Ph)Ala-OH, 
m/z 538, 100% 
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Appendix 5: GC Data 
Calculations 
Mesitylene Reference Solution 
Maximum concentration of substrate in the reaction: 
𝑐𝑚𝑎𝑥 (𝑟𝑒𝑎𝑐𝑡𝑖𝑜𝑛) =  
0.6 𝑚𝑚𝑜𝑙
3 𝑚𝐿
= 0.2 𝑚𝑚𝑜𝑙 𝑚𝐿−1 
For sampling a 30 uL aliquot is taken and diluted with 0.6 mL mesitylene standard. This 
gives a maximum substrate concentration in the GC sample of 0.0095 mmol mL-1: 
𝑐𝑚𝑎𝑥 (𝐺𝐶 𝑠𝑎𝑚𝑝𝑙𝑒) =  𝑐𝑚𝑎𝑥 (𝑟𝑒𝑎𝑐𝑡𝑖𝑜𝑛)  ∙  
𝑉 (𝑎𝑙𝑖𝑞𝑢𝑜𝑡)
𝑉𝑡𝑜𝑡𝑎𝑙  (𝐺𝐶 𝑠𝑎𝑚𝑝𝑙𝑒)
= 0.2 𝑚𝑚𝑜𝑙 𝑚𝐿−1  ∙  
0.03 𝑚𝐿
0.63 𝑚𝐿
= 0.0096 𝑚𝑚𝑜𝑙 𝑚𝐿−1 
0.6 mL of mesitylene reference solution should have the maximum substrate concentration: 
𝑛𝐺𝐶 𝑠𝑎𝑚𝑝𝑙𝑒(𝑚𝑒𝑠𝑖𝑡𝑦𝑙𝑒𝑛𝑒) =  𝑐𝑚𝑎𝑥(𝐺𝐶 𝑠𝑎𝑚𝑝𝑙𝑒) ∙  𝑉𝑡𝑜𝑡𝑎𝑙(𝐺𝐶 𝑠𝑎𝑚𝑝𝑙𝑒)
= 0.0095 𝑚𝑚𝑜𝑙 𝑚𝐿−1  ∙ 0.63 𝑚𝐿 = 0.006 𝑚𝑚𝑜𝑙 







 ∙ 0.006 𝑚𝑚𝑜𝑙 = 0.835 µ𝐿 







 ∙ 100 𝑚𝐿 = 139 µ𝐿 
Calibration Solutions 
Five solutions used at 100%, 80%, 60%, 40% and 20% concentrations of cmax(substrate). All 
solutions contain c(mesitylene) = 100% cmax(substrate), with Vtotal = 1 mL 
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Calculation of Conversion from Peak Area 
To calculate the substrate concentration in the GC sample: 
𝒄(𝒔𝒖𝒃𝒔𝒕𝒓𝒂𝒕𝒆) =  
𝒂𝒗.  𝒑𝒆𝒂𝒌 𝒂𝒓𝒆𝒂 (𝒔𝒖𝒃𝒔𝒕𝒓𝒂𝒕𝒆)
𝒂𝒗.𝒑𝒆𝒂𝒌 𝒂𝒓𝒆 (𝒔𝒕𝒂𝒏𝒅𝒂𝒓𝒅)⁄
𝑹𝑹𝑭 (𝒔𝒖𝒃𝒔𝒕𝒓𝒂𝒕𝒆)
 ∙  𝒄(𝒎𝒆𝒔𝒊𝒕𝒚𝒍𝒆𝒏𝒆)  
To calculate the substrate concentration in the reaction solution: 
𝑐(𝑠𝑢𝑏𝑠𝑡𝑟𝑎𝑡𝑒) =  𝑐𝐺𝐶 𝑠𝑎𝑚𝑝𝑙𝑒(𝑠𝑢𝑏𝑠𝑡𝑟𝑎𝑡𝑒)
∙  






To convert substrate concentration into conversion: 




Calculation of Error 
The maximum possible error is always accounted for. This is based on the maximum ratio of 






𝑝𝑒𝑎𝑘 𝑎𝑟𝑒𝑎 (𝑠𝑡𝑎𝑛𝑑𝑎𝑟𝑑)⁄ )
𝑠𝑙𝑜𝑝𝑒 (𝑅𝑅𝐹) ∙ (1 − 𝑠𝑡𝑎𝑛𝑑𝑎𝑟𝑑 𝑒𝑟𝑟𝑜𝑟)
 
∙  𝑐𝐺𝐶 𝑠𝑎𝑚𝑝𝑙𝑒(𝑠𝑢𝑏𝑠𝑡𝑟𝑎𝑡𝑒) 
  





Figure 89 Calibration plot to determine RRF for 1-methylindole 33. 
  




Figure 90 Calibration plot to determine RRF for benzofuran 239. 
  




Figure 91 Calibration plot to determine RRF for butylthiophene 241. 
  




Figure 92 Calibration plot to determine RRF for butylfuran 243. 
  





Figure 93 1st order exponential decay for arylation of 1-methylindole 33 with Pd/C. 
 
Figure 94 1st order exponential decay for arylation of 1-methylindole 33 with PVP–Pd 13. 
  




Figure 95 1st order exponential decay for arylation of 1-methylindole 33 with Pd(OAc)2. 
 
Figure 96 1st order exponential decay for arylation of benzofuran 239 with Pd/C. 
  




Figure 97 Exponential decay suggesting non-1st order kinetic profile for arylation of benzofuran 239 
with PVP–Pd 13. 
 
Figure 98 1st order exponential decay for arylation of butylthiophene 241 with Pd/C. 
  




Figure 99 Exponential decay suggesting non-1st order kinetic profile for arylation of butylthiophene 
241 with PVP–Pd 13. 
 
Figure 100 Exponential decay suggesting non-1st order kinetic profile for arylation of 
butylthiophene 241 with Pd(OAc)2. 
  




Figure 101 1st order exponential decay for arylation of butylthiophene 241 with Pd2(dba)3 238. 
 
Figure 102 1st order exponential decay for arylation of butylfuran 243 with Pd/C. 
  




Figure 103 1st order exponential decay for arylation of butylfuran 243 with PVP–Pd 13. 
 
Figure 104 1st order exponential decay for arylation of butylfuran 243 with Pd2(dba)3 238. 
  




Figure 105 1st order exponential decay for arylation of butylfuran 243 with Pd/C at 70 °C. 
 
Figure 106 1st order logarithmic growth for 2-phenylbutylfuran 246 from reaction of butylfuran with 
Pd/C at 70 °C. 
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Appendix 6: ESI–MS Data for Pdx(dba)y Clusters 
 
Figure 107 Measured vs. simulated mass values for [Pd2(dba)2H]+ cluster. 
 
Figure 108 Measured vs. simulated mass values for [Pd2(dba)2Na]+ cluster. 
 




Figure 109 Measured vs. simulated mass values for [Pd4(dba)2H]+ cluster. 
 
Figure 110 Measured vs. simulated mass values for [Pd4(dba)2Na]+ cluster. 




Figure 111 Measured vs. simulated mass values for [Pd5(dba)2H]+ cluster. 
 
Figure 112 Measured vs. simulated mass values for [Pd6(dba)2H]+ cluster. 




Figure 113 Measured vs. simulated mass values for [Pd4(dba)3H]+ cluster. 
 
Figure 114 Measured vs. simulated mass values for [Pd4(dba)3Na]+ cluster. 




Figure 115 Measured vs. simulated mass values for [Pd5(dba)3H]+ cluster. 
 
Figure 116 Measured vs. simulated mass values for [Pd6(dba)3H]+ cluster. 




Figure 117 Measured vs. simulated mass values for [Pd4(dba)4Na]+ cluster. 
 
Figure 118 Measured vs. simulated mass values for [Pd4(dba)5H]+ cluster. 




Figure 119 Measured vs. simulated mass values for [Pd5(dba)5H]+ cluster. 
 
Figure 120 Measured vs. simulated mass values for [Pd6(dba)5H]+ cluster. 




Figure 121 Measured vs. simulated mass values for [Pd6(dba)6Na]+ cluster. 
 
Figure 122 Measured vs. simulated mass values for [Pd6(dba)7Na]+ cluster. 




Figure 123 Measured vs. simulated mass values for [Pd7(dba)8H]+ cluster. 
 
Figure 124 Measured vs. simulated mass values for [Pd8(dba)8H]+ cluster. 




Figure 125 Measured vs. simulated mass values for [Pd8(dba)9Na]+ cluster. 
 
Figure 126 Measured vs. simulated mass values for [Pd8(dba)11Na]+ cluster. 
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Appendix 7: NMR Spectra 
 
Figure 127 1H NMR spectrum of 135 (400 MHz, CD3OD). 
 
Figure 128 13C NMR spectrum of 135 (101 MHz, CD3OD).  




Figure 129 1H NMR spectrum of 74 (400 MHz, CDCl3). 
 
Figure 130 13C NMR spectrum of 74 (101 MHz, CDCl3). 




Figure 131 1H NMR spectrum of 75 (400 MHz, CDCl3).  
 
Figure 132 13C NMR spectrum of 75 (101 MHz, CDCl3). 




Figure 133 1H NMR spectrum of 140 (400 MHz, CDCl3).  
 
Figure 134 13C NMR spectrum of 140 (101 MHz, CDCl3). 




Figure 135 19F NMR spectrum of 140 (376 MHz, CDCl3).  




Figure 136 1H NMR spectrum of 142 (400 MHz, CDCl3). 
 
Figure 137 13C NMR spectrum of 142 (101 MHz, CDCl3).  




Figure 138 1H NMR spectrum of 143 (400 MHz, CDCl3).  
 
Figure 139 13C NMR spectrum of 143 (101 MHz, CDCl3).  




Figure 140 1H NMR spectrum of 144 (400 MHz, CDCl3).  
 
Figure 141 13C NMR spectrum of 144 (101 MHz, CDCl3). 




Figure 142 11B NMR spectrum of 144 (128 MHz, CDCl3). 
 
Figure 143 19F NMR spectrum of 144 (376 MHz, CDCl3).  




Figure 144 1H NMR spectrum of 145 (400 MHz, (CD3)2SO).  
 
Figure 145 13C NMR spectrum of 145 (101 MHz, (CD3)2SO). 




Figure 146 19F NMR spectrum of 145 (376 MHz, (CD3)2SO). 
 
Figure 147 31P NMR spectrum of 145 (162 MHz, (CD3)2SO).  




Figure 148 1H NMR spectrum of 146 (400 MHz, (CD3)2SO).  
 
Figure 149 13C NMR spectrum of 146 (101 MHz, (CD3)2SO). 




Figure 150 19F NMR spectrum of 146 (376 MHz, (CD3)2SO).  




Figure 151 1H NMR spectrum of 132 (400 MHz, (CD3)2SO).  
 
Figure 152 13C NMR spectrum of 132 (101 MHz, (CD3)2SO).  




Figure 153 1H NMR spectrum of 149 (400 MHz, CDCl3).  
 
Figure 154 13C NMR spectrum of 149 (101 MHz, CDCl3).  




Figure 155 1H NMR spectrum of 152 (400 MHz, CDCl3).  
 
Figure 156 13C NMR spectrum of 152 (101 MHz, CDCl3).  




Figure 157 1H NMR spectrum of 155 (400 MHz, CD3OD).  
 
Figure 158 13C NMR spectrum of 155 (101 MHz, CD3OD).  




Figure 159 1H NMR spectrum of 156 (400 MHz, CDCl3).  
 
Figure 160 13C NMR spectrum of 156 (101 MHz, CDCl3).  




Figure 161 1H NMR spectrum of 158 (400 MHz, CDCl3).  
 
Figure 162 13C NMR spectrum of 158 (101 MHz, CDCl3).  




Figure 163 1H NMR spectrum of 160 (400 MHz, CDCl3).  
 
Figure 164 13C NMR spectrum of 160 (101 MHz, CDCl3).  




Figure 165 1H NMR spectrum of 161 (400 MHz, CDCl3).  
 
Figure 166 13C NMR spectrum of 161 (101 MHz, CDCl3).  




Figure 167 1H NMR spectrum of 163 (400 MHz, CD3OD).  
 
Figure 168 13C NMR spectrum of 163 (101 MHz, CD3OD).  




Figure 169 1H NMR spectrum of 92 (400 MHz, CDCl3).  
 
Figure 170 13C NMR spectrum of 92 (101 MHz, CDCl3). 




Figure 171 19F NMR spectrum of 92 (376 MHz, CDCl3).  




Figure 172 1H NMR spectrum of 166 (400 MHz, CDCl3).  
 
Figure 173 13C NMR spectrum of 166 (101 MHz, CDCl3). 




Figure 174 19F NMR spectrum of 166 (376 MHz, CDCl3).  




Figure 175 1H NMR spectrum of 167 (400 MHz, CDCl3).  
 
Figure 176 13C NMR spectrum of 167 (101 MHz, CDCl3). 




Figure 177 19F NMR spectrum of 167 (376 MHz, CDCl3).  




Figure 178 1H NMR spectrum of 169 (400 MHz, CD3OD). 
 
Figure 179 13C NMR spectrum of 169 (101 MHz, CD3OD). 




Figure 180 19F NMR spectrum of 169 (376 MHz, CDCl3).  




Figure 181 1H NMR spectrum of 170 (400 MHz, CDCl3).  
 
Figure 182 13C NMR spectrum of 170 (101 MHz, CDCl3). 




Figure 183 19F NMR spectrum of 170 (376 MHz, CDCl3).  




Figure 184 1H NMR spectrum of 171 (400 MHz, CDCl3).  
 
Figure 185 13C NMR spectrum of 171 (101 MHz, CDCl3). 




Figure 186 19F NMR spectrum of 171 (376 MHz, CDCl3).  




Figure 187 1H NMR spectrum of 172 (400 MHz, CDCl3).  
 
Figure 188 13C NMR spectrum of 172 (101 MHz, CDCl3). 




Figure 189 19F NMR spectrum of 172 (376 MHz, CDCl3).  




Figure 190 1H NMR spectrum of 173 (400 MHz, CDCl3).  
 
Figure 191 13C NMR spectrum of 173 (101 MHz, CDCl3). 




Figure 192 19F NMR spectrum of 173 (376 MHz, CDCl3).  




Figure 193 1H NMR spectrum of 174 (400 MHz, CDCl3).  
 
Figure 194 13C NMR spectrum of 174 (101 MHz, CDCl3). 




Figure 195 19F NMR spectrum of 174 (376 MHz, CDCl3).  




Figure 196 1H NMR spectrum of 175 (400 MHz, CDCl3).  
 
Figure 197 13C NMR spectrum of 175 (101 MHz, CDCl3). 




Figure 198 19F NMR spectrum of 175 (376 MHz, CDCl3).  




Figure 199 1H NMR spectrum of 176 (400 MHz, CDCl3).  
 
Figure 200 13C NMR spectrum of 176 (101 MHz, CDCl3). 




Figure 201 19F NMR spectrum of 176 (376 MHz, CDCl3).  




Figure 202 1H NMR spectrum of 48 (400 MHz, (CD3)2SO).  
 
Figure 203 13C NMR spectrum of 48 (101 MHz, (CD3)2SO). 




Figure 204 11B NMR spectrum of 48 (128 MHz, (CD3)2SO). 
 
Figure 205 19F NMR spectrum of 48 (376 MHz, (CD3)2SO).  




Figure 206 1H NMR spectrum of 192 (400 MHz, (CD3)2SO).  
 
Figure 207 13C NMR spectrum of 192 (101 MHz, (CD3)2SO). 




Figure 208 11B NMR spectrum of 192 (128 MHz, (CD3)2SO). 
 
Figure 209 19F NMR spectrum of 192 (376 MHz, (CD3)2SO).  




Figure 210 1H NMR spectrum of 193 (400 MHz, (CD3)2SO).  
 
Figure 211 13C NMR spectrum of 193 (101 MHz, (CD3)2SO). 




Figure 212 11B NMR spectrum of 193 (128 MHz, (CD3)2SO). 
 
Figure 213 19F NMR spectrum of 193 (376 MHz, (CD3)2SO).  




Figure 214 1H NMR spectrum of 194 (400 MHz, (CD3)2SO).  
 
Figure 215 13C NMR spectrum of 194 (101 MHz, (CD3)2SO).  




Figure 216 1H NMR spectrum of 195 (400 MHz, (CD3)2SO).  
 
Figure 217 13C NMR spectrum of 195 (101 MHz, (CD3)2SO). 




Figure 218 11B NMR spectrum of 195 (128 MHz, (CD3)2SO). 
 
Figure 219 19F NMR spectrum of 195 (376 MHz, (CD3)2SO).  




Figure 220 1H NMR spectrum of 196 (400 MHz, (CD3)2SO).  
 
Figure 221 13C NMR spectrum of 196 (101 MHz, (CD3)2SO). 




Figure 222 11B NMR spectrum of 196 (128 MHz, (CD3)2SO). 
 
Figure 223 19F NMR spectrum of 196 (376 MHz, (CD3)2SO).  




Figure 224 1H NMR spectrum of 197 (400 MHz, (CD3)2SO).  
 
Figure 225 13C NMR spectrum of 197 (101 MHz, (CD3)2SO). 




Figure 226 11B NMR spectrum of 197 (128 MHz, (CD3)2SO). 
 
Figure 227 19F NMR spectrum of 197 (376 MHz, (CD3)2SO).  




Figure 228 1H NMR spectrum of 198 (400 MHz, (CD3)2SO).  
 
Figure 229 13C NMR spectrum of 198 (101 MHz, (CD3)2SO). 




Figure 230 11B NMR spectrum of 198 (128 MHz, (CD3)2SO). 
 
Figure 231 19F NMR spectrum of 198 (376 MHz, (CD3)2SO).  




Figure 232 1H NMR spectrum of 199 (400 MHz, (CD3)2SO).  
 
Figure 233 13C NMR spectrum of 199 (101 MHz, (CD3)2SO). 




Figure 234 11B NMR spectrum of 199 (128 MHz, (CD3)2SO). 
 
Figure 235 19F NMR spectrum of 199 (376 MHz, (CD3)2SO).  




Figure 236 1H NMR spectrum of 200 (400 MHz, (CD3)2SO).  
 
Figure 237 13C NMR spectrum of 200 (101 MHz, (CD3)2SO). 




Figure 238 11B NMR spectrum of 200 (128 MHz, (CD3)2SO). 
 
Figure 239 19F NMR spectrum of 200 (376 MHz, (CD3)2SO).  




Figure 240 1H NMR spectrum of 201 (400 MHz, (CD3)2SO).  
 
Figure 241 13C NMR spectrum of 201 (101 MHz, (CD3)2SO). 




Figure 242 11B NMR spectrum of 201 (128 MHz, (CD3)2SO). 
 
Figure 243 19F NMR spectrum of 201 (376 MHz, (CD3)2SO).  




Figure 244 1H NMR spectrum of 202 (400 MHz, (CD3)2SO).  
 
Figure 245 13C NMR spectrum of 202 (101 MHz, (CD3)2SO). 




Figure 246 11B NMR spectrum of 202 (128 MHz, (CD3)2SO). 
 
Figure 247 19F NMR spectrum of 202 (376 MHz, (CD3)2SO).  




Figure 248 1H NMR spectrum of 203 (400 MHz, (CD3)2SO).  
 
Figure 249 13C NMR spectrum of 203 (101 MHz, (CD3)2SO). 




Figure 250 11B NMR spectrum of 203 (128 MHz, (CD3)2SO). 
 
Figure 251 19F NMR spectrum of 203 (376 MHz, (CD3)2SO).  




Figure 252 1H NMR spectrum of 54 (400 MHz, (CD3)2SO).  
 
Figure 253 13C NMR spectrum of 54 (101 MHz, (CD3)2SO). 




Figure 254 11B NMR spectrum of 54 (128 MHz, (CD3)2SO). 
 
Figure 255 19F NMR spectrum of 54 (376 MHz, (CD3)2SO).  




Figure 256 1H NMR spectrum of 204 (400 MHz, (CD3)2SO).  
 
Figure 257 13C NMR spectrum of 204 (101 MHz, (CD3)2SO).  




Figure 258 1H NMR spectrum of 76 (400 MHz, CDCl3).  
 
Figure 259 13C NMR spectrum of 76 (101 MHz, CDCl3).  




Figure 260 1H NMR spectrum of 205 (400 MHz, CDCl3).  
 
Figure 261 13C NMR spectrum of 205 (101 MHz, CDCl3).  




Figure 262 1H NMR spectrum of 206 (400 MHz, CDCl3).  
 
Figure 263 13C NMR spectrum of 206 (101 MHz, CDCl3).  




Figure 264 1H NMR spectrum of 207 (400 MHz, CDCl3).  
 
Figure 265 13C NMR spectrum of 207 (101 MHz, CDCl3).  




Figure 266 1H NMR spectrum of 77 (400 MHz, CDCl3).  
 
Figure 267 13C NMR spectrum of 77 (101 MHz, CDCl3).  




Figure 268 1H NMR spectrum of 208 (400 MHz, CDCl3).  
 
Figure 269 13C NMR spectrum of 208 (101 MHz, CDCl3).  




Figure 270 1H NMR spectrum of 120 (400 MHz, CDCl3). 
 
Figure 271 13C NMR spectrum of 120 (101 MHz, CDCl3). 




Figure 272 19F NMR spectrum of 120 (376 MHz, CDCl3).  




Figure 273 1H NMR spectrum of 79 (400 MHz, CDCl3).  
 
Figure 274 13C NMR spectrum of 79 (101 MHz, CDCl3).  




Figure 275 1H NMR spectrum of 209 (400 MHz, CDCl3).  
 
Figure 276 13C NMR spectrum of 209 (101 MHz, CDCl3).  




Figure 277 1H NMR spectrum of 210 (400 MHz, CDCl3).  
 
Figure 278 13C NMR spectrum of 210 (101 MHz, CDCl3).  




Figure 279 1H NMR spectrum of 211 (400 MHz, CDCl3).  
 
Figure 280 13C NMR spectrum of 211 (101 MHz, CDCl3).  




Figure 281 1H NMR spectrum of 215 (400 MHz, CD3OD). 
 
Figure 282 13C NMR spectrum of 215 (125 MHz, CD3OD).  




Figure 283 1H NMR spectrum of 224 (400 MHz, CDCl3).  
 
Figure 284 13C NMR spectrum of 224 (101 MHz, CDCl3).  




Figure 285 1H NMR spectrum of 231 (400 MHz, CDCl3).  
 
Figure 286 13C NMR spectrum of 231 (101 MHz, CDCl3).  




Figure 287 1H NMR spectrum of 232 (400 MHz, CDCl3).  
 
Figure 288 13C NMR spectrum of 232 (101 MHz, CDCl3).  




Figure 289 1H NMR spectrum of 233 (400 MHz, (CD3)2SO).  
 
Figure 290 13C NMR spectrum of 233 (101 MHz, CDCl3).  




Figure 291 1H NMR spectrum of 234 (400 MHz, CDCl3).  
 
Figure 292 13C NMR spectrum of 234 (101 MHz, CDCl3).  




Figure 293 1H NMR spectrum of 38 (400 MHz, (CD3)2SO).  
 
Figure 294 13C NMR spectrum of 38 (101 MHz, (CD3)2SO). 




Figure 295 19F NMR spectrum of 38 (376 MHz, (CD3)2SO).  




Figure 296 1H NMR spectrum of 34 (400 MHz, CDCl3).  
 
Figure 297 13C NMR spectrum of 34 (101 MHz, CDCl3).  




Figure 298 1H NMR spectrum of 240 (400 MHz, CDCl3).  
 
Figure 299 13C NMR spectrum of 240 (101 MHz, CDCl3).  




Figure 300 1H NMR spectrum of 242 (400 MHz, CDCl3).  
 
Figure 301 13C NMR spectrum of 242 (101 MHz, CDCl3).  




Figure 302 1H NMR spectrum of 246 (400 MHz, CDCl3). 
 
Figure 303 13C NMR spectrum of 246 (101 MHz, CDCl3).  




Figure 304 1H NMR spectrum of 247 (400 MHz, CDCl3).  
 
Figure 305 13C NMR spectrum of 247 (101 MHz, CDCl3).  




Figure 306 1H NMR spectrum of 238 (500 MHz, CDCl3).   




Figure 307 1H NMR spectrum of 252 (400 MHz, CD2Cl2).  
 
Figure 308 13C NMR spectrum of 252 (101 MHz, CD2Cl2). 




Figure 309 11B NMR spectrum of 252 (128 MHz, CD2Cl2). 
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